Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:taxane
go back to main search page
Accession:CHEBI:36064 term browser browse the term
Definition:A diterpene that has formula C20H36.
Synonyms:related_synonym: (4R,4aR,6S,9R,10S,12aR)-tetradecahydro-4,9,12a,13,13-pentamethyl-6,10-methanobenzocyclodecene;   (4R-(4alpha,4abeta,6alpha,9alpha,10alpha,12aalpha))-tetradecahydro-4,9,12a,13,13-pentamethyl-6,10-methanobenzocyclodecene;   Formula=C20H36;   InChI=1S/C20H36/c1-14-7-6-11-20(5)12-10-17-15(2)8-9-16(13-18(14)20)19(17,3)4/h14-18H,6-13H2,1-5H3/t14-,15-,16+,17+,18-,20+/m1/s1;   InChIKey=DKPFODGZWDEEBT-QFIAKTPHSA-N;   SMILES=[H][C@]12CC[C@@H](C)[C@]([H])(CC[C@]3(C)CCC[C@@H](C)[C@@]3([H])C1)C2(C)C
 xref: CAS:1605-68-1
 xref_mesh: MESH:C080625


show annotations for term's descendants           Sort by:
 
taxane term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP binding cassette subfamily B member 1A affects activity ISO taxane analog affects the activity of ABCB1 protein CTD PMID:15771464 NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 affects activity ISO taxane analog affects the activity of ABCC1 protein CTD PMID:15771464 NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 affects activity ISO taxane analog affects the activity of ABCG2 protein CTD PMID:15771464 NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
JBrowse link
6-hydroxypaclitaxel term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 increases chemical synthesis ISO CYP2C8 protein results in increased chemical synthesis of 6-hydroxytaxol CTD PMID:12401345 NCBI chr 1:147,236,480...147,307,988 JBrowse link
cabazitaxel term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1s1 AKT1 substrate 1 decreases expression ISO cabazitaxel results in decreased expression of AKT1S1 protein CTD PMID:32525019 NCBI chr 1:100,845,443...100,851,961
Ensembl chr 1:100,845,563...100,851,960
JBrowse link
G Foxo3 forkhead box O3 affects expression ISO cabazitaxel affects the expression of FOXO3 protein CTD PMID:32525019 NCBI chr20:46,428,078...46,519,156
Ensembl chr20:46,428,124...46,519,144
JBrowse link
paclitaxel term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca5 ATP binding cassette subfamily A member 5 increases expression ISO Paclitaxel results in increased expression of ABCA5 mRNA CTD PMID:20737486 NCBI chr10:98,573,226...98,645,028
Ensembl chr10:98,576,039...98,644,938
JBrowse link
G Abca7 ATP binding cassette subfamily A member 7 increases expression ISO Paclitaxel results in increased expression of ABCA7 mRNA CTD PMID:20737486 NCBI chr 7:12,742,433...12,762,423
Ensembl chr 7:12,742,433...12,762,341
JBrowse link
G Abcb11 ATP binding cassette subfamily B member 11 decreases activity ISO Paclitaxel results in decreased activity of ABCB11 protein CTD PMID:20829430, PMID:23956101 NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A affects metabolic processing
multiple interactions
increases expression
affects uptake
increases export
decreases response to substance
increases activity
increases transport
decreases uptake
increases response to substance
affects response to substance
ISO ABCB1 gene polymorphism affects the metabolism of Paclitaxel
[Curcumin co-treated with Calcitriol] inhibits the reaction [Paclitaxel results in increased expression of ABCB1 protein]; Calcitriol promotes the reaction [Curcumin inhibits the reaction [Paclitaxel results in increased expression of ABCB1 protein]]; Curcumin inhibits the reaction [Paclitaxel results in increased expression of ABCB1 protein]
ABCB1A protein affects the uptake of Paclitaxel
ABCB1 protein results in increased export of Paclitaxel
ABCB1 mRNA results in decreased susceptibility to Paclitaxel; ABCB1 protein results in decreased susceptibility to Paclitaxel
6-OH-BDE-47 inhibits the reaction [ABCB1 protein results in increased export of Paclitaxel]; [Calcitriol co-treated with Curcumin] inhibits the reaction [Paclitaxel results in increased expression of ABCB1 protein]; [Calcitriol co-treated with Paclitaxel] results in increased expression of ABCB1 mRNA; [Calcitriol co-treated with Paclitaxel] results in increased expression of ABCB1 protein; [Carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Paclitaxel]] which results in decreased susceptibility to Paclitaxel; [Curcumin co-treated with Calcitriol] inhibits the reaction [Paclitaxel results in increased expression of ABCB1 mRNA]; [Curcumin co-treated with Paclitaxel] results in increased expression of ABCB1 protein; [CXCL8 results in increased expression of ABCB1 mRNA] which results in decreased susceptibility to Paclitaxel; [CXCL8 results in increased expression of ABCB1 protein] which results in decreased susceptibility to Paclitaxel; [Cyclosporine results in decreased activity of ABCB1 protein] which results in increased susceptibility to Paclitaxel; [Paclitaxel co-treated with IL6 protein] results in increased expression of ABCB1 protein; [Paclitaxel results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 mRNA; [Paclitaxel results in increased expression of ABCB1] which results in decreased susceptibility to Cisplatin; [Paclitaxel results in increased expression of ABCB1] which results in decreased susceptibility to Doxorubicin; [Paclitaxel results in increased expression of ABCB1] which results in decreased susceptibility to Fluorouracil; [Paclitaxel results in increased expression of ABCB1] which results in decreased susceptibility to Vincristine; [valspodar results in decreased activity of ABCB1 protein] which results in increased susceptibility to Paclitaxel; [Verapamil results in decreased activity of ABCB1 protein] which results in increased susceptibility to Paclitaxel; ABCB1 protein affects the reaction [acetochlor results in increased susceptibility to Paclitaxel]; ABCB1 protein affects the reaction [alachlor results in increased susceptibility to Paclitaxel]; ABCB1 protein affects the reaction [metolachlor results in increased susceptibility to Paclitaxel]; ABCB1 protein results in increased export of and affects the susceptibility to Paclitaxel; Calcitriol inhibits the reaction [[Curcumin co-treated with Paclitaxel] results in increased expression of ABCB1 protein]; Calcitriol inhibits the reaction [Paclitaxel results in increased expression of ABCB1 protein]; Carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Paclitaxel]; CEP 33779 inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel]; cinchonine analog inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel]; cinchonine inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel]; Crizotinib inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel]; Curcumin analog inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel]; Curcumin inhibits the reaction [[Calcitriol co-treated with Paclitaxel] results in increased expression of ABCB1 mRNA]; Curcumin inhibits the reaction [[Calcitriol co-treated with Paclitaxel] results in increased expression of ABCB1 protein]; Curcumin inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel]; Curcumin inhibits the reaction [Paclitaxel results in increased expression of ABCB1 mRNA]; Curcumin inhibits the reaction [Paclitaxel results in increased expression of ABCB1 protein]; HIF1A protein affects the reaction [[Paclitaxel co-treated with IL6 protein] results in increased expression of ABCB1 protein]; Ketoconazole inhibits the reaction [Paclitaxel results in increased expression of ABCB1 mRNA]; Ketoconazole inhibits the reaction [Paclitaxel results in increased expression of ABCB1 protein]; NR1I2 protein promotes the reaction [Paclitaxel results in increased expression of and results in increased activity of ABCB1 protein]; Paclitaxel results in increased expression of and binds to and results in increased activity of ABCB1 protein; propiconazole inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel]; Quinidine inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel]; Verapamil inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel]; Verapamil inhibits the reaction [ABCB1 protein results in increased transport of Paclitaxel]
Paclitaxel results in increased expression of ABCB1 mRNA; Paclitaxel results in increased expression of ABCB1 protein
Paclitaxel results in increased activity of ABCB1 protein
ABCB1 protein results in decreased uptake of Paclitaxel
ABCB1 mRNA results in increased susceptibility to Paclitaxel
ABCB1 gene SNP affects the susceptibility to Paclitaxel
CTD PMID:10562306, PMID:10617675, PMID:12708479, PMID:14512701, PMID:15239142, PMID:15252144, PMID:15650019, PMID:15901749, PMID:15990222, PMID:16322897, PMID:16819505, PMID:16831368, PMID:16950614, PMID:17284363, PMID:17697605, PMID:18433974, PMID:18673531, PMID:20041327, PMID:20196146, PMID:21742513, PMID:21833476, PMID:22233293, PMID:22792399, PMID:23707768, PMID:25058526, PMID:25268938, PMID:26689174, PMID:27664577, PMID:28031414, PMID:29341321, PMID:29625142, PMID:31628941 NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
JBrowse link
G Abcb1b ATP-binding cassette, subfamily B (MDR/TAP), member 1B affects uptake ISO ABCB1B protein affects the uptake of Paclitaxel CTD PMID:10562306 NCBI chr 4:22,225,123...22,307,577
Ensembl chr 4:22,133,521...22,425,515
JBrowse link
G Abcb4 ATP binding cassette subfamily B member 4 decreases response to substance ISO ABCB4 protein results in decreased susceptibility to Paclitaxel CTD PMID:17697605 NCBI chr 4:22,133,984...22,192,687
Ensembl chr 4:22,133,521...22,425,515
JBrowse link
G Abcb6 ATP binding cassette subfamily B member 6 decreases expression ISO Paclitaxel results in decreased expression of ABCB6 mRNA CTD PMID:20737486 NCBI chr 9:82,373,950...82,382,228
Ensembl chr 9:82,373,946...82,382,272
JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 decreases response to substance
multiple interactions
ISO ABCC1 results in decreased susceptibility to Paclitaxel
[Paclitaxel co-treated with IL6 protein] results in increased expression of ABCC1 protein; HIF1A protein affects the reaction [[Paclitaxel co-treated with IL6 protein] results in increased expression of ABCC1 protein]
CTD PMID:15548710, PMID:29341321 NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
JBrowse link
G Abcc10 ATP binding cassette subfamily C member 10 multiple interactions
increases expression
decreases response to substance
ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [ABCC10 protein results in decreased abundance of and results in increased secretion of Paclitaxel]; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [ABCC10 protein results in decreased susceptibility to Paclitaxel]; ABCC10 protein results in decreased abundance of and results in increased secretion of Paclitaxel; Imatinib Mesylate inhibits the reaction [ABCC10 protein results in decreased abundance of and results in increased secretion of Paclitaxel]; Imatinib Mesylate inhibits the reaction [ABCC10 protein results in decreased susceptibility to Paclitaxel]
Paclitaxel results in increased expression of ABCC10 mRNA
CTD PMID:19841739, PMID:20737486 NCBI chr 9:17,041,351...17,061,263
Ensembl chr 9:17,041,389...17,063,780
JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 decreases response to substance
increases expression
affects expression
increases export
affects transport
multiple interactions
affects response to substance
ISO ABCC2 protein results in decreased susceptibility to Paclitaxel
Paclitaxel results in increased expression of ABCC2 mRNA; Paclitaxel results in increased expression of ABCC2 protein
Paclitaxel affects the expression of ABCC2 mRNA
ABCC2 protein results in increased export of Paclitaxel
ABCC2 protein affects the transport of Paclitaxel
montelukast inhibits the reaction [ABCC2 protein results in increased export of Paclitaxel]; Probenecid promotes the reaction [ABCC2 protein affects the transport of Paclitaxel]; Probenecid promotes the reaction [ABCC2 protein results in decreased susceptibility to Paclitaxel]; verlukast inhibits the reaction [ABCC2 protein results in increased export of Paclitaxel]
ABCC2 protein affects the susceptibility to Paclitaxel
CTD PMID:15645438, PMID:15849751, PMID:19952419, PMID:20737486, PMID:28242239 NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 increases expression ISO Paclitaxel results in increased expression of ABCC3 mRNA; Paclitaxel results in increased expression of ABCC3 protein CTD PMID:20737486, PMID:29625142 NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
JBrowse link
G Abcc4 ATP binding cassette subfamily C member 4 increases expression EXP Paclitaxel results in increased expression of ABCC4 mRNA CTD PMID:15585946 NCBI chr15:103,695,415...103,927,980
Ensembl chr15:103,696,557...103,927,592
JBrowse link
G Abcc5 ATP binding cassette subfamily C member 5 increases expression ISO Paclitaxel results in increased expression of ABCC5 mRNA CTD PMID:20737486 NCBI chr11:84,395,982...84,490,215
Ensembl chr11:84,396,033...84,490,211
JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 multiple interactions
decreases expression
ISO [Cisplatin co-treated with Paclitaxel] results in increased expression of ABCG2 mRNA; [ERBB2 results in increased expression of ABCG2] which results in decreased susceptibility to Paclitaxel; [Paclitaxel results in decreased expression of ABCG2] which results in decreased susceptibility to Cisplatin; [Paclitaxel results in decreased expression of ABCG2] which results in decreased susceptibility to Doxorubicin; [Paclitaxel results in decreased expression of ABCG2] which results in decreased susceptibility to Fluorouracil; [Paclitaxel results in decreased expression of ABCG2] which results in decreased susceptibility to Vincristine
Paclitaxel results in decreased expression of ABCG2 mRNA; Paclitaxel results in decreased expression of ABCG2 protein
CTD PMID:20705681, PMID:21712253, PMID:21833476 NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
JBrowse link
G Abl1 ABL proto-oncogene 1, non-receptor tyrosine kinase multiple interactions ISO [Paclitaxel co-treated with Metformin] results in decreased expression of ABL1 mRNA CTD PMID:29309887 NCBI chr 3:10,041,820...10,145,076
Ensembl chr 3:10,041,826...10,144,388
JBrowse link
G Acadl acyl-CoA dehydrogenase, long chain decreases expression ISO Paclitaxel results in decreased expression of ACADL protein CTD PMID:15907983 NCBI chr 9:73,833,368...73,871,857
Ensembl chr 9:73,833,388...73,871,888
JBrowse link
G Ackr3 atypical chemokine receptor 3 decreases response to substance ISO ACKR3 mRNA results in decreased susceptibility to Paclitaxel CTD PMID:16322897 NCBI chr 9:97,355,881...97,367,455
Ensembl chr 9:97,355,924...97,367,445
JBrowse link
G Acot8 acyl-CoA thioesterase 8 decreases expression ISO Paclitaxel results in decreased expression of ACOT8 protein CTD PMID:30667213 NCBI chr 3:161,260,837...161,272,495
Ensembl chr 3:161,259,735...161,272,460
JBrowse link
G Acta2 actin alpha 2, smooth muscle increases expression ISO Paclitaxel results in increased expression of ACTA2 protein CTD PMID:31170432 NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
JBrowse link
G Adamts13 ADAM metallopeptidase with thrombospondin type 1 motif, 13 multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in decreased expression of ADAMTS13 mRNA CTD PMID:20705681 NCBI chr 3:5,519,921...5,558,390
Ensembl chr 3:5,519,990...5,558,166
JBrowse link
G Adamts4 ADAM metallopeptidase with thrombospondin type 1 motif, 4 multiple interactions ISO [Cisplatin co-treated with Paclitaxel] affects the expression of ADAMTS4 mRNA CTD PMID:20705681 NCBI chr13:89,622,996...89,632,485
Ensembl chr13:89,622,632...89,634,419
JBrowse link
G Adamts5 ADAM metallopeptidase with thrombospondin type 1 motif, 5 multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in decreased expression of ADAMTS5 mRNA CTD PMID:20705681 NCBI chr11:25,411,174...25,456,639
Ensembl chr11:25,410,975...25,456,836
JBrowse link
G Adamts7 ADAM metallopeptidase with thrombospondin type 1 motif, 7 multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in decreased expression of ADAMTS7 mRNA CTD PMID:20705681 NCBI chr 8:97,535,777...97,575,661
Ensembl chr 8:97,535,777...97,575,655
JBrowse link
G Adamtsl4 ADAMTS-like 4 multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in decreased expression of ADAMTSL4 mRNA CTD PMID:20705681 NCBI chr 2:197,803,572...197,815,058
Ensembl chr 2:197,803,584...197,814,808
JBrowse link
G Adcy6 adenylate cyclase 6 decreases expression ISO Paclitaxel results in decreased expression of ADCY6 mRNA CTD PMID:15000894 NCBI chr 7:140,270,678...140,291,722
Ensembl chr 7:140,270,692...140,291,620
JBrowse link
G Add3 adducin 3 affects response to substance ISO ADD3 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 1:273,854,195...273,961,982
Ensembl chr 1:273,854,248...273,961,982
JBrowse link
G Adss adenylosuccinate synthase decreases expression ISO Paclitaxel results in decreased expression of ADSS2 protein CTD PMID:15907983 NCBI chr13:95,913,426...95,943,761
Ensembl chr13:95,913,426...95,943,761
JBrowse link
G Agt angiotensinogen multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in increased expression of AGT mRNA CTD PMID:20705681 NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
JBrowse link
G Aifm1 apoptosis inducing factor, mitochondria associated 1 multiple interactions
increases expression
ISO [Doxorubicin co-treated with Paclitaxel co-treated with Fluorouracil] results in increased expression of AIFM1 protein; [Doxorubicin co-treated with Paclitaxel] results in increased expression of AIFM1 protein; [Tretinoin co-treated with Paclitaxel] affects the localization of AIFM1 protein; [Tretinoin co-treated with Paclitaxel] results in increased expression of AIFM1 protein
Paclitaxel results in increased expression of AIFM1 mRNA
CTD PMID:16168113, PMID:17701358, PMID:18058816 NCBI chr  X:135,304,063...135,343,062
Ensembl chr  X:135,304,066...135,343,087
JBrowse link
G Akr1b1 aldo-keto reductase family 1 member B increases response to substance ISO AKR1B1 protein results in increased susceptibility to Paclitaxel CTD PMID:16734730 NCBI chr 4:61,706,866...61,720,959
Ensembl chr 4:61,706,864...61,720,956
JBrowse link
G Akr1b7 aldo-keto reductase family 1, member B7 increases expression EXP Paclitaxel analog results in increased expression of AKR1B7 mRNA CTD PMID:15585946 NCBI chr 4:61,850,256...61,879,733
Ensembl chr 4:61,850,348...61,862,526
JBrowse link
G Akr1c2 aldo-keto reductase family 1, member C2 increases response to substance ISO AKR1C2 mRNA results in increased susceptibility to Paclitaxel CTD PMID:16322897 NCBI chr17:69,388,337...69,435,160
Ensembl chr17:69,388,335...69,404,341
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
increases phosphorylation
decreases response to substance
decreases phosphorylation
increases activity
affects response to substance
ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Paclitaxel results in increased activity of AKT1 protein]; 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Paclitaxel results in increased activity of AKT1 protein]; [Paclitaxel co-treated with Metformin] results in decreased expression of AKT1 mRNA; [PDK1 protein binds to AKT1 protein] results in decreased susceptibility to [Paclitaxel co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one]; [PDK1 protein binds to AKT1 protein] which results in decreased susceptibility to Paclitaxel; [pifithrin co-treated with Paclitaxel] results in decreased phosphorylation of AKT1 protein; AKT1 protein affects the reaction [Paclitaxel results in increased activity of CASP3 protein]; AKT1 protein affects the reaction [Paclitaxel results in increased cleavage of PARP1 protein]; U 0126 inhibits the reaction [Paclitaxel results in increased activity of AKT1 protein]
Paclitaxel results in increased phosphorylation of AKT1 protein
AKT1 protein results in decreased susceptibility to Paclitaxel
Paclitaxel results in decreased phosphorylation of AKT1 protein
AKT1 protein affects the susceptibility to Paclitaxel
CTD PMID:10075725, PMID:16211241, PMID:16782806, PMID:17404021, PMID:18071906, PMID:18516295, PMID:19426673, PMID:20361045, PMID:23956100, PMID:27769712, PMID:29309887 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Akt2 AKT serine/threonine kinase 2 affects response to substance
increases phosphorylation
ISO AKT2 protein affects the susceptibility to Paclitaxel
Paclitaxel results in increased phosphorylation of AKT2 protein
CTD PMID:18071906 NCBI chr 1:84,400,939...84,451,223
Ensembl chr 1:84,411,726...84,450,162
JBrowse link
G Akt3 AKT serine/threonine kinase 3 affects response to substance ISO AKT3 protein affects the susceptibility to Paclitaxel CTD PMID:18071906 NCBI chr13:95,076,308...95,348,913
Ensembl chr13:95,081,390...95,348,913
JBrowse link
G Aldh1a1 aldehyde dehydrogenase 1 family, member A1 decreases expression
multiple interactions
ISO Paclitaxel results in decreased expression of ALDH1A1 protein
[Calcitriol co-treated with Curcumin] inhibits the reaction [Paclitaxel results in decreased expression of ALDH1A1 protein]
Paclitaxel results in decreased expression of ALDH1A1 mRNA; Paclitaxel results in decreased expression of ALDH1A1 protein
[Calcitriol co-treated with Curcumin] promotes the reaction [Paclitaxel results in decreased expression of ALDH1A1 mRNA]; [Calcitriol co-treated with Paclitaxel] promotes the reaction [Curcumin results in decreased expression of ALDH1A1 mRNA]; [Curcumin co-treated with Calcitriol] inhibits the reaction [Paclitaxel results in decreased expression of ALDH1A1 protein]; [Curcumin co-treated with Paclitaxel] promotes the reaction [Calcitriol results in decreased expression of ALDH1A1 mRNA]; Curcumin promotes the reaction [Paclitaxel results in decreased expression of ALDH1A1 protein]; Paclitaxel promotes the reaction [Calcitriol results in decreased expression of ALDH1A1 mRNA]; Paclitaxel promotes the reaction [Curcumin results in decreased expression of ALDH1A1 mRNA]
CTD PMID:31628941 NCBI chr 1:238,222,689...238,264,381
Ensembl chr 1:238,222,521...238,264,330
JBrowse link
G Aldh9a1 aldehyde dehydrogenase 9 family, member A1 increases expression ISO Paclitaxel results in increased expression of ALDH9A1 protein CTD PMID:15907983 NCBI chr13:85,580,828...85,597,497
Ensembl chr13:85,580,828...85,597,493
JBrowse link
G Alg8 ALG8, alpha-1,3-glucosyltransferase affects response to substance ISO ALG8 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 1:162,342,061...162,362,139
Ensembl chr 1:162,342,051...162,362,141
JBrowse link
G Amacr alpha-methylacyl-CoA racemase increases expression EXP Paclitaxel results in increased expression of AMACR mRNA CTD PMID:15585946 NCBI chr 2:60,949,276...60,961,342
Ensembl chr 2:60,949,256...60,961,326
JBrowse link
G Amfr autocrine motility factor receptor multiple interactions ISO AMFR mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] CTD PMID:16896004 NCBI chr19:11,473,538...11,509,500
Ensembl chr19:11,473,541...11,508,102
JBrowse link
G Ang angiogenin multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in increased expression of ANG mRNA CTD PMID:20705681 NCBI chr15:28,022,926...28,028,636 JBrowse link
G Angpt1 angiopoietin 1 multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in increased expression of ANGPT1 mRNA CTD PMID:20705681 NCBI chr 7:81,338,327...81,592,459
Ensembl chr 7:81,342,280...81,592,206
JBrowse link
G Angptl4 angiopoietin-like 4 multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in increased expression of ANGPTL4 mRNA CTD PMID:20705681 NCBI chr 7:18,627,814...18,634,043
Ensembl chr 7:18,627,808...18,634,079
JBrowse link
G Anp32a acidic nuclear phosphoprotein 32 family member A affects response to substance ISO ANP32A protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 8:67,295,578...67,333,075
Ensembl chr 8:67,295,727...67,333,247
JBrowse link
G Anxa1 annexin A1 increases response to substance ISO ANXA1 protein results in increased susceptibility to Paclitaxel CTD PMID:16734730 NCBI chr 1:237,893,983...237,910,002
Ensembl chr 1:237,893,966...237,910,012
JBrowse link
G Anxa4 annexin A4 decreases response to substance ISO ANXA4 results in decreased susceptibility to Paclitaxel CTD PMID:21636539 NCBI chr 4:118,538,775...118,595,591
Ensembl chr 4:118,538,777...118,595,580
JBrowse link
G Anxa8 annexin A8 increases response to substance ISO ANXA8 protein results in increased susceptibility to Paclitaxel CTD PMID:16734730 NCBI chr16:10,417,174...10,432,388
Ensembl chr16:10,417,185...10,432,393
JBrowse link
G Aox1 aldehyde oxidase 1 affects response to substance ISO AOX1 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 9:64,929,682...65,007,872
Ensembl chr 9:64,929,721...65,007,870
JBrowse link
G Apaf1 apoptotic peptidase activating factor 1 increases expression
multiple interactions
ISO Paclitaxel results in increased expression of APAF1 protein
[Paclitaxel co-treated with Metformin] results in increased expression of APAF1 mRNA
APAF1 protein affects the reaction [Paclitaxel results in increased activity of and results in increased cleavage of CASP3 protein]
CTD PMID:14749477, PMID:17652622, PMID:29309887 NCBI chr 7:31,699,309...31,784,192
Ensembl chr 7:31,699,885...31,784,192
JBrowse link
G Apbb1ip amyloid beta precursor protein binding family B member 1 interacting protein increases expression EXP Paclitaxel results in increased expression of APBB1IP mRNA CTD PMID:18754875 NCBI chr17:90,098,953...90,149,192
Ensembl chr17:90,099,025...90,149,894
JBrowse link
G Aplp2 amyloid beta precursor like protein 2 affects response to substance ISO APLP2 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 8:32,298,526...32,328,821
Ensembl chr 8:32,298,532...32,328,839
JBrowse link
G Apod apolipoprotein D increases expression ISO Paclitaxel results in increased expression of APOD mRNA CTD PMID:19682730 NCBI chr11:72,705,204...72,726,263
Ensembl chr11:72,705,129...72,726,301
JBrowse link
G Ar androgen receptor multiple interactions
decreases localization
ISO Paclitaxel inhibits the reaction [Dihydrotestosterone results in increased localization of AR protein]
Paclitaxel results in decreased localization of AR protein
CTD PMID:20807808 NCBI chr  X:67,656,253...67,828,998
Ensembl chr  X:67,656,253...67,829,026
JBrowse link
G Areg amphiregulin increases expression ISO Paclitaxel results in increased expression of AREG protein CTD PMID:20726858 NCBI chr14:18,521,921...18,531,179
Ensembl chr14:18,521,930...18,531,179
JBrowse link
G Arf3 ADP-ribosylation factor 3 affects response to substance ISO ARF3 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 7:140,412,463...140,438,751
Ensembl chr 7:140,398,199...140,437,467
JBrowse link
G Arhgap24 Rho GTPase activating protein 24 multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in increased expression of ARHGAP24 mRNA CTD PMID:20705681 NCBI chr14:8,383,211...8,600,526
Ensembl chr14:8,383,214...8,600,512
JBrowse link
G Arhgdia Rho GDP dissociation inhibitor alpha multiple interactions
affects response to substance
ISO ARHGDIA mRNA affects the reaction [Paclitaxel results in increased activity of CASP3 protein]
ARHGDIA mRNA affects the susceptibility to Paclitaxel
CTD PMID:17264767 NCBI chr10:109,754,012...109,757,506
Ensembl chr10:109,754,004...109,757,550
JBrowse link
G Arr3 arrestin 3 decreases response to substance ISO ARR3 mRNA results in decreased susceptibility to Paclitaxel CTD PMID:16322897 NCBI chr  X:70,438,590...70,452,140
Ensembl chr  X:70,438,617...70,452,067
JBrowse link
G Aspm assembly factor for spindle microtubules increases expression ISO Paclitaxel results in increased expression of ASPM mRNA CTD PMID:17374387 NCBI chr13:56,546,021...56,591,793
Ensembl chr13:56,546,021...56,591,793
JBrowse link
G Atf3 activating transcription factor 3 multiple interactions
increases expression
EXP Minocycline inhibits the reaction [Paclitaxel results in increased expression of ATF3 protein] CTD PMID:16854522, PMID:17005179, PMID:17686523, PMID:18754875, PMID:21050491 NCBI chr13:109,817,892...109,849,632
Ensembl chr13:109,817,728...109,849,632
JBrowse link
G Atf5 activating transcription factor 5 decreases expression ISO Paclitaxel results in decreased expression of ATF5 mRNA CTD PMID:15000894 NCBI chr 1:100,807,821...100,812,410
Ensembl chr 1:100,808,241...100,810,522
JBrowse link
G Atp2a2 ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 increases expression EXP Paclitaxel results in increased expression of ATP2A2 mRNA CTD PMID:15585946 NCBI chr12:39,553,903...39,603,326
Ensembl chr12:39,553,903...39,603,326
JBrowse link
G Atp6v1a ATPase H+ transporting V1 subunit A affects response to substance ISO ATP6V1A protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr11:61,531,386...61,584,634
Ensembl chr11:61,531,416...61,584,634
JBrowse link
G Atp7a ATPase copper transporting alpha decreases response to substance
increases expression
ISO ATP7A protein results in decreased susceptibility to Paclitaxel
Paclitaxel results in increased expression of ATP7A mRNA
CTD PMID:17510416, PMID:20737486 NCBI chr  X:77,076,085...77,193,644
Ensembl chr  X:77,076,106...77,193,644
JBrowse link
G Atr ATR serine/threonine kinase multiple interactions ISO [Paclitaxel co-treated with Metformin] results in decreased expression of ATR mRNA CTD PMID:29309887 NCBI chr 8:103,673,578...103,770,886
Ensembl chr 8:103,673,411...103,770,947
JBrowse link
G Aurka aurora kinase A increases expression ISO Paclitaxel results in increased expression of AURKA mRNA CTD PMID:17374387 NCBI chr 3:170,364,177...170,380,278
Ensembl chr 3:170,364,181...170,378,210
JBrowse link
G Aven apoptosis and caspase activation inhibitor multiple interactions ISO [Paclitaxel co-treated with Metformin] results in decreased expression of AVEN mRNA CTD PMID:29309887 NCBI chr 3:103,980,612...104,117,193
Ensembl chr 3:104,042,168...104,117,192
JBrowse link
G Axl Axl receptor tyrosine kinase increases response to substance ISO AXL protein results in increased susceptibility to Paclitaxel CTD PMID:16734730 NCBI chr 1:82,550,892...82,580,761
Ensembl chr 1:82,549,420...82,580,761
JBrowse link
G Bad BCL2-associated agonist of cell death increases expression
multiple interactions
ISO Paclitaxel results in increased expression of BAD mRNA; Paclitaxel results in increased expression of BAD protein
[PD168393 co-treated with Paclitaxel] results in increased expression of BAD protein
CTD PMID:10822281, PMID:16413505 NCBI chr 1:222,198,516...222,207,459
Ensembl chr 1:222,198,534...222,207,453
JBrowse link
G Bag1 BAG cochaperone 1 multiple interactions ISO [Paclitaxel co-treated with Metformin] results in decreased expression of BAG1 mRNA CTD PMID:29309887 NCBI chr 5:57,254,421...57,267,002
Ensembl chr 5:57,254,421...57,267,002
JBrowse link
G Bak1 BCL2-antagonist/killer 1 increases response to substance
increases expression
multiple interactions
affects expression
ISO BAK1 protein results in increased susceptibility to Paclitaxel
Paclitaxel results in increased expression of BAK1 mRNA; Paclitaxel results in increased expression of BAK1 protein
[BAK1 protein mutant form co-treated with BAX protein mutant form] inhibits the reaction [Paclitaxel results in increased activity of and results in increased cleavage of CASP3 protein]
Paclitaxel affects the expression of BAK1 mRNA; Paclitaxel affects the expression of BAK1 protein
CTD PMID:10822281, PMID:17652622, PMID:17688235, PMID:24126434 NCBI chr20:5,609,620...5,618,899
Ensembl chr20:5,609,625...5,618,260
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
increases expression
affects response to substance
ISO [Doxorubicin co-treated with Paclitaxel] results in increased expression of BAX protein; [esculetin co-treated with Paclitaxel] results in increased expression of BAX protein; [fisetin co-treated with Paclitaxel] results in increased expression of BAX mRNA; [Paclitaxel results in increased phosphorylation of BCL2 protein] inhibits the reaction [BCL2 protein binds to BAX protein]; Curcumin promotes the reaction [Paclitaxel promotes the reaction [Calcitriol results in increased expression of BAX protein]]; Curcumin promotes the reaction [Paclitaxel results in increased expression of BAX protein]; Fluorouracil promotes the reaction [[Doxorubicin co-treated with Paclitaxel] results in increased expression of BAX protein]; HIF1A protein affects the reaction [IL6 protein inhibits the reaction [Paclitaxel results in increased expression of BAX protein]]; IL6 protein inhibits the reaction [Paclitaxel results in increased expression of BAX protein]; Paclitaxel promotes the reaction [Calcitriol results in increased expression of BAX protein]; Paclitaxel promotes the reaction [Curcumin results in increased expression of BAX protein]
Paclitaxel results in increased expression of BAX mRNA
BAX protein affects the susceptibility to Paclitaxel
[BAK1 protein mutant form co-treated with BAX protein mutant form] inhibits the reaction [Paclitaxel results in increased activity of and results in increased cleavage of CASP3 protein]
[Paclitaxel results in increased expression of TP53 protein] which results in increased expression of BAX mRNA; Paclitaxel results in increased expression of BAX mRNA; Paclitaxel results in increased expression of BAX protein
CTD PMID:9041188, PMID:10516758, PMID:10822281, PMID:11726273, PMID:12632493, PMID:16051289, PMID:16168113, PMID:16513327, PMID:17449502, PMID:17652622, PMID:23956100, PMID:26884726, PMID:29341321, PMID:31628941 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bbc3 Bcl-2 binding component 3 increases response to substance
increases expression
ISO BBC3 protein results in increased susceptibility to Paclitaxel
Paclitaxel results in increased expression of BBC3 mRNA; Paclitaxel results in increased expression of BBC3 protein
CTD PMID:16481741 NCBI chr 1:78,261,491...78,267,802 JBrowse link
G Bbs4 Bardet-Biedl syndrome 4 multiple interactions ISO BBS4 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] CTD PMID:16896004 NCBI chr 8:64,115,005...64,154,432
Ensembl chr 8:64,121,392...64,154,396
JBrowse link
G Bcl2 BCL2, apoptosis regulator affects response to substance
increases phosphorylation
increases expression
decreases expression
increases cleavage
decreases degradation
affects localization
decreases activity
multiple interactions
increases response to substance
decreases response to substance
ISO BCL2 protein affects the susceptibility to Paclitaxel
Paclitaxel results in increased phosphorylation of BCL2 protein
Paclitaxel results in increased expression of BCL2 mRNA
Paclitaxel results in decreased expression of BCL2 mRNA; Paclitaxel results in decreased expression of BCL2 protein
Paclitaxel results in increased cleavage of BCL2 protein
Paclitaxel results in decreased degradation of BCL2 protein
Paclitaxel affects the localization of BCL2 protein
Paclitaxel results in decreased activity of BCL2 protein
3,3'-diindolylmethane promotes the reaction [Paclitaxel results in decreased expression of BCL2 protein]; [Curcumin co-treated with Calcitriol] promotes the reaction [Paclitaxel results in decreased expression of BCL2 protein]; [CXCL8 results in increased expression of BCL2 mRNA] which results in decreased susceptibility to Paclitaxel; [CXCL8 results in increased expression of BCL2 protein] which results in decreased susceptibility to Paclitaxel; [fisetin co-treated with Paclitaxel] results in increased expression of BCL2 mRNA; [Paclitaxel co-treated with Metformin] results in decreased expression of BCL2 mRNA; [Paclitaxel co-treated with Sorafenib] results in decreased expression of BCL2 protein; [Paclitaxel results in increased phosphorylation of BCL2 protein] inhibits the reaction [BCL2 protein binds to BAX protein]; [Paclitaxel results in increased phosphorylation of BCL2 protein] which results in increased susceptibility to Cisplatin; [pifithrin co-treated with Paclitaxel] results in increased phosphorylation of BCL2 protein; [Tretinoin co-treated with Paclitaxel] results in decreased expression of BCL2 protein; [Tretinoin co-treated with Paclitaxel] results in increased phosphorylation of BCL2 protein; aspartyl-glutamyl-valyl-aspartal inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein]; Calcitriol promotes the reaction [Paclitaxel results in decreased expression of BCL2 protein]; Curcumin inhibits the reaction [Paclitaxel results in increased expression of BCL2 protein]; Curcumin promotes the reaction [Calcitriol promotes the reaction [Paclitaxel results in decreased expression of BCL2 protein]]; Curcumin promotes the reaction [Paclitaxel results in decreased expression of BCL2 protein]; Cycloheximide inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein]; Cyclosporine promotes the reaction [Paclitaxel results in increased phosphorylation of and results in decreased activity of BCL2 protein]; Dactinomycin inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein]; Doxorubicin promotes the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein]; Genistein inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein]; HIF1A protein affects the reaction [IL6 protein inhibits the reaction [Paclitaxel results in decreased expression of BCL2 protein]]; IL6 protein inhibits the reaction [Paclitaxel results in decreased expression of BCL2 protein]; MAP3K1 protein affects the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein]; MAPK8 protein affects the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein]; Paclitaxel results in decreased expression of and affects the phosphorylation of BCL2 protein; Paclitaxel results in increased phosphorylation of and results in decreased activity of BCL2 protein; Quercetin inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein]; Resveratrol inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein]; Staurosporine inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein]; TYMP inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein]
BCL2 protein mutant form results in increased susceptibility to Paclitaxel
BCL2 mRNA results in decreased susceptibility to Paclitaxel; BCL2 protein results in decreased susceptibility to Paclitaxel
CTD PMID:7654318, PMID:10502406, PMID:10822281, PMID:10861090, PMID:10881025, PMID:11160861, PMID:11597122, PMID:11726273, PMID:11774260, PMID:12086014, PMID:12126962, PMID:12510025, PMID:12632493, PMID:12709826, PMID:14991574, PMID:15907805, PMID:15907983, PMID:16168113, PMID:16243823, PMID:16275990, PMID:16322897, PMID:16513327, PMID:16580691, PMID:17701358, PMID:18098270, PMID:18516295, PMID:18521433, PMID:19664330, PMID:19815708, PMID:20610805, PMID:21742513, PMID:26884726, PMID:29309887, PMID:29341321, PMID:31628941 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bcl2l1 Bcl2-like 1 decreases response to substance
increases phosphorylation
increases expression
decreases expression
multiple interactions
ISO BCL2L1 protein results in decreased susceptibility to Paclitaxel
Paclitaxel results in increased phosphorylation of BCL2L1 protein
Paclitaxel results in increased expression of BCL2L1 mRNA; Paclitaxel results in increased expression of BCL2L1 protein
Paclitaxel results in decreased expression of BCL2L1 mRNA; Paclitaxel results in decreased expression of BCL2L1 protein
[CXCL8 results in increased expression of BCL2L1 mRNA] which results in decreased susceptibility to Paclitaxel; [CXCL8 results in increased expression of BCL2L1 protein] which results in decreased susceptibility to Paclitaxel; [esculetin co-treated with Paclitaxel] results in decreased expression of BCL2L1 protein; Curcumin inhibits the reaction [Paclitaxel results in increased expression of BCL2L1 protein]
CTD PMID:10822281, PMID:11468182, PMID:11774260, PMID:14749477, PMID:16051289, PMID:16080463, PMID:16243823, PMID:16275990, PMID:18058816, PMID:18521433, PMID:21742513, PMID:23956100 NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
JBrowse link
G Bcl2l11 BCL2 like 11 affects response to substance ISO BCL2L11 protein affects the susceptibility to Paclitaxel CTD PMID:17652622 NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
JBrowse link
G Bcl6 BCL6, transcription repressor multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in increased expression of BCL6 mRNA CTD PMID:20705681 NCBI chr11:80,255,790...80,279,075
Ensembl chr11:80,255,790...80,279,075
JBrowse link
G Bcl6b BCL6B, transcription repressor increases expression EXP Paclitaxel results in increased expression of BCL6B mRNA CTD PMID:18754875 NCBI chr10:56,834,363...56,840,058
Ensembl chr10:56,834,364...56,839,437
JBrowse link
G Becn1 beclin 1 multiple interactions ISO BECN1 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] CTD PMID:16896004 NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
JBrowse link
G Bgn biglycan affects response to substance ISO BGN protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr  X:157,319,042...157,331,204
Ensembl chr  X:157,319,046...157,331,204
JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions
increases cleavage
increases expression
ISO [Tretinoin co-treated with Paclitaxel] results in increased cleavage of BID protein
Paclitaxel results in increased cleavage of BID protein
Paclitaxel results in increased expression of BID protein
CTD PMID:14749477, PMID:18098270 NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
JBrowse link
G Bin1 bridging integrator 1 increases expression ISO Paclitaxel results in increased expression of BIN1 mRNA CTD PMID:19682730 NCBI chr18:25,163,575...25,222,139
Ensembl chr18:25,163,561...25,222,135
JBrowse link
G Bin3 bridging integrator 3 decreases expression ISO Paclitaxel results in decreased expression of BIN3 protein CTD PMID:15907983 NCBI chr15:51,799,339...51,818,697
Ensembl chr15:51,779,839...51,818,699
JBrowse link
G Birc2 baculoviral IAP repeat-containing 2 decreases expression
affects response to substance
multiple interactions
ISO Paclitaxel results in decreased expression of BIRC2 protein
BIRC2 protein affects the susceptibility to Paclitaxel
[Tretinoin co-treated with Paclitaxel] results in decreased expression of BIRC2 protein; Curcumin inhibits the reaction [Paclitaxel results in increased expression of BIRC2 protein]
CTD PMID:14749477, PMID:16217747, PMID:16243823, PMID:17701358, PMID:18098270 NCBI chr 8:6,014,014...6,036,668
Ensembl chr 8:6,013,207...6,034,142
JBrowse link
G Birc3 baculoviral IAP repeat-containing 3 decreases expression
multiple interactions
ISO Paclitaxel results in decreased expression of BIRC3 protein
[Tretinoin co-treated with Paclitaxel] results in decreased expression of BIRC3 protein; Curcumin inhibits the reaction [Paclitaxel results in increased expression of BIRC3 protein]
CTD PMID:14749477, PMID:16243823, PMID:17701358, PMID:18098270 NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 decreases response to substance
multiple interactions
increases expression
decreases expression
ISO BIRC5 protein results in decreased susceptibility to Paclitaxel; BIRC5 results in decreased susceptibility to Paclitaxel
4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Paclitaxel results in increased expression of BIRC5]; [4-(6-cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide co-treated with Paclitaxel] results in decreased expression of BIRC5 protein; [Tretinoin co-treated with Paclitaxel] results in decreased expression of BIRC5 protein; Paclitaxel affects the reaction [BIRC5 protein affects the susceptibility to Melphalan]; Prodigiosin inhibits the reaction [Paclitaxel results in increased expression of BIRC5 protein]; vorinostat inhibits the reaction [Paclitaxel results in increased expression of BIRC5 protein]
Paclitaxel results in increased expression of BIRC5; Paclitaxel results in increased expression of BIRC5 protein
Paclitaxel results in decreased expression of BIRC5 mRNA; Paclitaxel results in decreased expression of BIRC5 promoter; Paclitaxel results in decreased expression of BIRC5 protein
CTD PMID:12517802, PMID:14749477, PMID:15970709, PMID:16170024, PMID:16202317, PMID:16211241, PMID:16373717, PMID:17399942, PMID:17701358, PMID:18098270, PMID:19133282, PMID:19875160 NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
JBrowse link
G Bmi1 BMI1 proto-oncogene, polycomb ring finger decreases expression ISO Paclitaxel results in decreased expression of BMI1 mRNA CTD PMID:12929121 NCBI chr17:85,360,439...85,370,283
Ensembl chr17:85,364,483...85,368,208
JBrowse link
G Bmp2 bone morphogenetic protein 2 multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in decreased expression of BMP2 mRNA CTD PMID:20705681 NCBI chr 3:126,335,963...126,346,771
Ensembl chr 3:126,335,863...126,346,318
JBrowse link
G Bmp4 bone morphogenetic protein 4 decreases expression ISO Paclitaxel results in decreased expression of BMP4 mRNA CTD PMID:23956100 NCBI chr15:20,776,060...20,791,013
Ensembl chr15:20,776,054...20,822,740
JBrowse link
G Bmp7 bone morphogenetic protein 7 increases response to substance ISO BMP7 mRNA results in increased susceptibility to Paclitaxel CTD PMID:16322897 NCBI chr 3:170,879,972...170,955,820
Ensembl chr 3:170,879,973...170,955,399
JBrowse link
G Brca1 BRCA1, DNA repair associated decreases expression ISO Paclitaxel results in decreased expression of BRCA1 mRNA CTD PMID:15607317 NCBI chr10:89,394,821...89,455,093
Ensembl chr10:89,394,803...89,454,681
JBrowse link
G Bscl2 BSCL2 lipid droplet biogenesis associated, seipin increases expression ISO Paclitaxel results in increased expression of BSCL2 mRNA CTD PMID:22003191 NCBI chr 1:225,035,956...225,046,137
Ensembl chr 1:225,037,737...225,046,040
JBrowse link
G Btg2 BTG anti-proliferation factor 2 decreases expression EXP Paclitaxel results in decreased expression of BTG2 mRNA CTD PMID:15585946 NCBI chr13:50,913,185...50,916,944
Ensembl chr13:50,913,180...50,916,982
JBrowse link
G Btg3 BTG anti-proliferation factor 3 multiple interactions
increases expression
ISO BTG3 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]
Paclitaxel results in increased expression of BTG3 protein
CTD PMID:15907983, PMID:16896004 NCBI chr11:16,873,642...16,889,100
Ensembl chr11:16,873,646...16,889,201
JBrowse link
G Bub1b BUB1 mitotic checkpoint serine/threonine kinase B multiple interactions
affects response to substance
ISO [arsenic trioxide co-treated with Paclitaxel] promotes the reaction [BUB1B protein binds to CDC20 protein]; [arsenic trioxide co-treated with Paclitaxel] results in increased expression of BUB1B protein modified form
BUB1B protein affects the susceptibility to Paclitaxel
CTD PMID:18691855, PMID:19781537 NCBI chr 3:110,367,949...110,420,471
Ensembl chr 3:110,367,939...110,420,458
JBrowse link
G Bub3 BUB3 mitotic checkpoint protein increases expression ISO Paclitaxel results in increased expression of BUB3 protein CTD PMID:15907983 NCBI chr 1:203,526,853...203,537,459
Ensembl chr 1:203,524,426...203,557,337
JBrowse link
G C1qa complement C1q A chain increases expression EXP Paclitaxel results in increased expression of C1QA mRNA CTD PMID:18754875 NCBI chr 5:155,261,254...155,264,101
Ensembl chr 5:155,261,250...155,264,143
JBrowse link
G C1qb complement C1q B chain increases expression EXP Paclitaxel results in increased expression of C1QB mRNA CTD PMID:18754875 NCBI chr 5:155,246,444...155,251,995
Ensembl chr 5:155,246,447...155,252,003
JBrowse link
G C1qc complement C1q C chain increases expression EXP Paclitaxel results in increased expression of C1QC mRNA CTD PMID:18754875 NCBI chr 5:155,255,013...155,258,631
Ensembl chr 5:155,255,005...155,258,392
JBrowse link
G C1s complement C1s increases expression EXP Paclitaxel results in increased expression of C1S mRNA CTD PMID:18754875 NCBI chr 4:157,143,592...157,155,592
Ensembl chr 4:157,143,592...157,155,609
JBrowse link
G C3 complement C3 increases expression EXP Paclitaxel results in increased expression of C3 mRNA CTD PMID:18754875 NCBI chr 9:9,721,137...9,747,084
Ensembl chr 9:9,721,105...9,747,167
JBrowse link
G C4a complement C4A increases expression EXP Paclitaxel results in increased expression of C4A mRNA CTD PMID:18754875 NCBI chr20:2,651,599...2,678,183
Ensembl chr20:2,651,599...2,678,141
JBrowse link
G Ca12 carbonic anhydrase 12 multiple interactions ISO CA12 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] CTD PMID:16896004 NCBI chr 8:72,405,770...72,461,425
Ensembl chr 8:72,405,748...72,460,240
JBrowse link
G Cacna2d1 calcium voltage-gated channel auxiliary subunit alpha2delta 1 increases expression ISO Paclitaxel results in increased expression of CACNA2D1 mRNA; Paclitaxel results in increased expression of CACNA2D1 protein CTD PMID:16687474, PMID:19336915 NCBI chr 4:15,706,974...16,130,848
Ensembl chr 4:15,710,417...16,130,848
JBrowse link
G Calca calcitonin-related polypeptide alpha multiple interactions
decreases expression
increases expression
EXP Cromolyn Sodium inhibits the reaction [Paclitaxel results in increased expression of CALCA protein]; Paclitaxel inhibits the reaction [Capsaicin results in increased secretion of CALCA protein]; Paclitaxel inhibits the reaction [Potassium results in increased secretion of CALCA protein]; pemirolast inhibits the reaction [Paclitaxel results in increased expression of CALCA protein]
Paclitaxel results in decreased expression of CALCA protein
CTD PMID:15033348, PMID:26883566 NCBI chr 1:184,184,018...184,188,922
Ensembl chr 1:184,184,020...184,188,911
JBrowse link
G Camk2b calcium/calmodulin-dependent protein kinase II beta affects response to substance ISO CAMK2B protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr14:86,208,876...86,297,727
Ensembl chr14:86,208,901...86,297,652
JBrowse link
G Caprin1 cell cycle associated protein 1 decreases expression ISO Paclitaxel results in decreased expression of CAPRIN1 mRNA CTD PMID:18058816 NCBI chr 3:93,701,830...93,789,580
Ensembl chr 3:93,702,487...93,789,617
JBrowse link
G Casp1 caspase 1 multiple interactions ISO [Paclitaxel co-treated with Metformin] results in increased expression of CASP1 mRNA CTD PMID:29309887 NCBI chr 8:2,605,743...2,614,637
Ensembl chr 8:2,604,962...2,614,631
JBrowse link
G Casp12 caspase 12 decreases expression
multiple interactions
increases expression
ISO Paclitaxel results in decreased expression of CASP12 protein
[Tretinoin co-treated with Paclitaxel] results in increased expression of CASP12 protein
Paclitaxel results in increased expression of CASP12 protein
CTD PMID:17701358, PMID:18098270 NCBI chr 8:2,658,892...2,686,160
Ensembl chr 8:2,659,865...2,686,160
JBrowse link
G Casp14 caspase 14 multiple interactions ISO [Paclitaxel co-treated with Metformin] results in increased expression of CASP14 mRNA CTD PMID:29309887 NCBI chr 7:13,938,376...13,944,286
Ensembl chr 7:13,938,302...13,945,130
JBrowse link
G Casp3 caspase 3 multiple interactions
increases activity
increases cleavage
increases expression
ISO [4-(6-cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide co-treated with Paclitaxel] results in increased activity of CASP3 protein; [6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine co-treated with Paclitaxel] results in increased activity of CASP3 protein; [Doxorubicin co-treated with Paclitaxel co-treated with Fluorouracil] results in increased activity of CASP3 protein; [Doxorubicin co-treated with Paclitaxel] results in increased activity of CASP3 protein; [esculetin co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of CASP3 protein; [fisetin co-treated with Paclitaxel] results in increased expression of CASP3 mRNA; [Luteolin co-treated with Paclitaxel] results in increased cleavage of CASP3 protein; [Paclitaxel co-treated with Cisplatin] results in increased activity of CASP3 protein; [PD168393 co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of CASP3 protein; [pifithrin co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of CASP3 protein; [Sirolimus co-treated with Paclitaxel] results in increased cleavage of CASP3 protein; [tipifarnib co-treated with Paclitaxel] results in increased activity of CASP3 protein; [Tretinoin co-treated with Paclitaxel] results in increased activity of CASP3 protein; AKT1 protein affects the reaction [Paclitaxel results in increased activity of CASP3 protein]; alvocidib promotes the reaction [Paclitaxel results in increased activity of CASP3 protein]; ARHGDIA mRNA affects the reaction [Paclitaxel results in increased activity of CASP3 protein]; CD40LG protein inhibits the reaction [Paclitaxel promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]]; CXCL8 inhibits the reaction [Paclitaxel results in increased activity of CASP3 protein]; inostamycin promotes the reaction [Paclitaxel results in increased expression of CASP3 protein modified form]; MAP2K4 protein affects the reaction [Paclitaxel results in increased activity of CASP3 protein]; MAP3K5 protein affects the reaction [Paclitaxel results in increased activity of CASP3 protein]; MAPK8 protein affects the reaction [Paclitaxel results in increased activity of CASP3 protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Paclitaxel results in increased activity of CASP3 protein]; Nicotine inhibits the reaction [Paclitaxel results in increased activity of CASP3 protein]; Paclitaxel promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]; Paclitaxel promotes the reaction [NSC 74859 results in decreased expression of CASP3 protein]; Paclitaxel results in increased activity of and results in increased cleavage of CASP3 protein; Paclitaxel results in increased cleavage of and results in increased activity of CASP3 protein; Paclitaxel results in increased expression of and results in increased activity of CASP3 protein; palbociclib inhibits the reaction [Paclitaxel results in increased activity of CASP3 protein]; TYMP mutant form promotes the reaction [Paclitaxel results in increased cleavage of CASP3 protein]
Paclitaxel results in increased expression of CASP3 mRNA
[BAK1 protein mutant form co-treated with BAX protein mutant form] inhibits the reaction [Paclitaxel results in increased activity of and results in increased cleavage of CASP3 protein]; APAF1 protein affects the reaction [Paclitaxel results in increased activity of and results in increased cleavage of CASP3 protein]; CASP9 protein affects the reaction [Paclitaxel results in increased activity of and results in increased cleavage of CASP3 protein]; Metoclopramide inhibits the reaction [Paclitaxel results in increased activity of CASP3 protein]; Paclitaxel results in increased activity of and results in increased cleavage of CASP3 protein
Paclitaxel results in increased expression of CASP3 mRNA; Paclitaxel results in increased expression of CASP3 protein; Paclitaxel results in increased expression of CASP3 protein modified form
CTD PMID:9818034, PMID:10075725, PMID:10430095, PMID:10516758, PMID:10733772, PMID:10822281, PMID:11716366, PMID:11774260, PMID:12086014, PMID:12709826, PMID:15492279, PMID:15728126, PMID:15753396, PMID:16051289, PMID:16140185, PMID:16168113, PMID:16170024, PMID:16413505, PMID:16545138, PMID:17264767, PMID:17399942, PMID:17449502, PMID:17652622, PMID:17701358, PMID:18071906, PMID:18098270, PMID:18516295, PMID:18521433, PMID:19426673, PMID:19815708, PMID:20106947, PMID:21742513, PMID:22302033, PMID:24126434, PMID:24525192, PMID:26091902, PMID:26884726, PMID:27664577, PMID:28987329, PMID:29027213, PMID:31433962 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp4 caspase 4 increases expression
multiple interactions
ISO Paclitaxel results in increased expression of CASP4 mRNA
[Paclitaxel co-treated with Metformin] results in increased expression of CASP4 mRNA
CTD PMID:18058816, PMID:29309887 NCBI chr 8:2,616,391...2,651,682
Ensembl chr 8:2,635,851...2,651,652
JBrowse link
G Casp7 caspase 7 increases activity
increases cleavage
multiple interactions
increases expression
ISO Paclitaxel results in increased activity of CASP7 protein
Paclitaxel results in increased cleavage of CASP7 protein
[Calcitriol co-treated with Curcumin] promotes the reaction [Paclitaxel results in increased expression of CASP7 protein]; [Doxorubicin co-treated with Paclitaxel co-treated with Fluorouracil] results in increased activity of CASP7 protein; [Resveratrol co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of CASP7 protein; [Sirolimus co-treated with Paclitaxel] results in increased cleavage of CASP7 protein; Calcitriol inhibits the reaction [Curcumin inhibits the reaction [Paclitaxel results in increased expression of CASP7 protein]]; Calcitriol inhibits the reaction [Paclitaxel results in increased expression of CASP7 protein]; Curcumin inhibits the reaction [Calcitriol inhibits the reaction [Paclitaxel results in increased expression of CASP7 protein]]; Curcumin inhibits the reaction [Paclitaxel results in increased expression of CASP7 protein]; palbociclib inhibits the reaction [Paclitaxel results in increased activity of CASP7 protein]
Paclitaxel results in increased expression of CASP7 mRNA; Paclitaxel results in increased expression of CASP7 protein
CTD PMID:14749477, PMID:15753396, PMID:16168113, PMID:18058816, PMID:22302033, PMID:27664577, PMID:31433962, PMID:31628941 NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
JBrowse link
G Casp8 caspase 8 multiple interactions
increases expression
increases cleavage
increases activity
ISO [Doxorubicin co-treated with Paclitaxel co-treated with Fluorouracil] results in increased activity of CASP8 protein; [Doxorubicin co-treated with Paclitaxel] results in increased activity of CASP8 protein; [esculetin co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of CASP8 protein; [Luteolin co-treated with Paclitaxel] results in increased cleavage of CASP8 protein; [Paclitaxel co-treated with Metformin] results in increased expression of CASP8 mRNA; [Resveratrol co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of CASP8 protein; [Tretinoin co-treated with Paclitaxel] results in increased cleavage of CASP8 protein; [TYMP mutant form co-treated with Paclitaxel] results in increased cleavage of CASP8 protein; Paclitaxel promotes the reaction [NSC 74859 results in decreased expression of CASP8 protein]
Paclitaxel results in increased expression of CASP8 mRNA
Paclitaxel results in increased expression of CASP8 mRNA; Paclitaxel results in increased expression of CASP8 protein
Paclitaxel results in increased cleavage of CASP8 protein
Paclitaxel results in increased activity of CASP8 protein
CTD PMID:11716366, PMID:14749477, PMID:15492279, PMID:15907983, PMID:16051289, PMID:16168113, PMID:18058816, PMID:18071906, PMID:18098270, PMID:24126434, PMID:24525192, PMID:26091902, PMID:29309887 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
JBrowse link
G Casp9 caspase 9 multiple interactions
increases activity
increases expression
affects response to substance
ISO [4-(6-cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide co-treated with Paclitaxel] results in increased activity of CASP9 protein; [6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine co-treated with Paclitaxel] results in increased activity of CASP9 protein; [benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone results in decreased activity of CASP9 protein] affects the reaction [SOD2 protein results in decreased susceptibility to Paclitaxel]; [benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone results in decreased activity of CASP9 protein] which results in decreased susceptibility to Paclitaxel; [Calcitriol co-treated with Paclitaxel] results in increased expression of CASP9 protein; [Curcumin co-treated with Calcitriol] promotes the reaction [Paclitaxel results in increased expression of CASP9 protein]; [Doxorubicin co-treated with Paclitaxel] results in increased activity of CASP9 protein; [Paclitaxel co-treated with Calcitriol] promotes the reaction [Curcumin results in increased expression of CASP9 protein]; [Paclitaxel co-treated with Curcumin] promotes the reaction [Calcitriol results in increased expression of CASP9 protein]; [Resveratrol co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of CASP9 protein; [Sirolimus co-treated with Paclitaxel] results in increased cleavage of CASP9 protein; [Tretinoin co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of CASP9 protein; Calcitriol inhibits the reaction [Paclitaxel results in increased expression of CASP9 protein]; Curcumin promotes the reaction [[Calcitriol co-treated with Paclitaxel] results in increased expression of CASP9 protein]; Fluorouracil promotes the reaction [[Doxorubicin co-treated with Paclitaxel] results in increased activity of CASP9 protein]; Paclitaxel promotes the reaction [Curcumin results in increased expression of CASP9 protein]; Paclitaxel results in increased cleavage of and results in increased activity of CASP9 protein
CASP9 protein affects the reaction [Paclitaxel results in increased activity of and results in increased cleavage of CASP3 protein]
Paclitaxel results in increased activity of CASP9 protein
Paclitaxel results in increased expression of CASP9 mRNA; Paclitaxel results in increased expression of CASP9 protein
CASP9 protein affects the susceptibility to Paclitaxel
CTD PMID:14749477, PMID:15753396, PMID:15907983, PMID:16168113, PMID:16170024, PMID:17652622, PMID:17701358, PMID:18058816, PMID:18098270, PMID:18594523, PMID:24126434, PMID:31628941 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Cat catalase affects response to substance
increases response to substance
ISO CAT protein affects the susceptibility to Paclitaxel
CAT results in increased susceptibility to Paclitaxel
CTD PMID:16217747, PMID:21689642 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Cav1 caveolin 1 increases response to substance ISO CAV1 mRNA results in increased susceptibility to Paclitaxel CTD PMID:16322897 NCBI chr 4:44,597,123...44,630,206
Ensembl chr 4:44,597,123...44,630,200
JBrowse link
G Ccar1 cell division cycle and apoptosis regulator 1 increases expression ISO Paclitaxel results in increased expression of CCAR1 mRNA CTD PMID:18058816 NCBI chr20:32,373,443...32,416,044
Ensembl chr20:32,373,443...32,416,044
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 increases response to substance ISO CCL2 results in increased susceptibility to Paclitaxel CTD PMID:21187454 NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
JBrowse link
G Ccn1 cellular communication network factor 1 increases response to substance ISO CCN1 protein results in increased susceptibility to Paclitaxel CTD PMID:16734730 NCBI chr 2:251,529,354...251,532,312
Ensembl chr 2:251,529,354...251,532,312
JBrowse link
G Ccn2 cellular communication network factor 2 multiple interactions ISO [Cisplatin co-treated with Paclitaxel] affects the expression of CCN2 mRNA CTD PMID:20705681 NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
JBrowse link
G Ccnb1 cyclin B1 increases response to substance
affects expression
multiple interactions
increases expression
ISO CCNB1 protein results in increased susceptibility to Paclitaxel
Paclitaxel affects the expression of CCNB1 protein
4-(4-(N-benzoylamino)anilino)-6-methoxy-7-(3-(1-morpholino)propoxy)quinazoline inhibits the reaction [Paclitaxel results in increased expression of CCNB1 protein]; [Paclitaxel co-treated with Metformin] results in decreased expression of CCNB1 mRNA; [pifithrin co-treated with Paclitaxel] results in increased expression of CCNB1 protein; alvocidib inhibits the reaction [Paclitaxel results in increased expression of CCNB1 protein]; CDK7 protein affects the reaction [Paclitaxel results in increased activity of [CDK2 protein binds to CCNB1 protein]]; Paclitaxel results in increased activity of [CDK2 protein binds to CCNB1 protein]; Paclitaxel results in increased expression of and results in increased activity of CCNB1 protein
CTD PMID:10430095, PMID:14646529, PMID:16356831, PMID:16849574, PMID:18516295, PMID:24748653, PMID:27378817, PMID:27769712, PMID:29309887 NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
JBrowse link
G Ccnb2 cyclin B2 affects response to substance
multiple interactions
ISO CCNB2 protein affects the susceptibility to Paclitaxel
[Paclitaxel co-treated with Metformin] results in decreased expression of CCNB2 mRNA
CTD PMID:16217747, PMID:29309887 NCBI chr 8:76,847,972...76,861,165 JBrowse link
G Ccnc cyclin C multiple interactions ISO [Paclitaxel co-treated with Metformin] results in decreased expression of CCNC mRNA CTD PMID:29309887 NCBI chr 5:35,865,598...35,883,732
Ensembl chr 5:35,865,605...35,883,706
JBrowse link
G Ccnd1 cyclin D1 multiple interactions
decreases expression
ISO [Paclitaxel co-treated with Metformin] results in decreased expression of CCND1 mRNA; Curcumin inhibits the reaction [Paclitaxel results in increased expression of CCND1 protein]
Paclitaxel results in decreased expression of CCND1 mRNA
CTD PMID:16243823, PMID:26091902, PMID:29309887 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Ccnd2 cyclin D2 multiple interactions ISO [Paclitaxel co-treated with Metformin] results in decreased expression of CCND2 mRNA CTD PMID:29309887 NCBI chr 4:159,674,885...159,697,207
Ensembl chr 4:159,674,885...159,697,207
JBrowse link
G Ccne1 cyclin E1 multiple interactions ISO [Paclitaxel co-treated with Metformin] results in decreased expression of CCNE1 mRNA CTD PMID:29309887 NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
JBrowse link
G Ccne2 cyclin E2 decreases expression ISO Paclitaxel results in decreased expression of CCNE2 mRNA CTD PMID:12929121, PMID:15000894 NCBI chr 5:24,434,077...24,446,406
Ensembl chr 5:24,434,872...24,446,406
JBrowse link
G Ccnf cyclin F multiple interactions ISO [Paclitaxel co-treated with Metformin] results in decreased expression of CCNF mRNA CTD PMID:29309887 NCBI chr10:13,594,687...13,619,935
Ensembl chr10:13,594,687...13,619,935
JBrowse link
G Ccng1 cyclin G1 multiple interactions ISO [Paclitaxel co-treated with Metformin] results in decreased expression of CCNG1 mRNA CTD PMID:29309887 NCBI chr10:25,903,925...25,910,298
Ensembl chr10:25,903,911...25,910,325
JBrowse link
G Ccng2 cyclin G2 increases expression
multiple interactions
ISO Paclitaxel results in increased expression of CCNG2 mRNA
[Paclitaxel co-treated with Metformin] results in decreased expression of CCNG2 mRNA
CTD PMID:12929121, PMID:29309887 NCBI chr14:16,267,572...16,276,068
Ensembl chr14:16,267,573...16,276,068
JBrowse link
G Ccnh cyclin H increases expression ISO Paclitaxel results in increased expression of CCNH protein CTD PMID:15907983 NCBI chr 2:13,593,100...13,613,910
Ensembl chr 2:13,593,100...13,613,910
JBrowse link
G Cd14 CD14 molecule multiple interactions
increases expression
affects response to substance
ISO
EXP
CD14 protein affects the reaction [Paclitaxel results in increased expression of IL12A mRNA]; CD14 protein affects the reaction [Paclitaxel results in increased expression of IL12B mRNA]; CD14 protein affects the reaction [Paclitaxel results in increased expression of PTGS2 mRNA]; CD14 protein affects the reaction [Paclitaxel results in increased phosphorylation of MAPK1 protein]; CD14 protein affects the reaction [Paclitaxel results in increased phosphorylation of MAPK3 protein]; CD14 protein affects the reaction [Paclitaxel results in increased phosphorylation of MAPK8 protein]
Paclitaxel results in increased expression of CD14 mRNA
CD14 protein affects the susceptibility to Paclitaxel
CTD PMID:11123339, PMID:11581577, PMID:18754875 NCBI chr18:29,560,341...29,562,290
Ensembl chr18:29,560,365...29,562,153
JBrowse link
G Cd163 CD163 molecule increases expression EXP Paclitaxel results in increased expression of CD163 mRNA CTD PMID:18754875 NCBI chr 4:156,752,063...156,785,467
Ensembl chr 4:156,752,082...156,785,467
JBrowse link
G Cd24 CD24 molecule decreases expression ISO Paclitaxel results in decreased expression of CD24 mRNA CTD PMID:19682730 NCBI chr20:48,335,540...48,340,847
Ensembl chr20:48,335,540...48,340,846
JBrowse link
G Cd274 CD274 molecule increases expression ISO Paclitaxel results in increased expression of CD274 protein CTD PMID:17920123 NCBI chr 1:247,519,890...247,539,659
Ensembl chr 1:247,519,939...247,537,943
JBrowse link
G Cd36 CD36 molecule increases expression EXP Paclitaxel analog results in increased expression of CD36 mRNA CTD PMID:15585946 NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
JBrowse link
G Cd40lg CD40 ligand multiple interactions
decreases response to substance
ISO [Paclitaxel co-treated with Metformin] results in decreased expression of CD40LG mRNA; CD40LG protein inhibits the reaction [Paclitaxel promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]]
CD40LG protein results in decreased susceptibility to Paclitaxel
CTD PMID:16545138, PMID:29309887 NCBI chr  X:159,703,703...159,714,886
Ensembl chr  X:159,703,578...159,716,562
JBrowse link
G Cd46 CD46 molecule increases response to substance ISO CD46 mRNA results in increased susceptibility to Paclitaxel CTD PMID:16322897 NCBI chr13:113,786,525...113,818,741
Ensembl chr13:113,787,349...113,817,995
JBrowse link
G Cd47 Cd47 molecule decreases response to substance ISO CD47 mRNA results in decreased susceptibility to Paclitaxel CTD PMID:16322897 NCBI chr11:53,511,485...53,575,754
Ensembl chr11:53,514,595...53,575,175
JBrowse link
G Cd68 Cd68 molecule increases expression EXP Paclitaxel results in increased expression of CD68 protein CTD PMID:16854522 NCBI chr10:56,268,726...56,270,605
Ensembl chr10:56,268,720...56,270,640
JBrowse link
G Cda cytidine deaminase affects response to substance ISO CDA protein affects the susceptibility to Paclitaxel CTD PMID:18728667 NCBI chr 5:156,703,579...156,734,541
Ensembl chr 5:156,703,579...156,734,541
JBrowse link
G Cdc14b cell division cycle 14B decreases expression ISO Paclitaxel results in decreased expression of CDC14B mRNA CTD PMID:18058816 NCBI chr17:1,709,703...1,797,732
Ensembl chr17:1,703,943...1,797,750
JBrowse link
G Cdc16 cell division cycle 16 multiple interactions ISO [Paclitaxel co-treated with Metformin] results in decreased expression of CDC16 mRNA CTD PMID:29309887 NCBI chr16:81,493,355...81,516,493
Ensembl chr16:81,493,355...81,516,493
JBrowse link
G Cdc20 cell division cycle 20 multiple interactions ISO [Arsenic Trioxide co-treated with Paclitaxel] promotes the reaction [BUB1B protein binds to CDC20 protein]; [Paclitaxel co-treated with Metformin] results in decreased expression of CDC20 mRNA CTD PMID:19781537, PMID:29309887 NCBI chr 5:137,260,728...137,264,931
Ensembl chr 5:137,260,739...137,265,015
JBrowse link
G Cdc25a cell division cycle 25A increases expression
multiple interactions
ISO Paclitaxel results in increased expression of CDC25A mRNA
[Paclitaxel co-treated with Metformin] results in decreased expression of CDC25A mRNA
CTD PMID:12929121, PMID:29309887 NCBI chr 8:117,953,223...117,971,552
Ensembl chr 8:117,953,444...117,971,519
JBrowse link
G Cdc25c cell division cycle 25C multiple interactions
decreases expression
ISO [arsenic trioxide co-treated with Paclitaxel] results in increased expression of CDC25C protein modified form; [pifithrin co-treated with Paclitaxel] results in increased phosphorylation of CDC25C protein
Paclitaxel results in decreased expression of CDC25C mRNA
CTD PMID:18058816, PMID:18516295, PMID:19781537 NCBI chr18:27,528,768...27,550,316
Ensembl chr18:27,528,354...27,550,224
JBrowse link
G Cdc27 cell division cycle 27 multiple interactions ISO [arsenic trioxide co-treated with Paclitaxel] results in increased expression of CDC27 protein modified form CTD PMID:19781537 NCBI chr10:92,551,754...92,602,214
Ensembl chr10:92,554,081...92,602,082
JBrowse link
G Cdc34 cell division cycle 34, ubiqiutin conjugating enzyme multiple interactions ISO [Paclitaxel co-treated with Metformin] results in decreased expression of CDC34 mRNA CTD PMID:29309887 NCBI chr 7:12,899,957...12,905,339
Ensembl chr 7:12,899,958...12,905,339
JBrowse link
G Cdc5l cell division cycle 5-like decreases expression ISO Paclitaxel results in decreased expression of CDC5L mRNA CTD PMID:18058816 NCBI chr 9:17,949,764...17,988,514
Ensembl chr 9:17,949,764...17,988,509
JBrowse link
G Cdc73 cell division cycle 73 decreases expression ISO Paclitaxel results in decreased expression of CDC73 mRNA CTD PMID:18058816 NCBI chr13:60,403,771...60,496,511
Ensembl chr13:60,403,771...60,496,511
JBrowse link
G Cdca7 cell division cycle associated 7 decreases expression ISO Paclitaxel results in decreased expression of CDCA7 mRNA CTD PMID:18058816 NCBI chr 3:59,153,281...59,163,916
Ensembl chr 3:59,153,280...59,163,913
JBrowse link
G Cdh11 cadherin 11 increases expression ISO Paclitaxel results in increased expression of CDH11 mRNA CTD PMID:19682730 NCBI chr19:2,391,181...2,551,245
Ensembl chr19:2,393,059...2,551,245
JBrowse link
G Cdk1 cyclin-dependent kinase 1 multiple interactions
decreases expression
increases activity
ISO [Arsenic Trioxide co-treated with Paclitaxel] results in increased activity of CDK1 protein; [Arsenic Trioxide co-treated with Paclitaxel] results in increased expression of CDK1 protein modified form; [Paclitaxel co-treated with Metformin] results in decreased expression of CDK1 mRNA; [pifithrin co-treated with Paclitaxel] results in decreased phosphorylation of CDK1 protein; bryostatin 1 inhibits the reaction [Paclitaxel results in increased activity of CDK1 protein]
Paclitaxel results in decreased expression of CDK1 mRNA
CTD PMID:10516758, PMID:18058816, PMID:18516295, PMID:19781537, PMID:29309887 NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
JBrowse link
G Cdk16 cyclin-dependent kinase 16 increases expression EXP Paclitaxel analog results in increased expression of CDK16 mRNA; Paclitaxel results in increased expression of CDK16 mRNA CTD PMID:15585946 NCBI chr  X:1,707,285...1,718,821
Ensembl chr  X:1,707,289...1,718,637
JBrowse link
G Cdk2 cyclin dependent kinase 2 multiple interactions
increases activity
ISO [Paclitaxel co-treated with Metformin] results in decreased expression of CDK2 mRNA; alvocidib inhibits the reaction [Paclitaxel results in increased activity of CDK2 protein]; CDK7 protein affects the reaction [Paclitaxel results in increased activity of [CDK2 protein binds to CCNB1 protein]]; Paclitaxel results in increased activity of [CDK2 protein binds to CCNB1 protein] CTD PMID:10430095, PMID:14646529, PMID:29309887 NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
JBrowse link
G Cdk20 cyclin-dependent kinase 20 decreases expression ISO Paclitaxel results in decreased expression of CDK20 mRNA CTD PMID:18058816 NCBI chr17:1,935,900...1,942,867
Ensembl chr17:1,936,163...1,942,865
JBrowse link
G Cdk4 cyclin-dependent kinase 4 multiple interactions ISO [Paclitaxel co-treated with Metformin] results in decreased expression of CDK4 mRNA CTD PMID:29309887 NCBI chr 7:70,345,971...70,352,689
Ensembl chr 7:70,349,863...70,352,418
JBrowse link
G Cdk5r1 cyclin-dependent kinase 5 regulatory subunit 1 multiple interactions ISO [Paclitaxel co-treated with Metformin] results in decreased expression of CDK5R1 mRNA CTD PMID:29309887 NCBI chr10:67,862,054...67,863,255
Ensembl chr10:67,862,054...67,863,255
JBrowse link
G Cdk7 cyclin-dependent kinase 7 multiple interactions
increases activity
ISO [Paclitaxel co-treated with Metformin] results in decreased expression of CDK7 mRNA; CDK7 protein affects the reaction [Paclitaxel results in increased activity of [CDK2 protein binds to CCNB1 protein]]
Paclitaxel results in increased activity of CDK7 protein
CTD PMID:14646529, PMID:29309887 NCBI chr 2:30,710,642...30,735,522
Ensembl chr 2:30,710,643...30,735,514
JBrowse link
G Cdk8 cyclin-dependent kinase 8 multiple interactions ISO [Paclitaxel co-treated with Metformin] results in decreased expression of CDK8 mRNA CTD PMID:29309887 NCBI chr12:10,496,273...10,561,335 JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A decreases expression
increases expression
multiple interactions
ISO Paclitaxel results in decreased expression of CDKN1A mRNA
Paclitaxel results in increased expression of CDKN1A mRNA; Paclitaxel results in increased expression of CDKN1A protein
[Cisplatin co-treated with Paclitaxel] results in increased expression of CDKN1A mRNA; [Doxorubicin co-treated with Paclitaxel] results in increased expression of CDKN1A protein; [PD168393 co-treated with Paclitaxel] results in increased expression of CDKN1A protein; Fluorouracil promotes the reaction [[Doxorubicin co-treated with Paclitaxel] results in increased expression of CDKN1A protein]; Nicotine inhibits the reaction [Paclitaxel results in increased expression of CDKN1A protein]; pifithrin inhibits the reaction [Paclitaxel results in increased expression of CDKN1A protein]
[Paclitaxel results in increased expression of TP53 protein] which results in increased expression of CDKN1A mRNA; Paclitaxel results in increased expression of CDKN1A protein
CTD PMID:9041188, PMID:9231689, PMID:12929121, PMID:16168113, PMID:16413505, PMID:16601104, PMID:18516295, PMID:20705681, PMID:24211769 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions ISO [Paclitaxel co-treated with Metformin] results in increased expression of CDKN1B mRNA CTD PMID:29309887 NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
JBrowse link
G Cdkn2c cyclin-dependent kinase inhibitor 2C affects response to substance ISO CDKN2C protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 5:129,347,731...129,352,886
Ensembl chr 5:129,347,732...129,352,886
JBrowse link
G Ceacam1 CEA cell adhesion molecule 1 multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in increased expression of CEACAM1 mRNA CTD PMID:20705681 NCBI chr 1:82,327,955...82,344,345
Ensembl chr 1:82,327,955...82,344,345
JBrowse link
G Cebpd CCAAT/enhancer binding protein delta increases expression EXP Paclitaxel results in increased expression of CEBPD mRNA CTD PMID:18754875 NCBI chr11:89,008,008...89,009,146
Ensembl chr11:89,008,008...89,009,146
JBrowse link
G Cenpf centromere protein F multiple interactions
increases expression
ISO Lovastatin promotes the reaction [Paclitaxel results in increased expression of CENPF protein]; Mevalonic Acid inhibits the reaction [Paclitaxel results in increased expression of CENPF protein] CTD PMID:12467231 NCBI chr13:108,132,499...108,178,609
Ensembl chr13:108,132,499...108,178,609
JBrowse link
G Cenps centromere protein S increases expression ISO Paclitaxel results in increased expression of CENPS mRNA CTD PMID:18058816 NCBI chr 5:165,946,106...165,955,723 JBrowse link
G Cfb complement factor B increases expression EXP Paclitaxel results in increased expression of CFB mRNA CTD PMID:18754875 NCBI chr20:4,536,206...4,542,073
Ensembl chr20:4,536,203...4,561,066
Ensembl chr20:4,536,203...4,561,066
JBrowse link
G Cfd complement factor D increases expression EXP Paclitaxel results in increased expression of CFD mRNA CTD PMID:18754875 NCBI chr 7:12,634,216...12,635,939
Ensembl chr 7:12,634,216...12,635,943
JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator decreases response to substance ISO CFLAR protein results in decreased susceptibility to Paclitaxel CTD PMID:16080463 NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
JBrowse link
G Chchd3 coiled-coil-helix-coiled-coil-helix domain containing 3 decreases expression ISO Paclitaxel results in decreased expression of CHCHD3 mRNA CTD PMID:12929121 NCBI chr 4:60,080,536...60,358,592
Ensembl chr 4:60,080,538...60,358,562
JBrowse link
G Chek1 checkpoint kinase 1 decreases expression
multiple interactions
ISO Paclitaxel results in decreased expression of CHEK1 mRNA
[Paclitaxel co-treated with Metformin] results in decreased expression of CHEK1 mRNA
CTD PMID:12929121, PMID:29309887 NCBI chr 8:39,181,162...39,201,588
Ensembl chr 8:39,181,163...39,243,882
JBrowse link
G Chek2 checkpoint kinase 2 multiple interactions ISO [Paclitaxel co-treated with Metformin] results in decreased expression of CHEK2 mRNA CTD PMID:29309887 NCBI chr12:51,845,574...51,878,098
Ensembl chr12:51,845,796...51,877,624
JBrowse link
G Chfr checkpoint with forkhead and ring finger domains affects response to substance
decreases response to substance
ISO CHFR protein modified form affects the susceptibility to Paclitaxel
CHFR protein results in decreased susceptibility to Paclitaxel
CTD PMID:17786301 NCBI chr12:52,562,594...52,596,162
Ensembl chr12:52,562,597...52,596,076
JBrowse link
G Chi3l1 chitinase 3 like 1 increases expression EXP Paclitaxel results in increased expression of CHI3L1 mRNA CTD PMID:18754875 NCBI chr13:51,022,844...51,030,797
Ensembl chr13:51,022,681...51,030,802
JBrowse link
G Cideb cell death-inducing DFFA-like effector b decreases expression ISO Paclitaxel results in decreased expression of CIDEB mRNA CTD PMID:12929121 NCBI chr15:34,439,844...34,444,244
Ensembl chr15:34,439,876...34,444,244
JBrowse link
G Cldn3 claudin 3 decreases response to substance ISO CLDN3 protein results in decreased susceptibility to Paclitaxel CTD PMID:16734730 NCBI chr12:21,831,341...21,832,813
Ensembl chr12:21,831,342...21,832,813
JBrowse link
G Clec10a C-type lectin domain containing 10A increases expression EXP Paclitaxel results in increased expression of CLEC10A mRNA CTD PMID:18754875 NCBI chr10:56,764,927...56,769,447
Ensembl chr10:56,764,927...56,769,457
JBrowse link
G Clec11a C-type lectin domain containing 11A increases expression ISO Paclitaxel results in increased expression of CLEC11A mRNA CTD PMID:19682730 NCBI chr 1:100,290,374...100,293,515
Ensembl chr 1:100,289,295...100,293,558
JBrowse link
G Clpx caseinolytic mitochondrial matrix peptidase chaperone subunit X increases expression ISO Paclitaxel results in increased expression of CLPX protein CTD PMID:15907983 NCBI chr 8:70,789,137...70,843,133
Ensembl chr 8:70,789,256...70,843,123
JBrowse link
G Clu clusterin decreases response to substance ISO CLU protein results in decreased susceptibility to Paclitaxel CTD PMID:15955107, PMID:16308731 NCBI chr15:42,626,612...42,665,858
Ensembl chr15:42,640,146...42,665,857
JBrowse link
G Cnr2 cannabinoid receptor 2 multiple interactions EXP [1-((3-benzyl-3-methyl-2,3-dihydro-1-benzofuran-6-yl)carbonyl)piperidine binds to and results in increased activity of CNR2 protein] which results in decreased susceptibility to Paclitaxel; [3-(1,1-dimethyl-heptyl)-1-9-dihydroxy-benzo(c)chromen-6-one binds to and results in increased activity of CNR2 protein] which results in decreased susceptibility to Paclitaxel; [AM 1241 binds to and results in increased activity of CNR2 protein] which results in decreased susceptibility to Paclitaxel; iodopravadoline inhibits the reaction [[1-((3-benzyl-3-methyl-2,3-dihydro-1-benzofuran-6-yl)carbonyl)piperidine binds to and results in increased activity of CNR2 protein] which results in decreased susceptibility to Paclitaxel]; SR 144528 inhibits the reaction [[3-(1,1-dimethyl-heptyl)-1-9-dihydroxy-benzo(c)chromen-6-one binds to and results in increased activity of CNR2 protein] which results in decreased susceptibility to Paclitaxel]; SR 144528 inhibits the reaction [[AM 1241 binds to and results in increased activity of CNR2 protein] which results in decreased susceptibility to Paclitaxel] CTD PMID:18664590, PMID:18846037 NCBI chr 5:154,242,010...154,268,126
Ensembl chr 5:154,260,062...154,268,126
JBrowse link
G Coch cochlin increases expression EXP Paclitaxel results in increased expression of COCH mRNA CTD PMID:18754875 NCBI chr 6:72,359,702...72,373,710
Ensembl chr 6:72,359,791...72,373,695
JBrowse link
G Col11a2 collagen type XI alpha 2 chain multiple interactions ISO [Cisplatin co-treated with Paclitaxel] affects the expression of COL11A2 mRNA CTD PMID:20705681 NCBI chr20:3,829,324...3,859,022
Ensembl chr20:3,830,164...3,859,018
JBrowse link
G Col15a1 collagen type XV alpha 1 chain decreases response to substance ISO COL15A1 mRNA results in decreased susceptibility to Paclitaxel CTD PMID:25199881 NCBI chr 5:62,840,360...62,950,240 JBrowse link
G Col17a1 collagen type XVII alpha 1 chain multiple interactions ISO [Cisplatin co-treated with Paclitaxel] affects the expression of COL17A1 mRNA CTD PMID:20705681 NCBI chr 1:267,416,681...267,465,049
Ensembl chr 1:267,417,459...267,463,705
JBrowse link
G Col18a1 collagen type XVIII alpha 1 chain increases expression ISO Paclitaxel results in increased expression of COL18A1 mRNA CTD PMID:19682730 NCBI chr20:12,225,202...12,332,858
Ensembl chr20:12,225,202...12,332,858
JBrowse link
G Col1a1 collagen type I alpha 1 chain increases expression ISO Paclitaxel results in increased expression of COL1A1 mRNA CTD PMID:19682730 NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
JBrowse link
G Col1a2 collagen type I alpha 2 chain increases response to substance
increases expression
ISO COL1A2 mRNA results in increased susceptibility to Paclitaxel
Paclitaxel results in increased expression of COL1A2 mRNA
CTD PMID:19682730, PMID:25199881 NCBI chr 4:31,534,225...31,569,152
Ensembl chr 4:31,534,225...31,569,151
JBrowse link
G Col20a1 collagen type XX alpha 1 chain multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in increased expression of COL20A1 mRNA CTD PMID:20705681 NCBI chr 3:176,491,292...176,526,009
Ensembl chr 3:176,494,768...176,526,018
JBrowse link
G Col3a1 collagen type III alpha 1 chain multiple interactions
decreases response to substance
ISO [Cisplatin co-treated with Paclitaxel] affects the expression of COL3A1 mRNA
COL3A1 mRNA results in decreased susceptibility to Paclitaxel
CTD PMID:20705681, PMID:25199881 NCBI chr 9:52,023,295...52,059,221
Ensembl chr 9:52,023,295...52,059,217
JBrowse link
G Col4a1 collagen type IV alpha 1 chain increases expression ISO Paclitaxel results in increased expression of COL4A1 mRNA CTD PMID:19682730 NCBI chr16:83,522,162...83,632,153
Ensembl chr16:83,522,162...83,632,153
JBrowse link
G Col4a2 collagen type IV alpha 2 chain multiple interactions
increases expression
ISO [Cisplatin co-treated with Paclitaxel] results in decreased expression of COL4A2 mRNA
Paclitaxel results in increased expression of COL4A2 mRNA
CTD PMID:19682730, PMID:20705681 NCBI chr16:83,386,388...83,522,169
Ensembl chr16:83,387,364...83,438,561
JBrowse link
G Col5a2 collagen type V alpha 2 chain decreases response to substance ISO COL5A2 mRNA results in decreased susceptibility to Paclitaxel CTD PMID:25199881 NCBI chr 9:52,091,088...52,238,735
Ensembl chr 9:52,092,511...52,238,564
JBrowse link
G Col6a1 collagen type VI alpha 1 chain increases expression ISO Paclitaxel results in increased expression of COL6A1 mRNA CTD PMID:19682730 NCBI chr20:12,657,913...12,676,370
Ensembl chr20:12,658,065...12,675,561
JBrowse link
G Col6a2 collagen type VI alpha 2 chain increases expression ISO Paclitaxel results in increased expression of COL6A2 mRNA CTD PMID:19682730 NCBI chr20:12,773,472...12,801,179
Ensembl chr20:12,773,427...12,801,180
JBrowse link
G Col6a3 collagen type VI alpha 3 chain affects response to substance ISO COL6A3 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 9:97,926,784...98,004,643
Ensembl chr 9:97,926,787...98,004,546
JBrowse link
G Col7a1 collagen type VII alpha 1 chain increases response to substance ISO COL7A1 protein results in increased susceptibility to Paclitaxel CTD PMID:16734730 NCBI chr 8:117,694,441...117,726,844
Ensembl chr 8:117,694,605...117,726,844
JBrowse link
G Cope COPI coat complex subunit epsilon affects response to substance ISO COPE protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr16:20,863,141...20,873,516
Ensembl chr16:20,863,141...20,873,521
JBrowse link
G Cox15 cytochrome c oxidase assembly homolog COX15 decreases expression ISO Paclitaxel results in decreased expression of COX15 mRNA CTD PMID:15000894 NCBI chr 1:263,494,850...263,511,510
Ensembl chr 1:263,494,852...263,511,505
JBrowse link
G Cox17 cytochrome c oxidase copper chaperone COX17 affects response to substance ISO COX17 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr11:64,962,663...64,968,437
Ensembl chr11:64,962,666...64,968,437
JBrowse link
G Cp ceruloplasmin increases expression EXP Paclitaxel results in increased expression of CP mRNA CTD PMID:18754875 NCBI chr 2:104,744,249...104,803,034
Ensembl chr 2:104,744,461...104,799,853
JBrowse link
G Cpt1a carnitine palmitoyltransferase 1A decreases expression ISO Paclitaxel results in decreased expression of CPT1A protein CTD PMID:30667213 NCBI chr 1:218,568,157...218,629,679
Ensembl chr 1:218,569,510...218,629,678
JBrowse link
G Cpt2 carnitine palmitoyltransferase 2 decreases expression ISO Paclitaxel results in decreased expression of CPT2 protein CTD PMID:30667213 NCBI chr 5:127,505,646...127,523,016
Ensembl chr 5:127,505,614...127,523,089
JBrowse link
G Creg1 cellular repressor of E1A-stimulated genes 1 affects response to substance ISO CREG1 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr13:83,972,186...83,984,675
Ensembl chr13:83,972,212...83,984,675
JBrowse link
G Csf3 colony stimulating factor 3 multiple interactions ISO [CSF3 protein co-treated with Paclitaxel] results in decreased abundance of Choline; [CSF3 protein co-treated with Paclitaxel] results in decreased abundance of Creatine; [CSF3 protein co-treated with Paclitaxel] results in decreased abundance of Inositol CTD PMID:9018096 NCBI chr10:86,616,785...86,619,160
Ensembl chr10:86,616,785...86,619,157
JBrowse link
G Ctbp1 C-terminal binding protein 1 multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in decreased expression of CTBP1 mRNA CTD PMID:20705681 NCBI chr14:82,762,109...82,789,350
Ensembl chr14:82,762,190...82,789,319
JBrowse link
G Ctcf CCCTC-binding factor decreases response to substance ISO CTCF mRNA results in decreased susceptibility to Paclitaxel CTD PMID:16322897 NCBI chr19:37,600,151...37,649,674
Ensembl chr19:37,600,148...37,649,673
JBrowse link
G Ctnnb1 catenin beta 1 decreases response to substance
decreases phosphorylation
ISO CTNNB1 results in decreased susceptibility to Paclitaxel
Paclitaxel results in decreased phosphorylation of CTNNB1 protein
CTD PMID:22000491, PMID:23956100 NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
JBrowse link
G Ctnnd2 catenin delta 2 multiple interactions ISO CTNND2 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] CTD PMID:16896004 NCBI chr 2:83,227,247...84,094,315
Ensembl chr 2:83,393,282...84,094,315
JBrowse link
G Ctse cathepsin E increases expression EXP Paclitaxel analog results in increased expression of CTSE mRNA; Paclitaxel results in increased expression of CTSE mRNA CTD PMID:15585946 NCBI chr13:48,426,833...48,449,493
Ensembl chr13:48,426,820...48,449,490
JBrowse link
G Ctsk cathepsin K increases expression EXP Paclitaxel analog results in increased expression of CTSK mRNA; Paclitaxel results in increased expression of CTSK mRNA CTD PMID:15585946 NCBI chr 2:196,655,469...196,666,447
Ensembl chr 2:196,655,469...196,666,446
JBrowse link
G Ctsl cathepsin L increases response to substance
decreases response to substance
ISO CTSL mRNA results in increased susceptibility to Paclitaxel
CTSL protein results in decreased susceptibility to Paclitaxel
CTD PMID:16322897, PMID:31370861 NCBI chr17:1,873,105...1,879,266
Ensembl chr17:1,872,848...1,879,279
JBrowse link
G Ctss cathepsin S increases expression EXP Paclitaxel results in increased expression of CTSS mRNA CTD PMID:18754875 NCBI chr 2:197,655,780...197,679,768
Ensembl chr 2:197,655,786...197,679,458
JBrowse link
G Cttn cortactin decreases expression ISO Paclitaxel results in decreased expression of CTTN protein CTD PMID:15907983 NCBI chr 1:217,602,698...217,638,196
NCBI chr 1:215,255,385...215,290,882
Ensembl chr 1:217,602,698...217,638,152
Ensembl chr 1:217,602,698...217,638,152
JBrowse link
G Cxcl1 C-X-C motif chemokine ligand 1 increases expression EXP Paclitaxel results in increased expression of CXCL1 mRNA CTD PMID:18754875 NCBI chr14:18,743,678...18,745,457
Ensembl chr14:18,743,685...18,745,457
JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 increases expression
multiple interactions
ISO Paclitaxel results in increased expression of CXCL10 mRNA
TLR4 protein affects the reaction [Paclitaxel results in increased expression of CXCL10 mRNA]
CTD PMID:11123339 NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
JBrowse link
G Cxcl14 C-X-C motif chemokine ligand 14 increases expression EXP Paclitaxel results in increased expression of CXCL14 mRNA CTD PMID:18754875 NCBI chr17:9,109,731...9,117,754
Ensembl chr17:9,109,731...9,117,750
JBrowse link
G Cxcr4 C-X-C motif chemokine receptor 4 multiple interactions
decreases response to substance
ISO [Cisplatin co-treated with Paclitaxel] results in increased expression of CXCR4 mRNA
CXCR4 mRNA results in decreased susceptibility to Paclitaxel
CTD PMID:16322897, PMID:20705681 NCBI chr13:45,314,952...45,318,856
Ensembl chr13:45,314,933...45,318,878
JBrowse link
G Cxcr6 C-X-C motif chemokine receptor 6 decreases response to substance ISO CXCR6 mRNA results in decreased susceptibility to Paclitaxel CTD PMID:16322897 NCBI chr 8:132,869,712...132,870,766
Ensembl chr 8:132,869,712...132,870,767
JBrowse link
G Cycs cytochrome c, somatic affects localization
multiple interactions
increases secretion
increases expression
ISO Paclitaxel affects the localization of CYCS protein
[esculetin co-treated with Paclitaxel] affects the localization of CYCS protein; [PD168393 co-treated with Paclitaxel] affects the localization of CYCS protein; [resveratrol co-treated with Paclitaxel] affects the localization of CYCS protein; [tipifarnib co-treated with Paclitaxel] affects the localization of CYCS protein
Paclitaxel results in increased secretion of CYCS protein
Paclitaxel results in increased expression of CYCS protein
CTD PMID:10516758, PMID:14749477, PMID:15728126, PMID:15907983, PMID:16051289, PMID:16413505, PMID:17404021, PMID:18521433 NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
JBrowse link
G Cyp19a1 cytochrome P450, family 19, subfamily a, polypeptide 1 increases activity ISO Paclitaxel results in increased activity of CYP19A1 protein CTD PMID:14691014 NCBI chr 8:58,744,849...58,772,408
Ensembl chr 8:58,744,849...58,772,408
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions ISO Paclitaxel inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] CTD PMID:11602686 NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 increases expression
decreases activity
EXP
ISO
Paclitaxel results in increased expression of CYP1A2 mRNA
Paclitaxel results in decreased activity of CYP1A2 protein
CTD PMID:15585946, PMID:19909766 NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
JBrowse link
G Cyp27b1 cytochrome P450, family 27, subfamily b, polypeptide 1 multiple interactions ISO [Paclitaxel co-treated with Metformin] results in increased expression of CYP27B1 mRNA CTD PMID:29309887 NCBI chr 7:70,333,150...70,340,006
Ensembl chr 7:70,335,061...70,340,005
JBrowse link
G Cyp2c12 cytochrome P450, family 2, subfamily c, polypeptide 12 increases expression EXP Paclitaxel analog results in increased expression of CYP2C12 mRNA CTD PMID:15585946 NCBI chr 1:258,709,726...258,766,873
Ensembl chr 1:258,709,721...258,766,881
JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 increases response to substance
affects response to substance
multiple interactions
increases oxidation
increases metabolic processing
increases hydroxylation
affects metabolic processing
ISO CYP2C8 mRNA results in increased susceptibility to Paclitaxel
CYP2C8 gene SNP affects the susceptibility to Paclitaxel
Cyclohexenes analog inhibits the reaction [CYP2C8 protein results in increased metabolism of Paclitaxel]; perfluorooctane sulfonic acid inhibits the reaction [CYP2C8 protein results in increased hydroxylation of Paclitaxel]; sitaxsentan inhibits the reaction [CYP2C8 protein results in increased metabolism of Paclitaxel]
CYP2C8 protein results in increased oxidation of Paclitaxel
CYP2C8 protein affects the metabolism of Paclitaxel
CTD PMID:12401345, PMID:12464242, PMID:15239142, PMID:15716363, PMID:15901749, PMID:15933212, PMID:16124035, PMID:17478480, PMID:17994679, PMID:19309152, PMID:20452209, PMID:21964418, PMID:23721565, PMID:27736846 NCBI chr 1:147,236,480...147,307,988 JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 decreases activity ISO Paclitaxel results in decreased activity of CYP2D6 protein CTD PMID:19909766 NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 decreases activity
multiple interactions
EXP Paclitaxel results in decreased activity of CYP2E1 protein
turmeric extract affects the reaction [Paclitaxel results in decreased activity of CYP2E1 protein]
CTD PMID:24882083 NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 increases expression
multiple interactions
EXP Paclitaxel results in increased expression of CYP3A4 protein
Plant Extracts inhibits the reaction [Paclitaxel results in increased expression of CYP3A4 protein]
CTD PMID:15918522 NCBI chr12:11,641,500...11,677,818
Ensembl chr12:11,655,402...11,733,136
JBrowse link
G Cyp4a1 cytochrome P450, family 4, subfamily a, polypeptide 1 increases expression EXP Paclitaxel results in increased expression of CYP4A22 mRNA CTD PMID:15585946 NCBI chr 5:134,492,734...134,507,158
Ensembl chr 5:134,492,756...134,507,154
JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 decreases expression EXP Paclitaxel results in decreased expression of CYP7A1 mRNA CTD PMID:15585946 NCBI chr 5:19,358,734...19,368,431
Ensembl chr 5:19,358,734...19,368,431
JBrowse link
G Dapk1 death associated protein kinase 1 multiple interactions ISO [Paclitaxel co-treated with Metformin] results in increased expression of DAPK1 mRNA CTD PMID:29309887 NCBI chr17:4,297,038...4,454,941
Ensembl chr17:4,297,224...4,454,778
JBrowse link
G Dbf4 DBF4 zinc finger decreases expression ISO Paclitaxel results in decreased expression of DBF4 mRNA CTD PMID:12929121 NCBI chr 4:22,898,527...22,914,091
Ensembl chr 4:22,898,527...22,914,177
JBrowse link
G Dcn decorin decreases response to substance ISO DCN mRNA results in decreased susceptibility to Paclitaxel CTD PMID:25199881 NCBI chr 7:38,742,250...38,782,282
Ensembl chr 7:38,742,051...38,782,323
JBrowse link
G Dctd dCMP deaminase affects response to substance ISO DCTD protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr16:47,177,144...47,222,850
Ensembl chr16:47,177,145...47,208,110
JBrowse link
G Ddx23 DEAD-box helicase 23 affects response to substance ISO DDX23 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 7:140,325,453...140,342,730
Ensembl chr 7:140,325,431...140,342,727
JBrowse link
G Dedd death effector domain-containing decreases expression ISO Paclitaxel results in decreased expression of DEDD mRNA CTD PMID:15000894 NCBI chr13:89,706,932...89,721,825
Ensembl chr13:89,718,066...89,721,454
JBrowse link
G Dffa DNA fragmentation factor subunit alpha decreases expression
multiple interactions
increases cleavage
ISO Paclitaxel results in decreased expression of DFFA protein
[Paclitaxel co-treated with Metformin] results in decreased expression of DFFA mRNA; [Tretinoin co-treated with Paclitaxel] results in increased cleavage of DFFA protein
Paclitaxel results in increased cleavage of DFFA protein
CTD PMID:15907983, PMID:17701358, PMID:18098270, PMID:29309887 NCBI chr 5:165,922,893...165,935,822
Ensembl chr 5:165,922,915...165,935,821
JBrowse link
G Dhcr24 24-dehydrocholesterol reductase affects response to substance ISO DHCR24 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 5:126,164,708...126,188,926
Ensembl chr 5:126,164,674...126,191,206
JBrowse link
G Dhcr7 7-dehydrocholesterol reductase multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in increased expression of DHCR7 mRNA CTD PMID:20705681 NCBI chr 1:217,018,916...217,034,890
Ensembl chr 1:217,018,916...217,034,904
JBrowse link
G Diablo diablo, IAP-binding mitochondrial protein affects localization
increases expression
multiple interactions
ISO Paclitaxel affects the localization of DIABLO protein
Paclitaxel results in increased expression of DIABLO protein
[resveratrol co-treated with Paclitaxel] affects the localization of DIABLO protein; [Tretinoin co-treated with Paclitaxel] affects the localization of DIABLO protein; [Tretinoin co-treated with Paclitaxel] results in increased expression of DIABLO protein
CTD PMID:14749477, PMID:17701358, PMID:18098270 NCBI chr12:38,490,230...38,503,344
Ensembl chr12:38,490,230...38,503,330
JBrowse link
G Dmtf1 cyclin D binding myb-like transcription factor 1 decreases expression ISO Paclitaxel results in decreased expression of DMTF1 mRNA CTD PMID:15000894 NCBI chr 4:21,862,297...21,902,798
Ensembl chr 4:21,862,313...21,902,762
JBrowse link
G Dnase1l3 deoxyribonuclease 1-like 3 decreases expression EXP Paclitaxel results in decreased expression of DNASE1L3 mRNA CTD PMID:15585946 NCBI chr15:18,710,492...18,736,476
Ensembl chr15:18,710,492...18,736,473
JBrowse link
G Dpyd dihydropyrimidine dehydrogenase affects expression
decreases expression
multiple interactions
ISO Paclitaxel affects the expression of DPYD mRNA
Paclitaxel results in decreased expression of DPYD mRNA
[Paclitaxel co-treated with doxifluridine] affects the expression of DPYD mRNA
CTD PMID:16568373, PMID:18630517 NCBI chr 2:221,823,692...222,694,627
Ensembl chr 2:221,823,687...222,694,627
JBrowse link
G Dsp desmoplakin affects response to substance ISO DSP protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr17:27,286,811...27,334,453
Ensembl chr17:27,286,796...27,334,379
JBrowse link
G Dst dystonin multiple interactions ISO [Cisplatin co-treated with Paclitaxel] affects the expression of DST mRNA CTD PMID:20705681 NCBI chr 9:37,902,336...38,296,961
Ensembl chr 9:37,902,303...38,196,273
JBrowse link
G Dusp3 dual specificity phosphatase 3 decreases expression ISO Paclitaxel results in decreased expression of DUSP3 mRNA CTD PMID:15000894 NCBI chr10:89,904,578...89,918,296
Ensembl chr10:89,904,560...89,918,427
JBrowse link
G E2f1 E2F transcription factor 1 increases response to substance ISO E2F1 protein results in increased susceptibility to Paclitaxel CTD PMID:16849574 NCBI chr 3:150,062,895...150,073,721
Ensembl chr 3:150,047,826...150,073,721
JBrowse link
G E2f3 E2F transcription factor 3 multiple interactions ISO E2F3 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] CTD PMID:16896004 NCBI chr17:36,334,136...36,408,831
Ensembl chr17:36,334,147...36,408,831
JBrowse link
G E2f4 E2F transcription factor 4 multiple interactions ISO [Paclitaxel co-treated with Metformin] results in decreased expression of E2F4 mRNA CTD PMID:29309887 NCBI chr19:37,252,828...37,260,239
Ensembl chr19:37,252,843...37,260,239
JBrowse link
G E2f5 E2F transcription factor 5 increases expression ISO Paclitaxel results in increased expression of E2F5 mRNA CTD PMID:15000894 NCBI chr 2:88,350,764...88,366,913
Ensembl chr 2:88,351,361...88,366,115
JBrowse link
G Ech1 enoyl-CoA hydratase 1 increases expression EXP Paclitaxel results in increased expression of ECH1 mRNA CTD PMID:15585946 NCBI chr 1:87,009,798...87,015,996
Ensembl chr 1:87,009,730...87,016,005
JBrowse link
G Ecm1 extracellular matrix protein 1 multiple interactions ISO [Cisplatin co-treated with Paclitaxel] affects the expression of ECM1 mRNA CTD PMID:20705681 NCBI chr 2:197,855,468...197,860,973
Ensembl chr 2:197,855,460...197,860,699
JBrowse link
G Eef2 eukaryotic translation elongation factor 2 decreases expression ISO Paclitaxel results in decreased expression of EEF2 mRNA CTD PMID:15000894 NCBI chr 7:11,401,501...11,406,771
Ensembl chr 7:11,401,501...11,406,771
JBrowse link
G Efcab7 EF-hand calcium binding domain 7 affects response to substance ISO EFCAB7 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 5:118,673,835...118,724,581
Ensembl chr 5:118,541,979...118,724,581
JBrowse link
G Efemp1 EGF containing fibulin extracellular matrix protein 1 multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in decreased expression of EFEMP1 mRNA CTD PMID:20705681 NCBI chr14:113,202,382...113,294,993
Ensembl chr14:113,202,419...113,295,014
JBrowse link
G Efna1 ephrin A1 decreases expression ISO Paclitaxel results in decreased expression of EFNA1 mRNA CTD PMID:19682730 NCBI chr 2:188,588,808...188,596,156
Ensembl chr 2:188,588,796...188,596,222
JBrowse link
G Egf epidermal growth factor multiple interactions
decreases expression
ISO Paclitaxel inhibits the reaction [EGF protein results in increased expression of PSA mRNA]
Paclitaxel results in decreased expression of EGF mRNA
CTD PMID:18058816, PMID:20807808 NCBI chr 2:68,820,616...68,895,537 JBrowse link
G Egfl6 EGF-like-domain, multiple 6 decreases response to substance ISO EGFL6 mRNA results in decreased susceptibility to Paclitaxel CTD PMID:25199881 NCBI chr  X:29,430,789...29,488,737
Ensembl chr  X:29,430,831...29,488,739
JBrowse link
G Egfr epidermal growth factor receptor multiple interactions
increases phosphorylation
decreases expression
ISO [PD168393 co-treated with Paclitaxel] results in decreased phosphorylation of EGFR protein; Paclitaxel promotes the reaction [HER3 protein binds to EGFR protein]
Paclitaxel results in increased phosphorylation of EGFR protein
Paclitaxel results in decreased expression of EGFR mRNA
CTD PMID:16211241, PMID:16413505, PMID:18058816, PMID:20726858 NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
JBrowse link
G Ehf ets homologous factor decreases expression ISO Paclitaxel results in decreased expression of EHF mRNA CTD PMID:19682730 NCBI chr 3:93,176,257...93,216,484
Ensembl chr 3:93,178,163...93,216,495
JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 affects response to substance ISO EIF2AK3 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 4:98,648,513...98,709,695
Ensembl chr 4:98,648,545...98,709,694
JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha affects phosphorylation ISO Paclitaxel affects the phosphorylation of EIF2S1 protein CTD PMID:29053414 NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
JBrowse link
G Eif4a1 eukaryotic translation initiation factor 4A1 decreases expression ISO Paclitaxel results in decreased expression of EIF4A1 protein CTD PMID:15907983 NCBI chr10:56,271,257...56,276,764
Ensembl chr10:56,271,257...56,276,764
JBrowse link
G Eif5a eukaryotic translation initiation factor 5A increases response to substance ISO EIF5A protein results in increased susceptibility to Paclitaxel CTD PMID:16734730 NCBI chr10:56,527,075...56,531,615
Ensembl chr10:56,527,085...56,531,483
JBrowse link
G Elk1 ETS transcription factor ELK1 decreases expression ISO Paclitaxel results in decreased expression of ELK1 mRNA CTD PMID:12929121 NCBI chr  X:1,287,875...1,304,822
Ensembl chr  X:1,297,099...1,304,822
JBrowse link
G Elmo3 engulfment and cell motility 3 increases expression ISO Paclitaxel results in increased expression of ELMO3 protein CTD PMID:15907983 NCBI chr19:37,260,330...37,264,832
Ensembl chr19:37,260,469...37,264,829
JBrowse link
G Emp1 epithelial membrane protein 1 increases expression EXP Paclitaxel results in increased expression of EMP1 mRNA CTD PMID:18754875 NCBI chr 4:169,161,076...169,181,967
Ensembl chr 4:169,147,243...169,181,966
JBrowse link
G Emp3 epithelial membrane protein 3 increases expression ISO Paclitaxel results in increased expression of EMP3 mRNA CTD PMID:19682730 NCBI chr 1:101,900,731...101,903,948
Ensembl chr 1:101,900,733...101,903,910
JBrowse link
G Enpp2 ectonucleotide pyrophosphatase/phosphodiesterase 2 increases expression ISO Paclitaxel results in increased expression of ENPP2 mRNA CTD PMID:19682730 NCBI chr 7:94,479,931...94,563,086
Ensembl chr 7:94,480,396...94,563,001
JBrowse link
G Epcam epithelial cell adhesion molecule multiple interactions
decreases expression
increases expression
ISO [Paclitaxel co-treated with Carboplatin] results in increased expression of EPCAM protein
Paclitaxel results in decreased expression of EPCAM mRNA; Paclitaxel results in decreased expression of EPCAM protein
Paclitaxel results in increased expression of EPCAM protein
CTD PMID:12695858, PMID:15907983, PMID:19682730 NCBI chr 6:11,282,194...11,308,870
Ensembl chr 6:11,281,964...11,298,216
JBrowse link
G Ephx2 epoxide hydrolase 2 increases expression EXP Paclitaxel results in increased expression of EPHX2 mRNA CTD PMID:18754875 NCBI chr15:42,757,241...42,794,211
Ensembl chr15:42,757,235...42,794,279
JBrowse link
G Epo erythropoietin decreases response to substance ISO EPO protein results in decreased susceptibility to Paclitaxel CTD PMID:17010629 NCBI chr12:22,274,828...22,278,268
Ensembl chr12:22,274,828...22,278,266
JBrowse link
G Erbb2 erb-b2 receptor tyrosine kinase 2 multiple interactions
decreases response to substance
affects response to substance
ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Paclitaxel]; 3,3'-diindolylmethane promotes the reaction [Paclitaxel results in decreased phosphorylation of and results in decreased activity of ERBB2 protein]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in decreased susceptibility to Paclitaxel]; [ERBB2 results in increased expression of ABCG2] which results in decreased susceptibility to Paclitaxel; Curcumin analog inhibits the reaction [ERBB2 protein results in decreased susceptibility to Paclitaxel]; Paclitaxel results in decreased phosphorylation of and results in decreased activity of ERBB2 protein
ERBB2 protein results in decreased susceptibility to Paclitaxel; ERBB2 results in decreased susceptibility to Paclitaxel
ERBB2 protein affects the susceptibility to Paclitaxel
CTD PMID:10327070, PMID:16580691, PMID:21712253, PMID:25866362 NCBI chr10:86,367,596...86,391,728
Ensembl chr10:86,367,596...86,391,728
JBrowse link
G Erbb3 erb-b2 receptor tyrosine kinase 3 decreases response to substance ISO ERBB3 protein results in decreased susceptibility to Paclitaxel CTD PMID:16734730 NCBI chr 7:2,989,202...3,010,610
Ensembl chr 7:2,989,340...3,010,350
JBrowse link
G Erbb4 erb-b2 receptor tyrosine kinase 4 multiple interactions ISO ERBB4 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] CTD PMID:16896004 NCBI chr 9:75,021,790...76,178,936
Ensembl chr 9:75,021,790...75,528,644
JBrowse link
G Ercc5 ERCC excision repair 5, endonuclease increases expression ISO Paclitaxel results in increased expression of ERCC5 mRNA CTD PMID:12929121 NCBI chr 9:50,928,847...50,970,962
Ensembl chr 9:50,925,619...50,970,955
JBrowse link
G Esr1 estrogen receptor 1 multiple interactions
increases expression
ISO alitretinoin inhibits the reaction [Paclitaxel results in increased expression of ESR1 mRNA]; beta Carotene inhibits the reaction [Paclitaxel results in increased expression of ESR1 mRNA]; Paclitaxel inhibits the reaction [Tamoxifen binds to ESR1 protein]; Vitamin A inhibits the reaction [Paclitaxel results in increased expression of ESR1 mRNA] CTD PMID:15283693, PMID:19340624 NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
JBrowse link
G Esr2 estrogen receptor 2 increases expression
decreases expression
multiple interactions
ISO Paclitaxel results in increased expression of ESR2 mRNA
Paclitaxel results in decreased expression of ESR2 mRNA
alitretinoin inhibits the reaction [Paclitaxel results in increased expression of ESR2 mRNA]
CTD PMID:19340624, PMID:23956100 NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
JBrowse link
G F13a1 coagulation factor XIII A1 chain increases expression EXP Paclitaxel results in increased expression of F13A1 mRNA CTD PMID:18754875 NCBI chr17:28,504,650...28,680,015
Ensembl chr17:28,504,623...28,680,362
JBrowse link
G F2 coagulation factor II multiple interactions ISO [Paclitaxel co-treated with F2 protein] affects the localization of RELA protein; [Paclitaxel co-treated with F2 protein] results in increased activity of F3 protein; [Paclitaxel co-treated with F2 protein] results in increased expression of F3 mRNA; [Paclitaxel co-treated with F2 protein] results in increased expression of F3 protein; [Paclitaxel co-treated with F2 protein] results in increased phosphorylation of MAPK8 protein; [Paclitaxel co-treated with F2 protein] results in increased phosphorylation of MAPK9 protein; epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased activity of F3 protein]; epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased expression of F3 mRNA]; epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased expression of F3 protein]; epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased phosphorylation of MAPK8 protein]; epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased expression of F3 protein] CTD PMID:19944065 NCBI chr 3:80,529,468...80,542,993
Ensembl chr 3:80,529,428...80,543,031
JBrowse link
G F3 coagulation factor III, tissue factor multiple interactions ISO [Paclitaxel co-treated with F2 protein] results in increased activity of F3 protein; [Paclitaxel co-treated with F2 protein] results in increased expression of F3 mRNA; [Paclitaxel co-treated with F2 protein] results in increased expression of F3 protein; epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased activity of F3 protein]; epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased expression of F3 mRNA]; epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased expression of F3 protein]; pyrazolanthrone inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased expression of F3 protein] CTD PMID:19944065 NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
JBrowse link
G Fabp1 fatty acid binding protein 1 decreases expression ISO Paclitaxel results in decreased expression of FABP1 protein CTD PMID:30667213 NCBI chr 4:99,063,181...99,066,957
Ensembl chr 4:99,063,181...99,066,954
JBrowse link
G Fadd Fas associated via death domain multiple interactions
increases phosphorylation
increases expression
ISO pyrazolanthrone inhibits the reaction [Paclitaxel results in increased phosphorylation of FADD protein]
Paclitaxel results in increased expression of FADD mRNA
CTD PMID:16450001, PMID:18058816 NCBI chr 1:217,746,176...217,748,581
Ensembl chr 1:217,742,929...217,748,628
JBrowse link
G Fam234b family with sequence similarity 234, member B multiple interactions ISO FAM234B mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] CTD PMID:16896004 NCBI chr 4:168,976,797...169,052,750
Ensembl chr 4:168,976,859...169,019,561
JBrowse link
G Fam3c FAM3 metabolism regulating signaling molecule C affects response to substance ISO FAM3C protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 4:49,388,962...49,439,892
Ensembl chr 4:49,387,989...49,439,867
JBrowse link
G Fancl FA complementation group L affects response to substance ISO FANCL protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr14:110,675,306...110,740,880
Ensembl chr14:110,676,090...110,740,317
JBrowse link
G Fas Fas cell surface death receptor multiple interactions
increases expression
decreases expression
increases response to substance
ISO [esculetin co-treated with Paclitaxel] results in increased expression of FAS protein; cacalol promotes the reaction [Paclitaxel results in decreased expression of FAS mRNA]; Paclitaxel promotes the reaction [cacalol results in decreased expression of FAS mRNA]
Paclitaxel results in increased expression of FAS mRNA
Paclitaxel results in increased expression of FAS protein
FAS protein results in increased susceptibility to Paclitaxel
CTD PMID:16051289, PMID:17449502, PMID:18074150, PMID:20665104 NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
JBrowse link
G Faslg Fas ligand multiple interactions
increases expression
increases response to substance
ISO [esculetin co-treated with Paclitaxel] results in increased expression of FASLG protein; TYMP inhibits the reaction [Paclitaxel results in increased expression of FASLG mRNA]; TYMP inhibits the reaction [Paclitaxel results in increased expression of FASLG protein]
Paclitaxel results in increased expression of FASLG mRNA; Paclitaxel results in increased expression of FASLG protein
FASLG protein results in increased susceptibility to Paclitaxel
CTD PMID:10502406, PMID:11716366, PMID:15907805, PMID:16051289, PMID:18074150 NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
JBrowse link
G Fasn fatty acid synthase decreases expression ISO Paclitaxel results in decreased expression of FASN protein CTD PMID:30667213 NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
JBrowse link
G Fbn1 fibrillin 1 increases expression ISO Paclitaxel results in increased expression of FBN1 mRNA CTD PMID:19682730 NCBI chr 3:117,569,708...117,766,160
Ensembl chr 3:117,569,697...117,766,120
JBrowse link
G Fbxo5 F-box protein 5 affects expression ISO Paclitaxel affects the expression of FBXO5 protein CTD PMID:27769712 NCBI chr 1:42,461,277...42,467,646
Ensembl chr 1:42,461,291...42,467,586
JBrowse link
G Fcgr2a Fc fragment of IgG receptor IIa increases expression EXP Paclitaxel results in increased expression of FCGR3 mRNA CTD PMID:18754875 NCBI chr13:91,146,878...91,163,691
Ensembl chr13:91,168,973...91,198,036
Ensembl chr13:91,168,973...91,198,036
JBrowse link
G Fcgr2b Fc fragment of IgG receptor IIb increases expression EXP Paclitaxel results in increased expression of FCGR2B mRNA CTD PMID:18754875 NCBI chr13:89,329,298...89,343,916
Ensembl chr13:89,327,794...89,433,815
JBrowse link
G Fdft1 farnesyl diphosphate farnesyl transferase 1 affects response to substance ISO FDFT1 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr15:46,339,248...46,367,302
Ensembl chr15:46,339,249...46,367,302
JBrowse link
G Fdps farnesyl diphosphate synthase increases response to substance ISO FDPS mRNA results in increased susceptibility to Paclitaxel CTD PMID:16322897 NCBI chr 2:188,403,595...188,413,219
Ensembl chr 2:188,392,858...188,413,219
JBrowse link
G Fgb fibrinogen beta chain decreases expression EXP Paclitaxel results in decreased expression of FGB mRNA CTD PMID:15585946 NCBI chr 2:182,028,044...182,035,026
Ensembl chr 2:182,027,115...182,038,178
JBrowse link
G Fgf2 fibroblast growth factor 2 decreases response to substance ISO FGF2 protein results in decreased susceptibility to Paclitaxel CTD PMID:16741658 NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
JBrowse link
G Fgf5 fibroblast growth factor 5 affects response to substance ISO FGF5 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr14:12,974,921...12,996,046
Ensembl chr14:12,974,921...12,995,584
JBrowse link
G Fgf7 fibroblast growth factor 7 multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in increased expression of FGF7 mRNA CTD PMID:20705681 NCBI chr 3:118,315,859...118,368,464
Ensembl chr 3:118,317,761...118,366,872
JBrowse link
G Fgfbp1 fibroblast growth factor binding protein 1 multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in increased expression of FGFBP1 mRNA CTD PMID:20705681 NCBI chr14:71,647,429...71,650,359
Ensembl chr14:71,649,274...71,650,354
JBrowse link
G Fgfrl1 fibroblast growth factor receptor-like 1 multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in decreased expression of FGFRL1 mRNA CTD PMID:20705681 NCBI chr14:2,020,110...2,032,169
Ensembl chr14:2,018,500...2,032,593
JBrowse link
G Fhl1 four and a half LIM domains 1 increases response to substance ISO FHL1 protein results in increased susceptibility to Paclitaxel CTD PMID:16734730 NCBI chr  X:159,112,516...159,172,528
Ensembl chr  X:159,112,880...159,172,524
JBrowse link
G Fis1 fission, mitochondrial 1 increases expression EXP Paclitaxel results in increased expression of FIS1 protein CTD PMID:26732598 NCBI chr12:22,750,485...22,765,324
Ensembl chr12:22,750,485...22,765,308
JBrowse link
G Fkbp1a FKBP prolyl isomerase 1A multiple interactions ISO [Paclitaxel co-treated with Metformin] results in increased expression of FKBP1A mRNA CTD PMID:29309887 NCBI chr 3:147,042,944...147,062,725
Ensembl chr 3:147,042,944...147,062,724
JBrowse link
G Fkbp3 FKBP prolyl isomerase 3 increases expression ISO Paclitaxel results in increased expression of FKBP3 mRNA CTD PMID:12929121 NCBI chr 6:86,810,865...86,822,115
Ensembl chr 6:86,810,809...86,822,094
JBrowse link
G Flt1 Fms related receptor tyrosine kinase 1 increases expression ISO Paclitaxel results in increased expression of FLT1 CTD PMID:21975929 NCBI chr12:9,033,993...9,205,886
Ensembl chr12:9,034,308...9,205,905
JBrowse link
G Fn1 fibronectin 1 multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in decreased expression of FN1 mRNA CTD PMID:20705681 NCBI chr 9:78,900,111...78,969,018
Ensembl chr 9:78,900,103...78,969,078
JBrowse link
G Fras1 Fraser extracellular matrix complex subunit 1 multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in increased expression of FRAS1 mRNA CTD PMID:20705681 NCBI chr14:14,438,392...14,853,016
Ensembl chr14:14,439,082...14,689,554
JBrowse link
G Fscn1 fascin actin-bundling protein 1 increases response to substance ISO FSCN1 protein results in increased susceptibility to Paclitaxel CTD PMID:16734730 NCBI chr12:13,655,459...13,668,595
Ensembl chr12:13,656,554...13,668,515
JBrowse link
G Fshr follicle stimulating hormone receptor decreases expression ISO Paclitaxel results in decreased expression of FSHR mRNA CTD PMID:23956100 NCBI chr 6:12,796,383...12,997,817
Ensembl chr 6:12,796,383...12,997,817
JBrowse link
G Fth1 ferritin heavy chain 1 decreases response to substance ISO FTH1 mRNA results in decreased susceptibility to Paclitaxel CTD PMID:16322897 NCBI chr 1:226,030,940...226,033,228
Ensembl chr 1:226,030,938...226,033,228
JBrowse link
G Ftl1 ferritin light chain 1 decreases response to substance ISO FTL mRNA results in decreased susceptibility to Paclitaxel CTD PMID:16322897 NCBI chr 1:101,448,190...101,450,034
Ensembl chr 1:101,448,346...101,449,829
JBrowse link
G Furin furin (paired basic amino acid cleaving enzyme) decreases response to substance ISO FURIN mRNA results in decreased susceptibility to Paclitaxel CTD PMID:16322897 NCBI chr 1:142,185,092...142,198,167
Ensembl chr 1:142,185,094...142,197,182
JBrowse link
G Fxyd3 FXYD domain-containing ion transport regulator 3 increases response to substance
decreases expression
ISO FXYD3 mRNA results in increased susceptibility to Paclitaxel
Paclitaxel results in decreased expression of FXYD3 mRNA
CTD PMID:16322897, PMID:19682730 NCBI chr 1:89,502,561...89,510,146
Ensembl chr 1:89,502,562...89,509,343
JBrowse link
G G0s2 G0/G1switch 2 increases expression EXP Paclitaxel analog results in increased expression of G0S2 mRNA; Paclitaxel results in increased expression of G0S2 mRNA CTD PMID:15585946 NCBI chr13:112,004,140...112,005,052
Ensembl chr13:112,004,140...112,005,052
JBrowse link
G G6pc glucose-6-phosphatase, catalytic subunit increases expression EXP Paclitaxel results in increased expression of G6PC mRNA CTD PMID:15585946 NCBI chr10:89,286,009...89,296,213
Ensembl chr10:89,285,855...89,296,213
JBrowse link
G Gadd45a growth arrest and DNA-damage-inducible, alpha increases expression
decreases response to substance
ISO [Paclitaxel results in increased expression of TP53 protein] which results in increased expression of GADD45A mRNA
GADD45A mRNA results in decreased susceptibility to Paclitaxel
CTD PMID:9041188, PMID:16322897 NCBI chr 4:97,782,512...97,784,814
Ensembl chr 4:97,782,512...97,784,842
JBrowse link
G Galnt7 polypeptide N-acetylgalactosaminyltransferase 7 affects response to substance ISO GALNT7 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr16:35,935,059...36,062,734
Ensembl chr16:35,934,970...36,062,719
JBrowse link
G Gamt guanidinoacetate N-methyltransferase multiple interactions ISO GAMT mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] CTD PMID:16896004 NCBI chr 7:12,314,848...12,317,998
Ensembl chr 7:12,314,848...12,317,998
JBrowse link
G Gchfr GTP cyclohydrolase I feedback regulator decreases response to substance ISO GCHFR protein results in decreased susceptibility to Paclitaxel CTD PMID:16734730 NCBI chr 3:110,975,923...110,979,957
Ensembl chr 3:110,975,923...110,979,957
JBrowse link
G Gckr glucokinase regulator increases expression EXP Paclitaxel results in increased expression of GCKR mRNA CTD PMID:15585946 NCBI chr 6:26,355,296...26,385,761
Ensembl chr 6:26,355,296...26,385,761
JBrowse link
G Gfap glial fibrillary acidic protein multiple interactions
increases expression
ISO
EXP
[Tretinoin co-treated with Paclitaxel] results in increased expression of GFAP protein
Paclitaxel results in increased expression of GFAP protein
CTD PMID:16854522, PMID:17005179, PMID:18098270 NCBI chr10:90,990,762...90,999,435
Ensembl chr10:90,990,762...90,999,506
JBrowse link
G Gfpt1 glutamine fructose-6-phosphate transaminase 1 decreases response to substance ISO GFPT1 protein results in decreased susceptibility to Paclitaxel CTD PMID:16734730 NCBI chr 4:118,852,046...118,901,583
Ensembl chr 4:118,852,062...118,901,591
JBrowse link
G Gfra1 GDNF family receptor alpha 1 multiple interactions ISO GFRA1 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] CTD PMID:16896004 NCBI chr 1:279,203,046...279,572,789 JBrowse link
G Gjb2 gap junction protein, beta 2 increases expression EXP Paclitaxel results in increased expression of GJB2 mRNA CTD PMID:18754875 NCBI chr15:37,377,313...37,394,494
Ensembl chr15:37,377,316...37,383,277
JBrowse link
G Gjb6 gap junction protein, beta 6 increases expression EXP Paclitaxel results in increased expression of GJB6 mRNA CTD PMID:18754875 NCBI chr15:37,400,888...37,411,656
Ensembl chr15:37,400,889...37,410,848
JBrowse link
G Gna13 G protein subunit alpha 13 multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in increased expression of GNA13 mRNA CTD PMID:20705681 NCBI chr10:97,647,196...97,680,030
Ensembl chr10:97,647,111...97,684,730
JBrowse link
G Gpc3 glypican 3 increases response to substance ISO GPC3 mRNA results in increased susceptibility to Paclitaxel CTD PMID:25199881 NCBI chr  X:139,579,268...139,947,093
Ensembl chr  X:139,579,268...139,916,883
JBrowse link
G Gpi glucose-6-phosphate isomerase affects response to substance ISO GPI protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 1:90,063,411...90,091,287
Ensembl chr 1:90,063,411...90,091,287
JBrowse link
G Gpnmb glycoprotein nmb increases expression EXP Paclitaxel results in increased expression of GPNMB mRNA CTD PMID:18754875 NCBI chr 4:78,694,447...78,715,685
Ensembl chr 4:78,694,447...78,715,683
JBrowse link
G Gpr35 G protein-coupled receptor 35 decreases response to substance ISO GPR35 protein results in decreased susceptibility to Paclitaxel CTD PMID:16734730 NCBI chr 9:100,129,428...100,141,269
Ensembl chr 9:100,137,881...100,138,801
JBrowse link
G Gsk3b glycogen synthase kinase 3 beta increases phosphorylation ISO Paclitaxel results in increased phosphorylation of GSK3B protein CTD PMID:19426673 NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
JBrowse link
G Gsn gelsolin decreases expression ISO Paclitaxel results in decreased expression of GSN mRNA CTD PMID:15000894 NCBI chr 3:14,456,106...14,508,922
Ensembl chr 3:14,467,330...14,508,911
JBrowse link
G Gstm1 glutathione S-transferase mu 1 multiple interactions ISO GSTM1 gene polymorphism affects the susceptibility to [Paclitaxel co-treated with Cisplatin] CTD PMID:12851839 NCBI chr 2:210,803,869...210,809,461
Ensembl chr 2:210,803,869...210,809,306
JBrowse link
G Gstm3l glutathione S-transferase mu 3-like decreases response to substance ISO GSTM5 mRNA results in decreased susceptibility to Paclitaxel CTD PMID:16322897 NCBI chr 2:210,761,729...210,766,501
Ensembl chr 2:210,761,729...210,766,501
JBrowse link
G Gstp1 glutathione S-transferase pi 1 affects response to substance
increases response to substance
ISO GSTP1 protein affects the susceptibility to Paclitaxel
GSTP1 mRNA results in increased susceptibility to Paclitaxel
CTD PMID:15239142, PMID:16217747 NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
JBrowse link
G Gstt1 glutathione S-transferase theta 1 multiple interactions ISO GSTT1 gene polymorphism affects the susceptibility to [Paclitaxel co-treated with Cisplatin] CTD PMID:12851839 NCBI chr20:13,799,102...13,816,527
Ensembl chr20:13,799,102...13,816,526
JBrowse link
G Gtf2a2 general transcription factor 2A subunit 2 increases expression EXP Paclitaxel analog results in increased expression of GTF2A2 mRNA; Paclitaxel results in increased expression of GTF2A2 mRNA CTD PMID:15585946 NCBI chr 8:76,422,341...76,435,587
Ensembl chr 8:76,422,359...76,435,473
JBrowse link
G Gtf2i general transcription factor II I decreases expression ISO Paclitaxel results in decreased expression of GTF2I mRNA CTD PMID:15000894 NCBI chr12:25,410,804...25,487,970
Ensembl chr12:25,411,207...25,488,156
JBrowse link
G Gtse1 G-2 and S-phase expressed 1 increases expression ISO Paclitaxel results in increased expression of GTSE1 protein CTD PMID:15907983 NCBI chr 7:126,736,416...126,753,221
Ensembl chr 7:126,736,732...126,753,220
JBrowse link
G Gusb glucuronidase, beta affects response to substance ISO GUSB protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr12:30,202,066...30,215,583
Ensembl chr12:30,198,822...30,227,771
JBrowse link
G H2ax H2A.X variant histone increases expression
multiple interactions
ISO Paclitaxel results in increased expression of H2AX protein; Paclitaxel results in increased expression of H2AX protein modified form
palbociclib inhibits the reaction [Paclitaxel results in increased expression of H2AX protein]
CTD PMID:18451153, PMID:22302033 NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
JBrowse link
G Hacl1 2-hydroxyacyl-CoA lyase 1 increases expression EXP Paclitaxel results in increased expression of HACL1 mRNA CTD PMID:15585946 NCBI chr16:7,720,047...7,758,119
Ensembl chr16:7,714,465...7,758,189
JBrowse link
G Hdac4 histone deacetylase 4 decreases expression EXP Paclitaxel results in decreased expression of HDAC4 protein CTD PMID:27474498 NCBI chr 9:99,052,945...99,299,715
Ensembl chr 9:99,057,089...99,299,715
JBrowse link
G Hdac9 histone deacetylase 9 increases response to substance ISO HDAC9 protein results in increased susceptibility to Paclitaxel CTD PMID:16734730 NCBI chr 6:53,487,367...54,358,694
Ensembl chr 6:53,488,883...54,059,119
JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha multiple interactions ISO HIF1A protein affects the reaction [[Paclitaxel co-treated with IL6 protein] results in increased expression of ABCB1 protein]; HIF1A protein affects the reaction [[Paclitaxel co-treated with IL6 protein] results in increased expression of ABCC1 protein]; HIF1A protein affects the reaction [IL6 protein inhibits the reaction [Paclitaxel results in decreased expression of BCL2 protein]]; HIF1A protein affects the reaction [IL6 protein inhibits the reaction [Paclitaxel results in increased expression of BAX protein]] CTD PMID:29341321 NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
JBrowse link
G Hmbs hydroxymethylbilane synthase decreases expression EXP Paclitaxel results in decreased expression of HMBS mRNA CTD PMID:15585946 NCBI chr 8:48,667,278...48,674,673
Ensembl chr 8:48,667,275...48,674,748
JBrowse link
G Hmcn1 hemicentin 1 increases response to substance ISO HMCN1 mRNA results in increased susceptibility to Paclitaxel CTD PMID:25199881 NCBI chr13:67,799,791...68,360,664
Ensembl chr13:67,799,791...68,360,664
JBrowse link
G Hmgb1 high mobility group box 1 affects response to substance
decreases expression
ISO
EXP
HMGB1 protein affects the susceptibility to Paclitaxel
Paclitaxel results in decreased expression of HMGB1 protein
CTD PMID:16217747, PMID:27474498 NCBI chr12:7,082,529...7,090,246
Ensembl chr16:37,500,017...37,502,237
JBrowse link
G Hmgcs2 3-hydroxy-3-methylglutaryl-CoA synthase 2 increases expression EXP Paclitaxel results in increased expression of HMGCS2 mRNA CTD PMID:15585946 NCBI chr 2:200,452,623...200,480,785
Ensembl chr 2:200,452,624...200,479,423
JBrowse link
G Hmgn3 high mobility group nucleosomal binding domain 3 affects response to substance ISO HMGN3 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 8:90,628,203...90,665,055
Ensembl chr 8:90,628,209...90,664,554
JBrowse link
G Hmmr hyaluronan-mediated motility receptor decreases expression ISO Paclitaxel results in decreased expression of HMMR protein CTD PMID:15907983 NCBI chr10:25,861,490...25,890,639
Ensembl chr10:25,861,490...25,890,639
JBrowse link
G Hnrnpa2b1 heterogeneous nuclear ribonucleoprotein A2/B1 decreases expression ISO Paclitaxel results in decreased expression of HNRNPA2B1 mRNA CTD PMID:15000894 NCBI chr 4:81,237,496...81,241,281
Ensembl chr 4:81,237,496...81,241,282
JBrowse link
G Hnrnpab heterogeneous nuclear ribonucleoprotein A/B decreases expression ISO Paclitaxel results in decreased expression of HNRNPAB mRNA CTD PMID:15000894 NCBI chr10:34,955,713...34,961,662
Ensembl chr10:34,955,716...34,961,608
JBrowse link
G Hnrnph1 heterogeneous nuclear ribonucleoprotein H1 decreases expression ISO Paclitaxel results in decreased expression of HNRNPH1 mRNA CTD PMID:15000894 NCBI chr10:35,872,619...35,879,911
Ensembl chr10:35,870,232...35,879,910
JBrowse link
G Hnrnpk heterogeneous nuclear ribonucleoprotein K multiple interactions ISO [Paclitaxel co-treated with Metformin] results in decreased expression of HNRNPK mRNA CTD PMID:29309887 NCBI chr17:6,664,730...6,676,753
Ensembl chr17:6,665,659...6,676,654
JBrowse link
G Hook1 hook microtubule-tethering protein 1 decreases expression ISO Paclitaxel results in decreased expression of HOOK1 mRNA CTD PMID:19682730 NCBI chr 5:114,940,053...115,000,691
Ensembl chr 5:114,940,053...115,000,691
JBrowse link
G Hras HRas proto-oncogene, GTPase multiple interactions ISO [Paclitaxel co-treated with Metformin] results in decreased expression of HRAS mRNA CTD PMID:29309887 NCBI chr 1:214,178,404...214,181,841
Ensembl chr 1:214,178,407...214,181,686
JBrowse link
G Hsd17b4 hydroxysteroid (17-beta) dehydrogenase 4 affects response to substance ISO HSD17B4 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr18:44,810,462...44,897,677
Ensembl chr18:44,810,388...44,897,640
JBrowse link
G Hspa1l heat shock protein family A (Hsp70) member 1 like increases expression EXP Paclitaxel analog results in increased expression of HSPA1L mRNA CTD PMID:15585946 NCBI chr20:4,879,998...4,965,191
Ensembl chr20:4,959,294...4,964,963
JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 increases expression EXP Paclitaxel results in increased expression of HSPA5 protein CTD PMID:26732598 NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
JBrowse link
G Hspb3 heat shock protein family B (small) member 3 increases expression ISO Paclitaxel results in increased expression of HSPB3 protein CTD PMID:15907983 NCBI chr 2:45,517,788...45,518,502
Ensembl chr 2:45,517,789...45,518,502
JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions
decreases expression
ISO Curcumin inhibits the reaction [Paclitaxel results in increased expression of ICAM1 protein]
Paclitaxel results in decreased expression of ICAM1 mRNA; Paclitaxel results in decreased expression of ICAM1 protein
CTD PMID:12649748, PMID:16243823, PMID:18058816 NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
JBrowse link
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 affects response to substance
decreases expression
ISO IDH2 protein affects the susceptibility to Paclitaxel
Paclitaxel results in decreased expression of IDH2 mRNA
CTD PMID:15000894, PMID:16217747 NCBI chr 1:141,874,354...141,893,674
Ensembl chr 1:141,866,283...141,893,705
JBrowse link
G Ier3 immediate early response 3 increases expression ISO Paclitaxel results in increased expression of IER3 mRNA CTD PMID:12929121 NCBI chr20:3,438,798...3,440,002
Ensembl chr20:3,438,798...3,440,769
JBrowse link
G Ifi30 IFI30, lysosomal thiol reductase decreases response to substance ISO IFI30 mRNA results in decreased susceptibility to Paclitaxel CTD PMID:16322897 NCBI chr16:20,426,566...20,430,772
Ensembl chr16:20,426,566...20,430,752
JBrowse link
G Ifng interferon gamma multiple interactions ISO [Paclitaxel co-treated with Metformin] results in increased expression of IFNG mRNA CTD PMID:29309887 NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
JBrowse link
G Igfbp4 insulin-like growth factor binding protein 4 multiple interactions
increases expression
ISO IGFBP4 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]
Paclitaxel results in increased expression of IGFBP4 mRNA
CTD PMID:16896004, PMID:19682730 NCBI chr10:86,950,555...86,962,563
Ensembl chr10:86,950,557...86,962,578
JBrowse link
G Igfbp6 insulin-like growth factor binding protein 6 increases expression EXP Paclitaxel results in increased expression of IGFBP6 mRNA CTD PMID:18754875 NCBI chr 7:143,749,385...143,754,018
Ensembl chr 7:143,749,221...143,754,054
JBrowse link
G Ikbkb inhibitor of nuclear factor kappa B kinase subunit beta affects response to substance
multiple interactions
ISO IKBKB protein affects the susceptibility to Paclitaxel
[Paclitaxel co-treated with Metformin] results in decreased expression of IKBKB mRNA
CTD PMID:20159942, PMID:29309887 NCBI chr16:74,177,233...74,230,809
Ensembl chr16:74,177,215...74,230,815
JBrowse link
G Il10 interleukin 10 increases expression ISO Paclitaxel results in increased expression of IL10 protein CTD PMID:14698135 NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
JBrowse link
G Il12a interleukin 12A multiple interactions
increases expression
ISO CD14 protein affects the reaction [Paclitaxel results in increased expression of IL12A mRNA]; ITGAM protein affects the reaction [Paclitaxel results in increased expression of IL12A mRNA]; ITGAM protein affects the reaction [Paclitaxel results in increased secretion of [IL12A protein binds to IL12B protein]]; Paclitaxel results in increased secretion of [IL12A protein binds to IL12B protein]; TLR4 protein affects the reaction [Paclitaxel results in increased expression of IL12A mRNA] CTD PMID:11123339 NCBI chr 2:165,076,945...165,083,996
Ensembl chr 2:165,076,607...165,084,318
JBrowse link
G Il12b interleukin 12B multiple interactions
increases expression
ISO CD14 protein affects the reaction [Paclitaxel results in increased expression of IL12B mRNA]; ITGAM protein affects the reaction [Paclitaxel results in increased secretion of [IL12A protein binds to IL12B protein]]; Paclitaxel results in increased secretion of [IL12A protein binds to IL12B protein]; TLR4 protein affects the reaction [Paclitaxel results in increased expression of IL12B mRNA] CTD PMID:11123339 NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
JBrowse link
G Il13ra2 interleukin 13 receptor subunit alpha 2 affects response to substance ISO IL13RA2 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr  X:118,443,955...118,514,716
Ensembl chr  X:118,443,823...118,513,061
JBrowse link
G Il17rb interleukin 17 receptor B decreases response to substance ISO IL17RB protein results in decreased susceptibility to Paclitaxel CTD PMID:16734730 NCBI chr16:6,064,287...6,077,978
Ensembl chr16:6,064,288...6,077,978
JBrowse link
G Il18 interleukin 18 multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in increased expression of IL18 mRNA CTD PMID:20705681 NCBI chr 8:55,009,666...55,016,286
Ensembl chr 8:54,993,859...55,016,299
JBrowse link
G Il1b interleukin 1 beta increases expression EXP
ISO
Paclitaxel results in increased expression of IL1B mRNA CTD PMID:17174526, PMID:28242239 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Il1r1 interleukin 1 receptor type 1 decreases expression ISO Paclitaxel results in decreased expression of IL1R1 protein CTD PMID:15907983 NCBI chr 9:46,962,291...47,038,139
Ensembl chr 9:46,962,288...47,036,670
JBrowse link
G Il6 interleukin 6 increases expression
multiple interactions
affects response to substance
ISO Paclitaxel results in increased expression of IL6 protein
[Paclitaxel co-treated with IL6 protein] results in increased expression of ABCB1 protein; [Paclitaxel co-treated with IL6 protein] results in increased expression of ABCC1 protein; HIF1A protein affects the reaction [[Paclitaxel co-treated with IL6 protein] results in increased expression of ABCB1 protein]; HIF1A protein affects the reaction [[Paclitaxel co-treated with IL6 protein] results in increased expression of ABCC1 protein]; HIF1A protein affects the reaction [IL6 protein inhibits the reaction [Paclitaxel results in decreased expression of BCL2 protein]]; HIF1A protein affects the reaction [IL6 protein inhibits the reaction [Paclitaxel results in increased expression of BAX protein]]; IL6 protein inhibits the reaction [Paclitaxel results in decreased expression of BCL2 protein]; IL6 protein inhibits the reaction [Paclitaxel results in increased expression of BAX protein]
TLR4 protein mutant form inhibits the reaction [Paclitaxel results in increased expression of IL6 mRNA]
IL6 protein affects the susceptibility to Paclitaxel
CTD PMID:14698135, PMID:18270703, PMID:28242239, PMID:29341321 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Insig1 insulin induced gene 1 affects response to substance ISO INSIG1 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 4:342,302...350,515
Ensembl chr 4:342,302...350,515
JBrowse link
G Ip6k1 inositol hexakisphosphate kinase 1 decreases expression EXP Paclitaxel results in decreased expression of IP6K1 mRNA CTD PMID:15585946 NCBI chr 8:116,781,957...116,826,152
Ensembl chr 8:116,804,451...116,823,540
JBrowse link
G Irf3 interferon regulatory factor 3 multiple interactions ISO [Paclitaxel co-treated with Metformin] results in decreased expression of IRF3 mRNA CTD PMID:29309887 NCBI chr 1:100,992,244...100,997,202
Ensembl chr 1:100,992,405...100,997,198
JBrowse link
G Irf5 interferon regulatory factor 5 multiple interactions ISO [Paclitaxel co-treated with Metformin] results in increased expression of IRF5 mRNA CTD PMID:29309887 NCBI chr 4:56,804,477...56,816,271
Ensembl chr 4:56,805,132...56,820,543
JBrowse link
G Irf7 interferon regulatory factor 7 increases expression
multiple interactions
EXP
ISO
Paclitaxel results in increased expression of IRF7 mRNA
[Paclitaxel co-treated with Metformin] results in increased expression of IRF7 mRNA
CTD PMID:15585946, PMID:29309887 NCBI chr 1:214,249,388...214,252,909
Ensembl chr 1:214,248,837...214,252,456
JBrowse link
G Irf8 interferon regulatory factor 8 increases expression
multiple interactions
ISO Paclitaxel results in increased expression of IRF8 mRNA
TLR4 protein affects the reaction [Paclitaxel results in increased expression of IRF8 mRNA]
CTD PMID:11123339 NCBI chr19:54,314,859...54,336,643
Ensembl chr19:54,314,865...54,336,640
JBrowse link
G Isg15 ISG15 ubiquitin-like modifier affects response to substance ISO ISG15 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 5:173,624,862...173,629,124
Ensembl chr 5:173,624,310...173,626,248
JBrowse link
G Itga1 integrin subunit alpha 1 increases response to substance ISO ITGA1 mRNA results in increased susceptibility to Paclitaxel CTD PMID:25199881 NCBI chr 2:47,127,403...47,281,387
Ensembl chr 2:47,127,219...47,281,421
JBrowse link
G Itga2 integrin subunit alpha 2 increases response to substance EXP ITGA2 protein results in increased susceptibility to Paclitaxel CTD PMID:18234883 NCBI chr 2:46,996,904...47,097,011
Ensembl chr 2:47,000,323...47,096,961
JBrowse link
G Itgal integrin subunit alpha L decreases expression ISO Paclitaxel results in decreased expression of ITGAL mRNA; Paclitaxel results in decreased expression of ITGAL protein CTD PMID:12649748 NCBI chr 1:198,744,053...198,781,745
Ensembl chr 1:198,744,050...198,781,750
JBrowse link
G Itgam integrin subunit alpha M multiple interactions
increases expression
ISO
EXP
ITGAM protein affects the reaction [Paclitaxel affects the localization of and results in increased activity of [NFKB1 protein binds to RELA protein]]; ITGAM protein affects the reaction [Paclitaxel results in increased expression of IL12A mRNA]; ITGAM protein affects the reaction [Paclitaxel results in increased expression of PTGS2 mRNA]; ITGAM protein affects the reaction [Paclitaxel results in increased phosphorylation of MAPK1 protein]; ITGAM protein affects the reaction [Paclitaxel results in increased phosphorylation of MAPK3 protein]; ITGAM protein affects the reaction [Paclitaxel results in increased phosphorylation of MAPK8 protein]; ITGAM protein affects the reaction [Paclitaxel results in increased secretion of [IL12A protein binds to IL12B protein]]
Paclitaxel results in increased expression of ITGAM mRNA
CTD PMID:11123339, PMID:17174526 NCBI chr 1:199,495,312...199,545,738
Ensembl chr 1:199,495,298...199,623,960
JBrowse link
G Itgb1 integrin subunit beta 1 increases response to substance EXP ITGB1 results in increased susceptibility to Paclitaxel CTD PMID:14984413 NCBI chr19:61,677,512...61,725,537
Ensembl chr19:61,677,542...61,725,535
JBrowse link
G Itgb1bp1 integrin subunit beta 1 binding protein 1 affects response to substance ISO ITGB1BP1 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 6:43,348,927...43,363,633
Ensembl chr 6:43,348,958...43,363,335
JBrowse link
G Itgb5 integrin subunit beta 5 decreases response to substance ISO ITGB5 mRNA results in decreased susceptibility to Paclitaxel CTD PMID:16322897 NCBI chr11:70,056,500...70,172,164
Ensembl chr11:70,056,500...70,172,372
JBrowse link
G Itgb6 integrin subunit beta 6 decreases expression ISO Paclitaxel results in decreased expression of ITGB6 mRNA CTD PMID:19682730 NCBI chr 3:46,652,624...46,775,362
Ensembl chr 3:46,652,623...46,726,958
JBrowse link
G Itih2 inter-alpha-trypsin inhibitor heavy chain 2 increases expression ISO Paclitaxel results in increased expression of ITIH2 mRNA CTD PMID:12929121 NCBI chr17:72,160,734...72,197,248
Ensembl chr17:72,160,735...72,195,509
JBrowse link
G Itm2b integral membrane protein 2B affects response to substance ISO ITM2B protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr15:55,254,703...55,277,713
Ensembl chr15:55,254,706...55,277,713
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit increases phosphorylation
increases expression
ISO
EXP
Paclitaxel results in increased phosphorylation of JUN protein
Paclitaxel results in increased expression of JUN protein
CTD PMID:15585644, PMID:17686523 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Kcnj16 potassium inwardly-rectifying channel, subfamily J, member 16 increases expression EXP Paclitaxel results in increased expression of KCNJ16 mRNA CTD PMID:18754875 NCBI chr10:99,330,894...99,391,551
Ensembl chr10:99,388,130...99,389,898
JBrowse link
G Kcnk3 potassium two pore domain channel subfamily K member 3 increases expression ISO Paclitaxel results in increased expression of KCNK3 protein CTD PMID:15907983 NCBI chr 6:27,154,274...27,190,209
Ensembl chr 6:27,151,612...27,190,132
JBrowse link
G Kcnma1 potassium calcium-activated channel subfamily M alpha 1 affects response to substance ISO KCNMA1 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr15:344,204...1,048,849
Ensembl chr15:344,360...1,047,956
JBrowse link
G Kdm4b lysine demethylase 4B multiple interactions ISO KDM4B mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] CTD PMID:16896004 NCBI chr 9:10,656,035...10,734,127
Ensembl chr 9:10,653,216...10,734,073
JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 multiple interactions ISO [KEAP1 protein results in decreased stability of NFE2L2 protein] which results in increased susceptibility to Paclitaxel CTD PMID:20530669 NCBI chr 8:22,250,518...22,259,868
Ensembl chr 8:22,250,518...22,259,779
JBrowse link
G Kif3a kinesin family member 3a multiple interactions ISO KIF3A mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] CTD PMID:16896004 NCBI chr10:38,918,705...38,953,958
Ensembl chr10:38,918,748...38,952,785
JBrowse link
G Kit KIT proto-oncogene receptor tyrosine kinase multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in increased expression of KIT mRNA; [Cisplatin co-treated with Paclitaxel] results in increased expression of KIT protein CTD PMID:20705681 NCBI chr14:35,072,131...35,149,638
Ensembl chr14:35,072,108...35,149,610
JBrowse link
G Kras KRAS proto-oncogene, GTPase multiple interactions ISO [Paclitaxel co-treated with Metformin] results in decreased expression of KRAS mRNA CTD PMID:29309887 NCBI chr 4:179,482,562...179,515,483
Ensembl chr 4:179,486,105...179,515,558
JBrowse link
G Krt13 keratin 13 decreases response to substance ISO KRT13 mRNA results in decreased susceptibility to Paclitaxel CTD PMID:16322897 NCBI chr10:88,032,130...88,036,040
Ensembl chr10:88,032,130...88,036,040
JBrowse link
G Krt18 keratin 18 increases expression ISO Paclitaxel results in increased expression of KRT18 protein modified form CTD PMID:22907900 NCBI chr 7:143,629,455...143,633,131
Ensembl chr 7:143,629,455...143,633,131
JBrowse link
G Krt19 keratin 19 increases expression EXP Paclitaxel results in increased expression of KRT19 mRNA CTD PMID:18754875 NCBI chr10:88,055,843...88,060,560
Ensembl chr10:88,055,841...88,060,561
JBrowse link
G Krt23 keratin 23 increases response to substance ISO KRT23 mRNA results in increased susceptibility to Paclitaxel CTD PMID:25199881 NCBI chr10:87,391,623...87,407,634
Ensembl chr10:87,391,623...87,407,634
JBrowse link
G Krt7 keratin 7 increases response to substance ISO KRT7 protein results in increased susceptibility to Paclitaxel CTD PMID:16734730 NCBI chr 7:143,059,731...143,075,907
Ensembl chr 7:143,059,764...143,075,907
JBrowse link
G Lama2 laminin subunit alpha 2 increases response to substance ISO LAMA2 mRNA results in increased susceptibility to Paclitaxel CTD PMID:25199881 NCBI chr 1:18,491,264...19,143,486
Ensembl chr 1:18,491,384...19,143,269
JBrowse link
G Lamp2 lysosomal-associated membrane protein 2 affects response to substance ISO LAMP2 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr  X:124,722,628...124,766,079
Ensembl chr  X:124,722,628...124,766,044
JBrowse link
G Lbp lipopolysaccharide binding protein increases expression EXP Paclitaxel results in increased expression of LBP mRNA CTD PMID:18754875 NCBI chr 3:154,786,232...154,812,910
Ensembl chr 3:154,786,215...154,813,464
JBrowse link
G Lcp2 lymphocyte cytosolic protein 2 increases expression ISO Paclitaxel results in increased expression of LCP2 protein CTD PMID:15907983 NCBI chr10:18,996,523...19,043,289
Ensembl chr10:18,996,523...19,043,286
JBrowse link
G Ldha lactate dehydrogenase A increases response to substance
increases expression
multiple interactions
ISO
EXP
LDHA mutant form results in increased susceptibility to Paclitaxel
Paclitaxel analog results in increased expression of LDHA mRNA; Paclitaxel results in increased expression of LDHA mRNA
[Oxamic Acid results in decreased activity of LDHA protein] which results in increased susceptibility to Paclitaxel
CTD PMID:15585946, PMID:21332213 NCBI chr 1:102,900,288...102,909,713
Ensembl chr 1:102,900,286...102,909,707
JBrowse link
G Ldlr low density lipoprotein receptor affects response to substance ISO LDLR protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 8:22,750,425...22,773,305
Ensembl chr 8:22,750,336...22,774,903
JBrowse link
G Lgals4 galectin 4 decreases response to substance ISO LGALS4 protein results in decreased susceptibility to Paclitaxel CTD PMID:16734730 NCBI chr 1:87,019,598...87,027,720
Ensembl chr 1:87,019,975...87,027,691
JBrowse link
G Lifr LIF receptor subunit alpha multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in decreased expression of LIFR mRNA CTD PMID:20705681 NCBI chr 2:56,424,910...56,489,346
Ensembl chr 2:56,426,367...56,489,415
JBrowse link
G Lig1 DNA ligase 1 decreases expression ISO Paclitaxel results in decreased expression of LIG1 mRNA CTD PMID:15000894 NCBI chr 1:75,356,212...75,394,757
Ensembl chr 1:75,356,220...75,394,758
JBrowse link
G Lilrb4 leukocyte immunoglobulin like receptor B4 increases expression EXP Paclitaxel results in increased expression of LILRB4 mRNA CTD PMID:18754875 NCBI chr 1:73,393,854...73,399,448
Ensembl chr 1:73,393,850...73,399,579
JBrowse link
G Lingo3 leucine rich repeat and Ig domain containing 3 multiple interactions ISO [Paclitaxel co-treated with Metformin] results in increased expression of LINGO3 mRNA CTD PMID:29309887 NCBI chr 7:11,737,293...11,746,703
Ensembl chr 7:11,737,293...11,746,703
JBrowse link
G Litaf lipopolysaccharide-induced TNF factor affects response to substance ISO LITAF protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr10:4,753,546...4,763,272
Ensembl chr10:4,719,713...4,763,510
JBrowse link
G Lox lysyl oxidase multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in decreased expression of LOX mRNA CTD PMID:20705681 NCBI chr18:47,500,320...47,577,819
Ensembl chr18:47,500,330...47,577,819
JBrowse link
G Lrp5 LDL receptor related protein 5 multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in decreased expression of LRP5 mRNA CTD PMID:20705681 NCBI chr 1:218,816,833...218,920,147
Ensembl chr 1:218,816,841...218,920,094
JBrowse link
G Ltbp2 latent transforming growth factor beta binding protein 2 affects response to substance ISO LTBP2 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 6:108,500,114...108,596,653
Ensembl chr 6:108,500,112...108,596,569
JBrowse link
G Lum lumican multiple interactions
decreases response to substance
ISO [Cisplatin co-treated with Paclitaxel] affects the expression of LUM mRNA
LUM mRNA results in decreased susceptibility to Paclitaxel
CTD PMID:20705681, PMID:25199881 NCBI chr 7:38,820,058...38,826,862
Ensembl chr 7:38,819,771...38,826,862
JBrowse link
G Ly6c Ly6-C antigen increases expression EXP Paclitaxel results in increased expression of LY6C mRNA CTD PMID:15585946
G Mad2l1 mitotic arrest deficient 2 like 1 affects response to substance
decreases expression
ISO MAD2L1 protein affects the susceptibility to Paclitaxel
Paclitaxel results in decreased expression of MAD2L1 mRNA
CTD PMID:12929121, PMID:18691855 NCBI chr 4:97,530,993...97,543,179
Ensembl chr 4:97,531,083...97,537,086
JBrowse link
G Madd MAP-kinase activating death domain decreases expression ISO Paclitaxel results in decreased expression of MADD mRNA CTD PMID:15000894 NCBI chr 3:79,960,301...80,003,023
Ensembl chr 3:79,960,301...80,003,032
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta increases expression ISO Paclitaxel results in increased expression of MAP1LC3B mRNA; Paclitaxel results in increased expression of MAP1LC3B protein CTD PMID:19815708 NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 multiple interactions ISO [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein] affects the reaction [SOD2 protein results in decreased susceptibility to Paclitaxel]; [MAP2K1 protein affects the activity of [MAPK1 protein co-treated with MAPK3 protein]] affects the reaction [SOD2 protein results in decreased susceptibility to Paclitaxel]; [Tretinoin co-treated with Paclitaxel] results in decreased expression of MAP2K1 protein CTD PMID:18098270, PMID:18594523 NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
JBrowse link
G Map2k3 mitogen activated protein kinase kinase 3 multiple interactions ISO [Paclitaxel co-treated with Metformin] results in decreased expression of MAP2K3 mRNA CTD PMID:29309887 NCBI chr10:45,089,455...45,110,802
Ensembl chr10:47,182,433...47,203,753
JBrowse link
G Map2k4 mitogen activated protein kinase kinase 4 multiple interactions ISO MAP2K4 protein affects the reaction [Paclitaxel results in increased activity of CASP3 protein]; MAP2K4 protein affects the reaction [Paclitaxel results in increased cleavage of PARP1 protein] CTD PMID:10075725 NCBI chr10:52,196,121...52,301,887
Ensembl chr10:52,196,124...52,290,657
JBrowse link
G Map3k1 mitogen-activated protein kinase kinase kinase 1 multiple interactions
increases cleavage
affects localization
ISO aspartyl-glutamyl-valyl-aspartal inhibits the reaction [Paclitaxel results in increased cleavage of MAP3K1 protein]; MAP3K1 protein affects the reaction [Paclitaxel results in increased activity of MAPK8 protein]; MAP3K1 protein affects the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein]; Paclitaxel promotes the reaction [MAPK8 protein binds to MAP3K1 protein modified form]
Paclitaxel affects the localization of MAP3K1 protein
CTD PMID:11160861 NCBI chr 2:43,329,516...43,393,203
Ensembl chr 2:43,329,516...43,393,207
JBrowse link
G Map3k2 mitogen activated protein kinase kinase kinase 2 multiple interactions ISO [Paclitaxel co-treated with Metformin] results in decreased expression of MAP3K2 mRNA CTD PMID:29309887 NCBI chr18:24,961,250...25,025,488
Ensembl chr18:24,961,245...25,025,897
JBrowse link
G Map3k5 mitogen-activated protein kinase kinase kinase 5 multiple interactions ISO MAP3K5 protein affects the reaction [Paclitaxel results in increased activity of CASP3 protein]; MAP3K5 protein affects the reaction [Paclitaxel results in increased cleavage of PARP1 protein] CTD PMID:10075725 NCBI chr 1:15,412,603...15,613,752
Ensembl chr 1:15,412,603...15,613,746
JBrowse link
G Map3k7 mitogen activated protein kinase kinase kinase 7 multiple interactions ISO [Paclitaxel co-treated with Metformin] results in decreased expression of MAP3K7 mRNA CTD PMID:29309887 NCBI chr 5:47,183,142...47,244,424
Ensembl chr 5:47,186,558...47,244,416
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases phosphorylation
decreases phosphorylation
increases activity
decreases activity
ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Paclitaxel results in increased activity of MAPK1 protein]; 3,3'-diindolylmethane promotes the reaction [Paclitaxel results in decreased phosphorylation of and results in decreased activity of MAPK1 protein]; 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Paclitaxel results in increased activity of MAPK1 protein]; [esculetin co-treated with Paclitaxel] results in decreased expression of MAPK1 protein; [MAP2K1 protein affects the activity of [MAPK1 protein co-treated with MAPK3 protein]] affects the reaction [SOD2 protein results in decreased susceptibility to Paclitaxel]; [PD168393 co-treated with Paclitaxel] results in decreased phosphorylation of and results in decreased activity of MAPK1 protein; Nicotine inhibits the reaction [Paclitaxel results in increased activity of MAPK1 protein]; Paclitaxel results in decreased phosphorylation of and results in decreased activity of MAPK1 protein; Paclitaxel results in increased phosphorylation of and results in increased activity of MAPK1 protein; Paclitaxel results in increased phosphorylation of and results in increased expression of MAPK1 protein; SOD2 protein affects the reaction [Paclitaxel results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Paclitaxel results in increased activity of MAPK1 protein]
CD14 protein affects the reaction [Paclitaxel results in increased phosphorylation of MAPK1 protein]; ITGAM protein affects the reaction [Paclitaxel results in increased phosphorylation of MAPK1 protein]
Paclitaxel results in decreased phosphorylation of MAPK1 protein
Paclitaxel results in decreased activity of MAPK1 protein
CTD PMID:11123339, PMID:12510025, PMID:15907805, PMID:16051289, PMID:16211241, PMID:16413505, PMID:16580691, PMID:18594523, PMID:19815708, PMID:20106947, PMID:23956100 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk13 mitogen activated protein kinase 13 increases expression ISO Paclitaxel results in increased expression of MAPK13 protein CTD PMID:15907983 NCBI chr20:6,018,374...6,027,467
Ensembl chr20:6,018,374...6,027,473
JBrowse link
G Mapk14 mitogen activated protein kinase 14 multiple interactions ISO [esculetin co-treated with Paclitaxel] results in decreased expression of MAPK14 protein; [Paclitaxel co-treated with Metformin] results in decreased expression of MAPK14 mRNA CTD PMID:16051289, PMID:29309887 NCBI chr20:5,933,290...5,995,137
Ensembl chr20:5,933,303...5,995,137
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation
increases activity
decreases phosphorylation
ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Paclitaxel results in increased activity of MAPK3 protein]; 3,3'-diindolylmethane promotes the reaction [Paclitaxel results in decreased phosphorylation of and results in decreased activity of MAPK3 protein]; 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Paclitaxel results in increased activity of MAPK3 protein]; [esculetin co-treated with Paclitaxel] results in decreased expression of MAPK3 protein; [MAP2K1 protein affects the activity of [MAPK1 protein co-treated with MAPK3 protein]] affects the reaction [SOD2 protein results in decreased susceptibility to Paclitaxel]; [PD168393 co-treated with Paclitaxel] results in decreased phosphorylation of and results in decreased activity of MAPK3 protein; [Tretinoin co-treated with Paclitaxel] results in increased phosphorylation of MAPK3 protein; Nicotine inhibits the reaction [Paclitaxel results in increased activity of MAPK3 protein]; Paclitaxel results in decreased phosphorylation of and results in decreased activity of MAPK3 protein; Paclitaxel results in increased phosphorylation of and results in increased activity of MAPK3 protein; Paclitaxel results in increased phosphorylation of and results in increased expression of MAPK3 protein; SOD2 protein affects the reaction [Paclitaxel results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Paclitaxel results in increased activity of MAPK3 protein]
CD14 protein affects the reaction [Paclitaxel results in increased phosphorylation of MAPK3 protein]; ITGAM protein affects the reaction [Paclitaxel results in increased phosphorylation of MAPK3 protein]
Paclitaxel results in decreased phosphorylation of MAPK3 protein
CTD PMID:11123339, PMID:12510025, PMID:15907805, PMID:16051289, PMID:16211241, PMID:16413505, PMID:16580691, PMID:18098270, PMID:18594523, PMID:20106947, PMID:23956100 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions
increases phosphorylation
increases expression
increases activity
ISO [esculetin co-treated with Paclitaxel] results in increased expression of MAPK8 protein; [Paclitaxel co-treated with F2 protein] results in increased phosphorylation of MAPK8 protein; aspartyl-glutamyl-valyl-aspartal inhibits the reaction [Paclitaxel results in increased activity of MAPK8 protein]; epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased phosphorylation of MAPK8 protein]; MAP3K1 protein affects the reaction [Paclitaxel results in increased activity of MAPK8 protein]; MAPK8 protein affects the reaction [Paclitaxel results in increased activity of CASP3 protein]; MAPK8 protein affects the reaction [Paclitaxel results in increased cleavage of PARP1 protein]; MAPK8 protein affects the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein]; Paclitaxel promotes the reaction [MAPK8 protein binds to MAP3K1 protein modified form]
Paclitaxel results in increased phosphorylation of MAPK8 protein
CD14 protein affects the reaction [Paclitaxel results in increased phosphorylation of MAPK8 protein]; ITGAM protein affects the reaction [Paclitaxel results in increased phosphorylation of MAPK8 protein]
Paclitaxel results in increased expression of MAPK8 protein
CTD PMID:10075725, PMID:11123339, PMID:11160861, PMID:16051289, PMID:19426673, PMID:19944065 NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions
increases expression
ISO
EXP
[esculetin co-treated with Paclitaxel] results in increased expression of MAPK9 protein; [Paclitaxel co-treated with F2 protein] results in increased phosphorylation of MAPK9 protein; epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased phosphorylation of MAPK9 protein]
Paclitaxel results in increased expression of MAPK9 protein
Paclitaxel analog results in increased expression of MAPK9 mRNA
CTD PMID:15585946, PMID:16051289, PMID:19944065 NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
JBrowse link
G Mapkapk5 MAPK activated protein kinase 5 affects response to substance ISO MAPKAPK5 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr12:40,510,378...40,529,332
Ensembl chr12:40,510,378...40,529,338
JBrowse link
G Mapre1 microtubule-associated protein, RP/EB family, member 1 multiple interactions
decreases localization
ISO olesoxime inhibits the reaction [Paclitaxel results in decreased localization of MAPRE1 protein] CTD PMID:20417191 NCBI chr 3:149,221,346...149,249,469
Ensembl chr 3:149,221,377...149,249,273
JBrowse link
G Mapre3 microtubule-associated protein, RP/EB family, member 3 affects localization
multiple interactions
ISO Paclitaxel affects the localization of MAPRE3 protein
olesoxime inhibits the reaction [Paclitaxel results in decreased localization of MAPRE3 protein]
CTD PMID:20417191 NCBI chr 6:26,878,738...26,923,459
Ensembl chr 6:26,878,744...26,889,882
JBrowse link
G Mapt microtubule-associated protein tau multiple interactions
decreases expression
ISO
EXP
MAPT mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]
Paclitaxel inhibits the reaction [annonacin affects the localization of MAPT protein]
Paclitaxel results in decreased expression of MAPT mRNA; Paclitaxel results in decreased expression of MAPT protein
CTD PMID:16896004, PMID:16930453, PMID:17634376 NCBI chr10:92,289,002...92,386,517
Ensembl chr10:92,288,910...92,386,517
JBrowse link
G Marveld1 MARVEL domain containing 1 increases response to substance ISO MARVELD1 protein results in increased susceptibility to Paclitaxel CTD PMID:27447558 NCBI chr 1:261,389,804...261,393,736
Ensembl chr 1:261,389,804...261,393,736
JBrowse link
G Matk megakaryocyte-associated tyrosine kinase multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in decreased expression of MATK mRNA CTD PMID:20705681 NCBI chr 7:11,325,246...11,334,311
Ensembl chr 7:11,325,254...11,330,278
JBrowse link
G Matn2 matrilin 2 multiple interactions
decreases response to substance
ISO [Cisplatin co-treated with Paclitaxel] results in decreased expression of MATN2 mRNA
MATN2 mRNA results in decreased susceptibility to Paclitaxel
CTD PMID:20705681, PMID:25199881 NCBI chr 7:72,985,832...73,210,093
Ensembl chr 7:72,985,495...73,207,695
JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member decreases expression ISO Paclitaxel results in decreased expression of MCL1 protein CTD PMID:14749477 NCBI chr 2:197,786,212...197,788,992 JBrowse link
G Mdm2 MDM2 proto-oncogene decreases response to substance ISO MDM2 protein results in decreased susceptibility to Paclitaxel CTD PMID:13130078 NCBI chr 7:60,719,060...60,743,618
Ensembl chr 7:60,719,066...60,743,328
JBrowse link
G Med1 mediator complex subunit 1 multiple interactions ISO Paclitaxel promotes the reaction [NR1I2 protein binds to MED1 protein] CTD PMID:15650019 NCBI chr10:86,101,560...86,145,271
Ensembl chr10:86,103,600...86,144,880
JBrowse link
G Med13l mediator complex subunit 13L multiple interactions ISO MED13L mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] CTD PMID:16896004 NCBI chr12:43,421,317...43,576,859
Ensembl chr12:43,421,308...43,576,804
JBrowse link
G Med4 mediator complex subunit 4 affects response to substance ISO MED4 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr15:55,406,543...55,416,816
Ensembl chr15:55,406,543...55,416,815
JBrowse link
G Melk maternal embryonic leucine zipper kinase multiple interactions ISO MELK mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] CTD PMID:16896004 NCBI chr 5:59,783,835...59,844,356
Ensembl chr 5:59,783,890...59,844,356
JBrowse link
G Men1 menin 1 increases expression EXP Paclitaxel results in increased expression of MEN1 mRNA CTD PMID:15585946 NCBI chr 1:221,704,394...221,710,343
Ensembl chr 1:221,704,493...221,710,331
JBrowse link
G Metrn meteorin, glial cell differentiation regulator multiple interactions ISO METRN mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] CTD PMID:16896004 NCBI chr10:15,164,439...15,166,457
Ensembl chr10:15,164,439...15,166,457
JBrowse link
G Mfap5 microfibril associated protein 5 multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in decreased expression of MFAP5 mRNA CTD PMID:20705681 NCBI chr 4:155,313,671...155,336,228
Ensembl chr 4:155,313,671...155,336,228
JBrowse link
G Mfn2 mitofusin 2 decreases expression EXP Paclitaxel results in decreased expression of MFN2 mRNA CTD PMID:28587902 NCBI chr 5:164,684,244...164,715,414
Ensembl chr 5:164,684,509...164,714,145
JBrowse link
G Mgmt O-6-methylguanine-DNA methyltransferase increases expression ISO Paclitaxel results in increased expression of MGMT mRNA CTD PMID:12929121 NCBI chr 1:209,237,255...209,464,189
Ensembl chr 1:209,237,233...209,464,190
JBrowse link
G Micb MHC class I polypeptide-related sequence B increases response to substance ISO MICB protein results in increased susceptibility to Paclitaxel CTD PMID:16734730 NCBI chr 1:79,754,587...79,772,092
Ensembl chr 1:79,754,587...79,772,092
JBrowse link
G Mir874 microRNA 874 increases response to substance ISO MIR874 mRNA results in increased susceptibility to Paclitaxel CTD PMID:30004169 NCBI chr17:7,025,014...7,025,089
Ensembl chr17:7,025,014...7,025,089
JBrowse link
G Mlec malectin affects response to substance ISO MLEC protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr12:47,219,071...47,233,769
Ensembl chr12:47,218,969...47,252,286
JBrowse link
G Mmp1 matrix metallopeptidase 1 affects response to substance
multiple interactions
ISO MMP1 protein affects the susceptibility to Paclitaxel
[Cisplatin co-treated with Paclitaxel] results in decreased expression of MMP1 mRNA
CTD PMID:16217747, PMID:20705681 NCBI chr 8:5,703,206...5,723,593
Ensembl chr 8:5,703,206...5,723,591
JBrowse link
G Mmp10 matrix metallopeptidase 10 multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in decreased expression of MMP10 mRNA CTD PMID:20705681 NCBI chr 8:5,734,348...5,742,243
Ensembl chr 8:5,734,348...5,742,243
JBrowse link
G Mmp16 matrix metallopeptidase 16 decreases expression ISO Paclitaxel results in decreased expression of MMP16 mRNA CTD PMID:18058816 NCBI chr 5:31,568,344...31,818,368
Ensembl chr 5:31,568,419...31,810,484
JBrowse link
G Mmp17 matrix metallopeptidase 17 decreases expression ISO Paclitaxel results in decreased expression of MMP17 mRNA CTD PMID:18058816 NCBI chr12:30,353,874...30,356,526
NCBI chr12:30,701,900...30,728,683
Ensembl chr12:30,702,571...30,728,655
JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in increased expression of MMP2 mRNA CTD PMID:20705681 NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
JBrowse link
G Mmp3 matrix metallopeptidase 3 increases expression
multiple interactions
EXP
ISO
Paclitaxel results in increased expression of MMP3; Paclitaxel results in increased expression of MMP3 mRNA
[Cisplatin co-treated with Paclitaxel] results in increased expression of MMP3 mRNA
CTD PMID:18754875, PMID:20705681 NCBI chr 8:5,676,608...5,698,579
Ensembl chr 8:5,676,665...5,698,579
JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in increased expression of MMP9 mRNA; Curcumin inhibits the reaction [Paclitaxel results in increased expression of MMP9 protein] CTD PMID:16243823, PMID:20705681 NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
JBrowse link
G Mok MOK protein kinase affects response to substance ISO MOK protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 6:135,228,755...135,259,645
Ensembl chr 6:135,228,803...135,259,603
JBrowse link
G Mphosph6 M phase phosphoprotein 6 decreases expression ISO Paclitaxel results in decreased expression of MPHOSPH6 protein CTD PMID:15907983 NCBI chr19:50,357,314...50,367,137
Ensembl chr19:50,357,338...50,367,187
JBrowse link
G Mpp3 membrane palmitoylated protein 3 increases expression ISO Paclitaxel results in increased expression of MPP3 protein CTD PMID:15907983 NCBI chr10:89,930,270...89,959,462
Ensembl chr10:89,930,241...89,959,176
JBrowse link
G Mpzl2 myelin protein zero-like 2 decreases expression
increases expression
ISO
EXP
Paclitaxel results in decreased expression of MPZL2 mRNA
Paclitaxel results in increased expression of MPZL2 mRNA
CTD PMID:18754875, PMID:19682730 NCBI chr 8:49,342,067...49,353,080
Ensembl chr 8:49,342,067...49,353,080
JBrowse link
G Mrc1 mannose receptor, C type 1 increases expression EXP Paclitaxel results in increased expression of MRC1 mRNA CTD PMID:18754875 NCBI chr17:81,352,700...81,433,743
Ensembl chr17:81,352,700...81,433,743
JBrowse link
G Mrpl40 mitochondrial ribosomal protein L40 affects response to substance ISO MRPL40 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr11:86,276,616...86,282,452
Ensembl chr11:86,276,616...86,282,451
JBrowse link
G Mrpl57 mitochondrial ribosomal protein L57 affects response to substance ISO MRPL57 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr15:38,096,994...38,097,856
Ensembl chr15:38,095,803...38,097,835
JBrowse link
G Mrps15 mitochondrial ribosomal protein S15 affects response to substance ISO MRPS15 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 5:144,054,452...144,065,045
Ensembl chr 5:144,054,452...144,065,045
JBrowse link
G Mrps18b mitochondrial ribosomal protein S18B decreases expression ISO Paclitaxel results in decreased expression of MRPS18B protein CTD PMID:15907983 NCBI chr20:3,344,870...3,350,929
Ensembl chr20:3,344,870...3,350,927
JBrowse link
G Msmo1 methylsterol monooxygenase 1 affects response to substance ISO MSMO1 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr16:26,859,441...26,875,880
Ensembl chr16:26,859,397...26,875,973
JBrowse link
G Mt2A metallothionein 2A increases response to substance ISO MT2A mRNA results in increased susceptibility to Paclitaxel CTD PMID:16322897 NCBI chr19:11,307,966...11,308,740
Ensembl chr19:11,307,967...11,308,740
JBrowse link
G Mtor mechanistic target of rapamycin kinase increases phosphorylation ISO Paclitaxel results in increased phosphorylation of MTOR protein CTD PMID:27769712 NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
JBrowse link
G Muc16 mucin 16, cell surface associated multiple interactions
decreases expression
ISO [Paclitaxel co-treated with Cisplatin] results in decreased expression of MUC16 protein
Paclitaxel results in decreased expression of MUC16 protein
CTD PMID:8751544, PMID:11706781 NCBI chr 8:18,438,838...18,639,777 JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions
affects response to substance
decreases expression
ISO [Cisplatin co-treated with Paclitaxel] results in decreased expression of MYC mRNA; [Paclitaxel co-treated with Metformin] results in decreased expression of MYC mRNA; Curcumin inhibits the reaction [Paclitaxel results in increased expression of MYC protein]
MYC protein affects the susceptibility to Paclitaxel
Paclitaxel results in decreased expression of MYC protein
CTD PMID:15907983, PMID:16243823, PMID:18802399, PMID:20705681, PMID:29309887 NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
JBrowse link
G Myo5a myosin VA increases response to substance ISO MYO5A protein results in increased susceptibility to Paclitaxel CTD PMID:16734730 NCBI chr 8:82,038,966...82,156,507
Ensembl chr 8:82,037,977...82,156,617
JBrowse link
G Nampt nicotinamide phosphoribosyltransferase multiple interactions
decreases expression
ISO [Cisplatin co-treated with Paclitaxel] results in increased expression of NAMPT mRNA
Paclitaxel results in decreased expression of NAMPT mRNA
CTD PMID:12929121, PMID:20705681 NCBI chr 6:52,122,085...52,156,473
Ensembl chr 6:52,122,085...52,156,472
JBrowse link
G Nanog Nanog homeobox multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in increased expression of NANOG mRNA; [Cisplatin co-treated with Paclitaxel] results in increased expression of NANOG protein CTD PMID:20705681 NCBI chr 4:155,531,906...155,539,268
Ensembl chr 4:155,531,906...155,539,268
JBrowse link
G Nat1 N-acetyltransferase 1 decreases activity
decreases expression
ISO Paclitaxel results in decreased activity of NAT1 mRNA; Paclitaxel results in decreased activity of NAT1 protein
Paclitaxel results in decreased expression of NAT1 mRNA
CTD PMID:15015580, PMID:17564303 NCBI chr16:23,970,742...23,991,573
Ensembl chr16:23,970,743...23,991,573
JBrowse link
G Nav3 neuron navigator 3 affects response to substance ISO NAV3 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 7:52,164,805...52,508,145
Ensembl chr 7:52,165,233...52,404,774
JBrowse link
G Ncapg non-SMC condensin I complex, subunit G affects response to substance ISO NCAPG protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr14:69,898,268...69,927,885
Ensembl chr14:69,899,128...69,927,938
JBrowse link
G Ncoa1 nuclear receptor coactivator 1 multiple interactions ISO Ketoconazole inhibits the reaction [Paclitaxel promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Paclitaxel promotes the reaction [NR1I2 protein binds to NCOA1 protein] CTD PMID:16819505 NCBI chr 6:28,677,563...28,931,844
Ensembl chr 6:28,677,540...28,931,843
JBrowse link
G Ncoa3 nuclear receptor coactivator 3 multiple interactions ISO Paclitaxel promotes the reaction [NR1I2 protein binds to NCOA3 protein] CTD PMID:15650019 NCBI chr 3:162,692,176...162,788,582
Ensembl chr 3:162,692,185...162,787,548
JBrowse link
G Ndufa1 NADH:ubiquinone oxidoreductase subunit A1 affects response to substance ISO NDUFA1 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr  X:123,803,109...123,806,760
Ensembl chr  X:124,513,269...124,516,705
Ensembl chr  X:124,513,269...124,516,705
JBrowse link
G Ndufa13 NADH:ubiquinone oxidoreductase subunit A13 affects response to substance ISO NDUFA13 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr16:21,275,311...21,282,246
Ensembl chr16:21,275,311...21,282,246
JBrowse link
G Ndufa3 NADH:ubiquinone oxidoreductase subunit A3 affects response to substance ISO NDUFA3 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 1:64,172,462...64,175,174
Ensembl chr 1:64,172,540...64,175,099
JBrowse link
G Ndufb2 NADH:ubiquinone oxidoreductase subunit B2 affects response to substance ISO NDUFB2 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 4:67,378,188...67,385,267
Ensembl chr 4:67,378,188...67,385,266
JBrowse link
G Ndufb7 NADH:ubiquinone oxidoreductase subunit B7 affects response to substance ISO NDUFB7 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr19:24,701,067...24,705,405
Ensembl chr19:24,701,049...24,705,405
JBrowse link
G Ndufs4 NADH:ubiquinone oxidoreductase subunit S4 multiple interactions ISO Paclitaxel inhibits the reaction [NDUFS4 protein affects the reaction [Rotenone results in increased abundance of Dopamine]]; Paclitaxel inhibits the reaction [NDUFS4 protein affects the reaction [Rotenone results in increased abundance of Reactive Oxygen Species]] CTD PMID:21383081 NCBI chr 2:46,372,488...46,476,162
Ensembl chr 2:46,372,518...46,476,203
JBrowse link
G Ndufs8 NADH:ubiquinone oxidoreductase core subunit S8 affects response to substance ISO NDUFS8 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 1:219,141,289...219,144,610
Ensembl chr 1:219,141,292...219,144,610
JBrowse link
G Ndufv1 NADH:ubiquinone oxidoreductase core subunit V1 decreases expression ISO Paclitaxel results in decreased expression of NDUFV1 mRNA CTD PMID:15000894 NCBI chr 1:219,254,293...219,259,328
Ensembl chr 1:219,254,279...219,259,448
JBrowse link
G Nes nestin multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in increased expression of NES mRNA CTD PMID:20705681 NCBI chr 2:187,343,109...187,352,972
Ensembl chr 2:187,344,056...187,352,969
JBrowse link
G Neurod4 neuronal differentiation 4 decreases expression ISO Paclitaxel results in decreased expression of NEUROD4 mRNA CTD PMID:12929121 NCBI chr 7:9,699,964...9,712,067
Ensembl chr 7:9,699,961...9,711,928
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 decreases response to substance
multiple interactions
decreases expression
ISO
EXP
NFE2L2 results in decreased susceptibility to Paclitaxel
[KEAP1 protein results in decreased stability of NFE2L2 protein] which results in increased susceptibility to Paclitaxel
Paclitaxel results in decreased expression of NFE2L2 mRNA
CTD PMID:15585946, PMID:20530669 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions ISO ITGAM protein affects the reaction [Paclitaxel affects the localization of and results in increased activity of [NFKB1 protein binds to RELA protein]]; Paclitaxel affects the localization of and results in increased activity of [NFKB1 protein binds to RELA protein]
[Paclitaxel co-treated with Metformin] results in decreased expression of NFKB1 mRNA; Curcumin inhibits the reaction [Paclitaxel results in increased activity of NFKB1 protein]
CTD PMID:11123339, PMID:16243823, PMID:29309887 NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
JBrowse link
G Nfkb2 nuclear factor kappa B subunit 2 multiple interactions ISO [Paclitaxel co-treated with Metformin] results in decreased expression of NFKB2 mRNA CTD PMID:29309887 NCBI chr 1:266,050,634...266,059,277
Ensembl chr 1:266,053,002...266,059,256
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO Curcumin inhibits the reaction [Paclitaxel results in increased phosphorylation of and results in increased degradation of NFKBIA protein] CTD PMID:16243823 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Ngf nerve growth factor decreases response to substance
multiple interactions
decreases expression
EXP NGF protein results in decreased susceptibility to Paclitaxel
Tretinoin inhibits the reaction [Paclitaxel results in decreased expression of NGF protein]
CTD PMID:9622663, PMID:10553948, PMID:21865574 NCBI chr 2:204,886,158...204,939,523
Ensembl chr 2:204,886,202...204,940,453
JBrowse link
G Nkain1 Sodium/potassium transporting ATPase interacting 1 multiple interactions ISO NKAIN1 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] CTD PMID:16896004 NCBI chr 5:148,635,537...148,669,709
Ensembl chr 5:148,661,070...148,667,746
JBrowse link
G Nme1 NME/NM23 nucleoside diphosphate kinase 1 increases expression EXP Paclitaxel results in increased expression of NME1 mRNA CTD PMID:15585946 NCBI chr10:81,657,152...81,666,542
Ensembl chr10:81,657,153...81,666,523
JBrowse link
G Nme4 NME/NM23 nucleoside diphosphate kinase 4 decreases expression ISO Paclitaxel results in decreased expression of NME4 protein CTD PMID:15907983 NCBI chr10:15,461,567...15,465,422
Ensembl chr10:15,431,638...15,465,413
JBrowse link
G Nmrk2 nicotinamide riboside kinase 2 decreases response to substance ISO ITGB1BP3 mRNA results in decreased susceptibility to Paclitaxel CTD PMID:25199881 NCBI chr 7:11,382,966...11,386,170
Ensembl chr 7:11,383,116...11,386,948
JBrowse link
G Nod1 nucleotide-binding oligomerization domain containing 1 multiple interactions ISO [Paclitaxel co-treated with Metformin] results in decreased expression of NOD1 mRNA CTD PMID:29309887 NCBI chr 4:85,123,965...85,175,206
Ensembl chr 4:85,123,960...85,174,951
JBrowse link
G Nop58 NOP58 ribonucleoprotein decreases expression ISO Paclitaxel results in decreased expression of NOL5 mRNA CTD PMID:12929121 NCBI chr 9:66,495,881...66,520,521
Ensembl chr 9:66,495,832...66,519,788
JBrowse link
G Nos3 nitric oxide synthase 3 decreases expression
multiple interactions
ISO Paclitaxel results in decreased expression of NOS3 mRNA; Paclitaxel results in decreased expression of NOS3 protein
Aspirin inhibits the reaction [Paclitaxel results in decreased expression of NOS3 protein]; cilostazol inhibits the reaction [Paclitaxel results in decreased expression of NOS3 protein]
CTD PMID:19520256, PMID:19815708 NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
JBrowse link
G Npm1 nucleophosmin 1 decreases response to substance ISO NPM1 protein results in decreased susceptibility to Paclitaxel CTD PMID:24736981 NCBI chr10:18,080,949...18,091,062
Ensembl chr10:18,080,950...18,090,950
JBrowse link
G Npy neuropeptide Y increases expression EXP Paclitaxel results in increased expression of NPY protein CTD PMID:17686523 NCBI chr 4:79,557,856...79,565,059
Ensembl chr 4:79,557,854...79,565,097
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 increases activity
increases abundance
multiple interactions
ISO Paclitaxel results in increased activity of NR1I2 protein
NR1I2 gene mutant form results in increased abundance of Paclitaxel
[Paclitaxel results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 mRNA; [SR 12813 results in increased activity of NR1I2 protein] which results in decreased susceptibility to Paclitaxel; Ketoconazole inhibits the reaction [Paclitaxel promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Ketoconazole inhibits the reaction [Paclitaxel results in increased activity of NR1I2 protein]; NR1I2 protein promotes the reaction [Paclitaxel results in increased expression of and results in increased activity of ABCB1 protein]; Paclitaxel binds to and results in increased activity of NR1I2 protein; Paclitaxel promotes the reaction [NR1I2 protein binds to MED1 protein]; Paclitaxel promotes the reaction [NR1I2 protein binds to NCOA1 protein]; Paclitaxel promotes the reaction [NR1I2 protein binds to NCOA3 protein]
CTD PMID:12065438, PMID:14977870, PMID:15650019, PMID:15864135, PMID:16819505, PMID:17438109, PMID:18839173, PMID:19746521, PMID:20041327 NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
JBrowse link
G Nras NRAS proto-oncogene, GTPase multiple interactions ISO [Paclitaxel co-treated with Metformin] results in decreased expression of NRAS mRNA CTD PMID:29309887 NCBI chr 2:205,553,119...205,563,716
Ensembl chr 2:205,553,163...205,560,791
JBrowse link
G Nrp1 neuropilin 1 increases expression ISO Paclitaxel results in increased expression of NRP1 mRNA CTD PMID:19682730 NCBI chr19:61,332,351...61,486,166
Ensembl chr19:61,332,351...61,485,858
JBrowse link
G Nudt12 nudix hydrolase 12 increases expression ISO Paclitaxel results in increased expression of NUDT12 mRNA CTD PMID:12929121 NCBI chr 9:105,680,603...105,693,374
Ensembl chr 9:105,680,670...105,693,357
JBrowse link
G Nudt15 nudix hydrolase 15 affects response to substance ISO NUDT15 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr15:55,417,774...55,456,698
Ensembl chr15:55,419,502...55,456,698
JBrowse link
G Nudt4 nudix hydrolase 4 affects response to substance ISO NUDT4 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 7:36,643,916...36,660,334
Ensembl chr 7:36,643,916...36,660,141
JBrowse link
G Nupr1 nuclear protein 1, transcriptional regulator increases expression EXP Paclitaxel results in increased expression of NUPR1 mRNA CTD PMID:18754875 NCBI chr 1:194,767,484...194,769,519
Ensembl chr 1:194,767,474...194,769,524
JBrowse link
G Nus1 NUS1 dehydrodolichyl diphosphate synthase subunit decreases expression ISO Paclitaxel results in decreased expression of NUS1 mRNA CTD PMID:12929121 NCBI chr20:33,557,052...33,584,011
Ensembl chr20:33,557,052...33,584,010
JBrowse link
G Nusap1 nucleolar and spindle associated protein 1 affects response to substance ISO NUSAP1 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 3:111,422,267...111,452,600
Ensembl chr 3:111,422,267...111,452,971
JBrowse link
G Oat ornithine aminotransferase increases expression EXP Paclitaxel analog results in increased expression of OAT mRNA; Paclitaxel results in increased expression of OAT mRNA CTD PMID:15585946 NCBI chr 1:204,562,289...204,582,070
Ensembl chr 1:204,562,289...204,582,070
JBrowse link
G Obp3 alpha-2u globulin PGCL4 increases expression EXP Paclitaxel results in increased expression of OBP3 mRNA CTD PMID:18754875 NCBI chr 5:77,313,357...77,316,875 JBrowse link
G Ogg1 8-oxoguanine DNA glycosylase increases expression ISO Paclitaxel results in increased expression of OGG1 protein CTD PMID:15907983 NCBI chr 4:145,282,828...145,289,367
Ensembl chr 4:145,282,797...145,289,326
JBrowse link
G Ogn osteoglycin multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in increased expression of OGN mRNA CTD PMID:20705681 NCBI chr17:14,607,442...14,628,274
Ensembl chr17:15,447,716...15,467,359
Ensembl chr17:15,447,716...15,467,359
JBrowse link
G Olfml3 olfactomedin-like 3 increases expression ISO Paclitaxel results in increased expression of OLFML3 mRNA CTD PMID:19682730 NCBI chr 2:206,219,419...206,222,248
Ensembl chr 2:206,219,419...206,222,248
JBrowse link
G Osbpl10 oxysterol binding protein-like 10 affects response to substance ISO OSBPL10 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 8:123,029,722...123,303,553
Ensembl chr 8:123,126,667...123,293,562
JBrowse link
G Osmr oncostatin M receptor increases response to substance ISO OSMR protein results in increased susceptibility to Paclitaxel CTD PMID:16734730 NCBI chr 2:56,107,491...56,163,522
Ensembl chr 2:56,110,777...56,151,531
JBrowse link
G Osr2 odd-skipped related transciption factor 2 multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in decreased expression of OSR2 mRNA CTD PMID:20705681 NCBI chr 7:74,047,820...74,055,096
Ensembl chr 7:74,047,814...74,055,256
JBrowse link
G Oxt oxytocin/neurophysin I prepropeptide increases expression EXP Paclitaxel analog results in increased expression of OXT mRNA; Paclitaxel results in increased expression of OXT mRNA CTD PMID:15585946 NCBI chr 3:123,106,694...123,107,534
Ensembl chr 3:123,106,694...123,107,534
JBrowse link
G Padi2 peptidyl arginine deiminase 2 decreases expression ISO Paclitaxel results in decreased expression of PADI2 protein CTD PMID:15907983 NCBI chr 5:159,428,479...159,471,113
Ensembl chr 5:159,428,515...159,471,144
JBrowse link
G Papln papilin, proteoglycan-like sulfated glycoprotein multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in decreased expression of PAPLN mRNA CTD PMID:20705681 NCBI chr 6:107,245,573...107,282,256
Ensembl chr 6:107,245,820...107,276,755
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 increases cleavage
affects response to substance
multiple interactions
ISO Paclitaxel results in increased cleavage of PARP1 protein
PARP1 protein affects the susceptibility to Paclitaxel
[3,3'-diindolylmethane co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of PARP1 protein; [Luteolin co-treated with Paclitaxel] results in decreased expression of PARP1 protein; [resveratrol co-treated with Paclitaxel] results in increased cleavage of PARP1 protein; AKT1 protein affects the reaction [Paclitaxel results in increased cleavage of PARP1 protein]; alvocidib promotes the reaction [Paclitaxel results in increased cleavage of PARP1 protein]; CD40LG protein inhibits the reaction [Paclitaxel promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]]; MAP2K4 protein affects the reaction [Paclitaxel results in increased cleavage of PARP1 protein]; MAP3K5 protein affects the reaction [Paclitaxel results in increased cleavage of PARP1 protein]; MAPK8 protein affects the reaction [Paclitaxel results in increased cleavage of PARP1 protein]; Paclitaxel promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]; TYMP inhibits the reaction [Paclitaxel results in increased cleavage of PARP1 protein]; TYMP mutant form promotes the reaction [Paclitaxel results in increased cleavage of PARP1 protein]
CTD PMID:10075725, PMID:10430095, PMID:10502406, PMID:11774260, PMID:14749477, PMID:15492279, PMID:15585644, PMID:15907805, PMID:16545138, PMID:16580691, PMID:17404021, PMID:18071906, PMID:18451153, PMID:19426673, PMID:20610805, PMID:24126434, PMID:24525192 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Pawr pro-apoptotic WT1 regulator multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in increased expression of PAWR mRNA CTD PMID:20705681 NCBI chr 7:51,273,764...51,353,700
Ensembl chr 7:51,273,771...51,353,068
JBrowse link
G Pcca propionyl-CoA carboxylase subunit alpha decreases expression ISO Paclitaxel results in decreased expression of PCCA protein CTD PMID:15907983 NCBI chr15:108,960,509...109,306,879
Ensembl chr15:108,960,562...109,306,603
JBrowse link
G Pccb propionyl-CoA carboxylase subunit beta increases expression EXP Paclitaxel results in increased expression of PCCB mRNA CTD PMID:15585946 NCBI chr 8:109,368,887...109,418,871
Ensembl chr 8:109,368,624...109,418,872
JBrowse link
G Pcna proliferating cell nuclear antigen multiple interactions
increases expression
ISO [Imatinib Mesylate co-treated with Paclitaxel] results in decreased expression of PCNA protein
Paclitaxel results in increased expression of PCNA
CTD PMID:9858906, PMID:15867366 NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
JBrowse link
G Pcolce procollagen C-endopeptidase enhancer increases expression ISO Paclitaxel results in increased expression of PCOLCE mRNA CTD PMID:19682730 NCBI chr12:22,153,995...22,160,311
Ensembl chr12:22,153,983...22,160,337
JBrowse link
G Pdk1 pyruvate dehydrogenase kinase 1 multiple interactions ISO [PDK1 protein binds to AKT1 protein] results in decreased susceptibility to [Paclitaxel co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one]; [PDK1 protein binds to AKT1 protein] which results in decreased susceptibility to Paclitaxel CTD PMID:20361045 NCBI chr 3:58,530,870...58,561,494
Ensembl chr 3:58,530,870...58,558,027
JBrowse link
G Pdpk1 3-phosphoinositide dependent protein kinase-1 decreases response to substance ISO PDPK1 protein results in decreased susceptibility to Paclitaxel CTD PMID:16782806 NCBI chr10:13,446,373...13,525,248
Ensembl chr10:13,451,624...13,515,448
JBrowse link
G Pecam1 platelet and endothelial cell adhesion molecule 1 multiple interactions ISO [Imatinib Mesylate co-treated with Paclitaxel] results in decreased expression of PECAM1 protein; zoledronic acid promotes the reaction [[Imatinib Mesylate co-treated with Paclitaxel] results in decreased expression of PECAM1 protein] CTD PMID:15867366 NCBI chr10:94,850,971...94,913,202 JBrowse link
G Perp p53 apoptosis effector related to PMP22 increases expression ISO Paclitaxel results in increased expression of PERP mRNA CTD PMID:18058816 NCBI chr 1:14,224,392...14,236,838
Ensembl chr 1:14,224,393...14,236,846
JBrowse link
G Phgdh phosphoglycerate dehydrogenase decreases expression EXP Paclitaxel results in decreased expression of PHGDH protein CTD PMID:21118710 NCBI chr 2:200,484,245...200,513,564
Ensembl chr 2:200,484,246...200,513,564
JBrowse link
G Pik3c2a phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha affects response to substance ISO PIK3C2A protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 1:185,210,922...185,326,314
Ensembl chr 1:185,210,922...185,326,314
JBrowse link
G Pkd2 polycystin 2, transient receptor potential cation channel increases response to substance ISO PKD2 protein results in increased susceptibility to Paclitaxel CTD PMID:16734730 NCBI chr14:6,602,004...6,645,257
Ensembl chr14:6,602,004...6,645,257
JBrowse link
G Pklr pyruvate kinase L/R decreases expression ISO Paclitaxel results in decreased expression of PKLR mRNA CTD PMID:12929121 NCBI chr 2:188,449,158...188,458,034
Ensembl chr 2:188,449,210...188,459,592
JBrowse link
G Pkm pyruvate kinase M1/2 affects response to substance ISO PKM protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 8:64,480,963...64,502,957
Ensembl chr 8:64,481,172...64,502,722
JBrowse link
G Pkp2 plakophilin 2 decreases response to substance ISO PKP2 protein results in decreased susceptibility to Paclitaxel CTD PMID:16734730 NCBI chr11:88,912,163...88,972,213 JBrowse link
G Pla2g2a phospholipase A2 group IIA increases expression EXP Paclitaxel results in increased expression of PLA2G2A mRNA CTD PMID:18754875 NCBI chr 5:157,282,650...157,285,295
Ensembl chr 5:157,282,669...157,285,328
JBrowse link
G Pla2g2d phospholipase A2, group IID increases expression EXP Paclitaxel results in increased expression of PLA2G2D mRNA CTD PMID:18754875 NCBI chr 5:157,222,636...157,228,795
Ensembl chr 5:157,222,636...157,228,791
JBrowse link
G Plce1 phospholipase C, epsilon 1 decreases response to substance ISO PLCE1 protein results in decreased susceptibility to Paclitaxel CTD PMID:16734730 NCBI chr 1:257,156,023...257,465,440
Ensembl chr 1:257,157,264...257,466,064
JBrowse link
G Plcl1 phospholipase C-like 1 increases expression EXP Paclitaxel analog results in increased expression of PLCL1 mRNA; Paclitaxel results in increased expression of PLCL1 mRNA CTD PMID:15585946 NCBI chr 9:62,016,112...62,349,244
Ensembl chr 9:62,291,405...62,349,309
JBrowse link
G Plk1 polo-like kinase 1 multiple interactions ISO [pifithrin co-treated with Paclitaxel] results in increased expression of PLK1 protein CTD PMID:18516295 NCBI chr 1:192,115,990...192,125,969
Ensembl chr 1:192,115,966...192,125,989
JBrowse link
G Plk4 polo-like kinase 4 decreases expression ISO Paclitaxel results in decreased expression of PLK4 mRNA CTD PMID:15000894 NCBI chr 2:127,686,911...127,705,518
Ensembl chr 2:127,686,925...127,705,518
JBrowse link
G Plpp1 phospholipid phosphatase 1 decreases response to substance ISO PLPP1 protein results in decreased susceptibility to Paclitaxel CTD PMID:16734730 NCBI chr 2:44,664,076...44,726,820
Ensembl chr 2:44,664,124...44,726,689
JBrowse link
G Plpp2 phospholipid phosphatase 2 decreases expression ISO Paclitaxel results in decreased expression of PLPP2 mRNA CTD PMID:19682730 NCBI chr 7:13,062,168...13,070,281
Ensembl chr 7:13,062,196...13,070,280
JBrowse link
G Pmp22 peripheral myelin protein 22 decreases response to substance ISO PMP22 mRNA results in decreased susceptibility to Paclitaxel CTD PMID:16322897 NCBI chr10:49,538,588...49,568,583
Ensembl chr10:49,538,588...49,568,583
JBrowse link
G Polk DNA polymerase kappa decreases expression ISO Paclitaxel results in decreased expression of POLK mRNA CTD PMID:15000894 NCBI chr 2:27,305,718...27,364,906
Ensembl chr 2:27,305,728...27,364,906
JBrowse link
G Por cytochrome p450 oxidoreductase increases response to substance ISO POR mRNA results in increased susceptibility to Paclitaxel CTD PMID:15239142 NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
JBrowse link
G Postn periostin decreases response to substance
increases expression
ISO POSTN mRNA results in decreased susceptibility to Paclitaxel
Paclitaxel results in increased expression of POSTN mRNA
CTD PMID:19682730, PMID:25199881 NCBI chr 2:143,656,820...143,688,087
Ensembl chr 2:143,656,793...143,688,087
JBrowse link
G Pou5f1 POU class 5 homeobox 1 multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in increased expression of POU5F1 mRNA; [Cisplatin co-treated with Paclitaxel] results in increased expression of POU5F1 protein CTD PMID:20705681 NCBI chr20:3,747,231...3,751,994
Ensembl chr20:3,747,221...3,751,994
JBrowse link
G Ppib peptidylprolyl isomerase B affects response to substance ISO PPIB protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 8:71,719,681...71,725,538
Ensembl chr 8:71,719,563...71,725,562
JBrowse link
G Ppp1cb protein phosphatase 1 catalytic subunit beta affects response to substance ISO PPP1CB protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 6:23,548,507...23,581,136
Ensembl chr 6:23,549,317...23,581,052
JBrowse link
G Ppp1r12a protein phosphatase 1, regulatory subunit 12A decreases expression ISO Paclitaxel results in decreased expression of PPP1R12A mRNA CTD PMID:12929121 NCBI chr 7:51,404,971...51,515,382
Ensembl chr 7:51,404,919...51,515,373
JBrowse link
G Ppp1r9a protein phosphatase 1, regulatory subunit 9A decreases expression ISO Paclitaxel results in decreased expression of PPP1R9A mRNA CTD PMID:15000894 NCBI chr 4:29,976,485...30,247,371
Ensembl chr 4:29,978,739...30,241,911
JBrowse link
G Ppt1 palmitoyl-protein thioesterase 1 decreases expression ISO Paclitaxel results in decreased expression of PPT1 protein CTD PMID:30667213 NCBI chr 5:140,538,260...140,558,163
Ensembl chr 5:140,538,260...140,558,162
JBrowse link
G Prc1 protein regulator of cytokinesis 1 increases expression ISO Paclitaxel results in increased expression of PRC1 mRNA CTD PMID:17374387 NCBI chr 1:142,087,181...142,108,746
Ensembl chr 1:142,087,208...142,108,746
JBrowse link
G Prdm1 PR/SET domain 1 multiple interactions ISO [Paclitaxel co-treated with Metformin] results in increased expression of PRDM1 mRNA CTD PMID:29309887 NCBI chr20:49,464,921...49,556,623
Ensembl chr20:49,464,919...49,556,518
JBrowse link
G Prdm4 PR/SET domain 4 decreases expression ISO Paclitaxel results in decreased expression of PRDM4 protein CTD PMID:15907983 NCBI chr 7:23,959,932...23,986,535
Ensembl chr 7:23,960,378...23,985,525
JBrowse link
G Prdx2 peroxiredoxin 2 affects response to substance ISO PRDX2 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr19:26,084,816...26,090,095
Ensembl chr19:26,084,903...26,090,094
JBrowse link
G Prkcd protein kinase C, delta affects localization ISO Paclitaxel affects the localization of PRKCD protein CTD PMID:9852137 NCBI chr16:6,655,131...6,675,746
Ensembl chr16:6,655,120...6,675,746
JBrowse link
G Prkce protein kinase C, epsilon affects response to substance EXP PRKCE protein affects the susceptibility to Paclitaxel CTD PMID:11738263 NCBI chr 6:9,483,400...9,973,396
Ensembl chr 6:9,790,422...9,973,396
JBrowse link
G Prom1 prominin 1 multiple interactions
decreases response to substance
ISO [Cisplatin co-treated with Paclitaxel] results in increased expression of PROM1 mRNA
PROM1 results in decreased susceptibility to Paclitaxel
CTD PMID:20705681, PMID:21919130 NCBI chr14:71,532,321...71,637,400
Ensembl chr14:71,533,063...71,637,417
JBrowse link
G Prrg4 proline rich and Gla domain 4 decreases expression ISO Paclitaxel results in decreased expression of PRRG4 mRNA CTD PMID:19682730 NCBI chr 3:94,783,866...94,808,861
Ensembl chr 3:94,784,008...94,808,861
JBrowse link
G Psap prosaposin decreases expression ISO Paclitaxel results in decreased expression of PSAP mRNA CTD PMID:15000894 NCBI chr20:29,831,302...29,856,876
Ensembl chr20:29,831,314...29,856,875
JBrowse link
G Psma4 proteasome 20S subunit alpha 4 affects response to substance ISO PSMA4 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 8:59,532,456...59,539,916
Ensembl chr 8:59,532,389...59,539,920
JBrowse link
G Psmb1 proteasome 20S subunit beta 1 affects response to substance ISO PSMB1 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 1:57,470,878...57,491,359
Ensembl chr 1:57,470,632...57,489,727
JBrowse link
G Psmb6 proteasome 20S subunit beta 6 affects response to substance ISO PSMB6 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr10:57,131,339...57,133,685
Ensembl chr10:57,131,386...57,133,637
JBrowse link
G Pten phosphatase and tensin homolog increases response to substance
increases activity
ISO PTEN results in increased susceptibility to Paclitaxel
Paclitaxel results in increased activity of PTEN protein
CTD PMID:11707646, PMID:15548710 NCBI chr 1:251,421,814...251,487,634
Ensembl chr 1:251,421,596...251,487,832
JBrowse link
G Ptger4 prostaglandin E receptor 4 decreases expression EXP Paclitaxel results in decreased expression of PTGER4 mRNA CTD PMID:15585946 NCBI chr 2:54,951,625...54,966,470
Ensembl chr 2:54,952,821...54,963,448
JBrowse link
G Ptges3 prostaglandin E synthase 3 affects response to substance ISO PTGES3 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 7:2,479,267...2,497,024
Ensembl chr 7:2,479,311...2,497,013
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions
increases expression
decreases expression
ISO Curcumin inhibits the reaction [Paclitaxel results in increased expression of PTGS2 mRNA]; Curcumin inhibits the reaction [Paclitaxel results in increased expression of PTGS2 protein]; PTGS2 protein results in decreased susceptibility to [Platinum co-treated with Paclitaxel]
CD14 protein affects the reaction [Paclitaxel results in increased expression of PTGS2 mRNA]; ITGAM protein affects the reaction [Paclitaxel results in increased expression of PTGS2 mRNA]; TLR4 protein affects the reaction [Paclitaxel results in increased expression of PTGS2 mRNA]
Paclitaxel results in decreased expression of PTGS2 protein
CTD PMID:11123339, PMID:15907983, PMID:16243823, PMID:16831230 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Ptk6 protein tyrosine kinase 6 increases expression ISO Paclitaxel results in increased expression of PTK6 mRNA CTD PMID:15000894 NCBI chr 3:176,698,305...176,706,896
Ensembl chr 3:176,698,305...176,706,896
JBrowse link
G Ptpn13 protein tyrosine phosphatase, non-receptor type 13 increases response to substance ISO PTPN13 protein results in increased susceptibility to Paclitaxel CTD PMID:16734730 NCBI chr14:7,688,551...7,863,664
Ensembl chr14:7,688,551...7,863,664
JBrowse link
G Ptpn7 protein tyrosine phosphatase, non-receptor type 7 increases expression ISO Paclitaxel results in increased expression of PTPN7 protein CTD PMID:15907983 NCBI chr13:51,958,023...51,971,431
Ensembl chr13:51,958,834...51,972,777
JBrowse link
G Pttg1 PTTG1 regulator of sister chromatid separation, securin affects expression ISO Paclitaxel affects the expression of PTTG1 protein CTD PMID:27769712 NCBI chr10:29,014,332...29,026,088
Ensembl chr10:29,020,049...29,026,002
JBrowse link
G Qrich1 glutamine-rich 1 increases phosphorylation ISO Paclitaxel results in increased phosphorylation of QRICH1 protein CTD PMID:17510977 NCBI chr 8:117,305,803...117,346,738
Ensembl chr 8:117,307,339...117,346,736
JBrowse link
G Qsox1 quiescin sulfhydryl oxidase 1 decreases expression ISO Paclitaxel results in decreased expression of QSOX1 mRNA CTD PMID:15000894 NCBI chr13:73,423,396...73,460,890
Ensembl chr13:73,423,397...73,460,935
JBrowse link
G Rab34 RAB34, member RAS oncogene family increases expression ISO Paclitaxel results in increased expression of RAB34 mRNA CTD PMID:12929121 NCBI chr10:65,448,111...65,452,178
Ensembl chr10:65,448,950...65,452,177
JBrowse link
G Rac1 Rac family small GTPase 1 decreases expression ISO Paclitaxel results in decreased expression of RAC1 mRNA CTD PMID:15000894 NCBI chr12:13,090,316...13,111,841
Ensembl chr12:13,090,172...13,111,873
JBrowse link
G Rad23a RAD23 homolog A, nucleotide excision repair protein decreases expression ISO Paclitaxel results in decreased expression of RAD23A mRNA CTD PMID:12929121 NCBI chr19:25,949,488...25,956,677
Ensembl chr19:25,949,490...25,955,391
JBrowse link
G Raf1 Raf-1 proto-oncogene, serine/threonine kinase increases phosphorylation
multiple interactions
ISO Paclitaxel results in increased phosphorylation of RAF1 protein
[pifithrin co-treated with Paclitaxel] results in increased phosphorylation of RAF1 protein; resveratrol inhibits the reaction [Paclitaxel results in increased phosphorylation of RAF1 protein]
CTD PMID:12510025, PMID:18516295 NCBI chr 4:147,532,040...147,592,769
Ensembl chr 4:147,532,042...147,592,699
JBrowse link
G Ramp1 receptor activity modifying protein 1 multiple interactions ISO RAMP1 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] CTD PMID:16896004 NCBI chr 9:98,313,632...98,364,206
Ensembl chr 9:98,313,632...98,364,205
JBrowse link
G Rapgef5 Rap guanine nucleotide exchange factor 5 increases expression ISO Paclitaxel results in increased expression of RAPGEF5 protein CTD PMID:15907983 NCBI chr 6:145,387,890...145,625,243
Ensembl chr 6:145,546,595...145,625,236
JBrowse link
G Rarb retinoic acid receptor, beta multiple interactions
increases expression
EXP Tretinoin promotes the reaction [Paclitaxel results in increased expression of RARB mRNA] CTD PMID:21865574 NCBI chr15:9,915,223...10,262,599
Ensembl chr15:10,120,206...10,262,599
JBrowse link
G Rb1 RB transcriptional corepressor 1 multiple interactions
increases phosphorylation
ISO 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Paclitaxel results in increased phosphorylation of RB1 protein] CTD PMID:15138593 NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
JBrowse link
G Rbbp9 RB binding protein 9, serine hydrolase decreases expression ISO Paclitaxel results in decreased expression of RBBP9 mRNA CTD PMID:15000894 NCBI chr 3:138,701,579...138,708,332
Ensembl chr 3:138,701,586...138,708,332
JBrowse link
G Rbp1 retinol binding protein 1 increases response to substance ISO RBP1 protein results in increased susceptibility to Paclitaxel CTD PMID:16734730 NCBI chr 8:106,449,321...106,470,842
Ensembl chr 8:106,449,321...106,470,842
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit decreases expression
multiple interactions
ISO Paclitaxel results in decreased expression of RELA protein
ITGAM protein affects the reaction [Paclitaxel affects the localization of and results in increased activity of [NFKB1 protein binds to RELA protein]]; Paclitaxel affects the localization of and results in increased activity of [NFKB1 protein binds to RELA protein]
[gemcitabine co-treated with Doxorubicin co-treated with Paclitaxel] affects the localization of RELA protein; [gemcitabine co-treated with Doxorubicin co-treated with Paclitaxel] results in increased expression of RELA protein; [Paclitaxel co-treated with F2 protein] affects the localization of RELA protein; [Paclitaxel co-treated with Metformin] results in decreased expression of RELA mRNA; [Tretinoin co-treated with Paclitaxel] results in decreased expression of RELA protein; caffeic acid phenethyl ester inhibits the reaction [Paclitaxel results in increased activity of RELA protein]; Curcumin inhibits the reaction [Paclitaxel results in increased activity of RELA protein]
CTD PMID:11123339, PMID:15291876, PMID:16243823, PMID:17039268, PMID:17701358, PMID:18098270, PMID:19944065, PMID:29309887 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Rfc5 replication factor C subunit 5 decreases expression ISO Paclitaxel results in decreased expression of RFC5 protein CTD PMID:15907983 NCBI chr12:44,931,494...44,941,051
Ensembl chr12:44,931,494...44,941,324
JBrowse link
G Rfx5 regulatory factor X5 decreases response to substance ISO RFX5 mRNA results in decreased susceptibility to Paclitaxel CTD PMID:16322897 NCBI chr 2:196,119,054...196,128,109
Ensembl chr 2:196,120,580...196,128,095
JBrowse link
G Rfxank regulatory factor X-associated ankyrin-containing protein affects response to substance ISO RFXANK protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr16:21,029,449...21,037,080
Ensembl chr16:21,029,596...21,037,078
JBrowse link
G Rhot2 ras homolog family member T2 affects response to substance ISO RHOT2 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr10:15,205,943...15,211,739
Ensembl chr10:15,205,534...15,211,325
JBrowse link
G Ripk2 receptor-interacting serine-threonine kinase 2 multiple interactions ISO [Paclitaxel co-treated with Metformin] results in decreased expression of RIPK2 mRNA CTD PMID:29309887 NCBI chr 5:29,838,713...29,870,390
Ensembl chr 5:29,838,747...29,870,735
JBrowse link
G Rnf19a ring finger protein 19A, RBR E3 ubiquitin protein ligase decreases expression ISO Paclitaxel results in decreased expression of RNF19A mRNA CTD PMID:12929121 NCBI chr 7:75,058,758...75,098,331
Ensembl chr 7:75,058,758...75,098,331
JBrowse link
G Rock1 Rho-associated coiled-coil containing protein kinase 1 increases expression ISO Paclitaxel results in increased expression of ROCK1 mRNA CTD PMID:15000894 NCBI chr18:1,273,490...1,390,790
Ensembl chr18:1,273,453...1,390,190
JBrowse link
G Rpl10 ribosomal protein L10 affects response to substance ISO RPL10 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr  X:156,438,251...156,440,461
Ensembl chr  X:156,438,251...156,440,461
JBrowse link
G Rpl22l1 ribosomal protein L22 like 1 decreases expression ISO Paclitaxel results in decreased expression of RPL22L1 mRNA CTD PMID:12929121 NCBI chr 2:115,362,799...115,364,735
Ensembl chr 2:115,362,799...115,364,729
JBrowse link
G Rpl23a ribosomal protein L23a decreases response to substance ISO RPL23A mRNA results in decreased susceptibility to Paclitaxel CTD PMID:16322897 NCBI chr10:65,441,295...65,443,981
Ensembl chr10:65,441,295...65,443,981
JBrowse link
G Rplp1 ribosomal protein lateral stalk subunit P1 decreases response to substance ISO RPLP1 mRNA results in decreased susceptibility to Paclitaxel CTD PMID:16322897 NCBI chr 8:66,862,143...66,863,476
Ensembl chr 8:66,862,143...66,863,476
JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 multiple interactions ISO [Paclitaxel co-treated with Metformin] results in decreased expression of RPS6KB1 mRNA CTD PMID:29309887 NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
JBrowse link
G Rrm2 ribonucleotide reductase regulatory subunit M2 multiple interactions ISO RRM2 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] CTD PMID:16896004 NCBI chr 6:43,884,627...43,890,818
Ensembl chr 6:43,884,678...43,889,515
JBrowse link
G Rrm2b ribonucleotide reductase regulatory TP53 inducible subunit M2B increases expression ISO Paclitaxel results in increased expression of RRM2B mRNA CTD PMID:21704725 NCBI chr 7:76,750,045...76,780,817
Ensembl chr 7:76,750,050...76,780,817
JBrowse link
G Rs1 retinoschisin 1 decreases secretion ISO Paclitaxel results in decreased secretion of RS1 protein CTD PMID:21738583 NCBI chr  X:35,749,957...35,777,243
Ensembl chr  X:35,749,957...35,777,243
JBrowse link
G Rsrp1 arginine and serine rich protein 1 affects response to substance ISO RSRP1 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr 5:153,260,930...153,264,669
Ensembl chr 5:153,260,930...153,264,669
JBrowse link
G RT1-EC2 RT1 class Ib, locus EC2 increases expression EXP Paclitaxel results in increased expression of RT1-EC2 mRNA CTD PMID:18754875
G Rtkn rhotekin multiple interactions
decreases response to substance
ISO Curcumin inhibits the reaction [RTKN protein results in decreased susceptibility to Paclitaxel] CTD PMID:15480428 NCBI chr 4:114,833,453...114,850,705
Ensembl chr 4:114,835,064...114,850,701
JBrowse link
G Ruvbl2 RuvB-like AAA ATPase 2 decreases expression ISO Paclitaxel results in decreased expression of RUVBL2 protein CTD PMID:15907983 NCBI chr 1:101,413,766...101,426,970
Ensembl chr 1:101,413,766...101,426,852
JBrowse link
G S100a4 S100 calcium-binding protein A4 increases expression ISO Paclitaxel results in increased expression of S100A4 mRNA CTD PMID:19682730 NCBI chr 2:189,997,278...189,999,587
Ensembl chr 2:189,997,129...189,999,604
JBrowse link
G Scg5 secretogranin V increases expression
affects response to substance
EXP
ISO
Paclitaxel results in increased expression of SCG5 mRNA
SCG5 protein affects the susceptibility to Paclitaxel
CTD PMID:15585946, PMID:16217747 NCBI chr 3:105,235,065...105,279,475
Ensembl chr 3:105,235,050...105,279,462
JBrowse link
G Scube2 signal peptide, CUB domain and EGF like domain containing 2 multiple interactions ISO SCUBE2 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] CTD PMID:16896004 NCBI chr 1:174,428,056...174,495,356
Ensembl chr 1:174,428,699...174,495,258
JBrowse link
G Sdc2 syndecan 2 increases expression ISO Paclitaxel results in increased expression of SDC2 mRNA CTD PMID:19682730 NCBI chr 7:71,572,731...71,686,139
Ensembl chr 7:71,572,941...71,686,044
JBrowse link
G Selp selectin P increases expression EXP Paclitaxel results in increased expression of SELP mRNA CTD PMID:18754875 NCBI chr13:82,428,914...82,464,629
Ensembl chr13:82,429,063...82,464,628
JBrowse link
G Serpina3n serine (or cysteine) peptidase inhibitor, clade A, member 3N increases expression EXP Paclitaxel results in increased expression of SERPINA3N mRNA CTD PMID:18754875 NCBI chr 6:128,073,344...128,080,878
Ensembl chr 6:127,941,526...128,080,889
JBrowse link
G Serpinb2 serpin family B member 2 affects response to substance ISO SERPINB2 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr13:27,449,907...27,463,015
Ensembl chr13:27,449,934...27,463,010
JBrowse link
G Serpine1 serpin family E member 1 affects response to substance ISO SERPINE1 protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
JBrowse link
G Serpinf1 serpin family F member 1 increases expression ISO Paclitaxel results in increased expression of SERPINF1 mRNA CTD PMID:19682730 NCBI chr10:62,241,750...62,254,145
Ensembl chr10:62,241,756...62,254,287
JBrowse link
G Sgcb sarcoglycan, beta affects response to substance ISO SGCB protein affects the susceptibility to Paclitaxel CTD PMID:16217747 NCBI chr14:37,113,194...37,128,623
Ensembl chr14:37,113,210...37,128,737
JBrowse link
G Sgk1 serum/glucocorticoid regulated kinase 1 decreases expression EXP Paclitaxel results in decreased expression of SGK1 mRNA CTD PMID:15585946 NCBI chr 1:24,185,451...24,302,309
Ensembl chr 1:24,185,435...24,302,298
JBrowse link
G Sh2d2a SH2 domain containing 2A multiple interactions ISO [Cisplatin co-treated with Paclitaxel] results in increased expression of SH2D2A mRNA CTD PMID:20705681 NCBI chr 2:187,218,851...187,225,000
Ensembl chr 2:187,218,851...187,225,002
JBrowse link
G Sh3bp2 SH3-domain binding protein 2 decreases expression ISO Paclitaxel results in decreased expression of SH3BP2 protein CTD PMID:15907983 NCBI chr14:81,435,445...81,473,013
Ensembl chr14:81,435,449...81,472,952
JBrowse link
G Sigmar1 sigma non-opioid intracellular receptor 1 increases expression EXP Paclitaxel analog results in increased expression of SIGMAR1 mRNA CTD PMID:15585946 NCBI chr 5:58,121,824...58,124,687
Ensembl chr 5:58,121,786...58,124,681